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ABSTRACT 
 
DEVELOPMENT OF THIOAMIDES AS PROTEIN PROBES 
Daniel Miklos Szantai-Kis 
E. James Petersson 
Thioamides have been used for various applications with small molecules and 
peptides, including as protease sensors, fluorescence quenching probes, folding probes, 
and handles for site-specific chemical modification. However, their use in proteins has 
been limited due to cumbersome incorporation through semi-synthesis, as well as their 
unknown effects on protein structure. In this work, I address these issues from multiple 
perspectives. I present improvements for the synthesis of thioamide-containing peptides, 
which are needed for semi-synthesis. I also investigate the effects that thioamide 
substitutions have on tertiary structure in a model protein and show that based on thermal 
denaturation experiments, the position of thioamide substitution can have a significant 
impact on the tertiary fold. Furthermore, I demonstrate a new semi-synthetic strategy to 
obtain mg quantities of a thioamide-containing protein that will enable structural 
investigation by Nuclear Magnetic Resonance spectroscopy and X-Ray crystallography. 
Finally, I describe my attempts at the genetic incorporation of thioamides using a 
combination of unnatural amino acid mutagenesis and amber suppression. While the last 
part was not successful, the efforts to improve semi-synthesis of thioamides will enable 
the use of thioamides as probes in proteins in a similar fashion as they have been used 
previously in peptides. 
 
 
vii 
 
 
TABLE OF CONTENTS 
DEVELOPMENT OF THIOAMIDES AS PROTEIN PROBES............................................... I 
DEDICATION ............................................................................................................................. III 
ACKNOWLEDGMENT .............................................................................................................. IV 
ABSTRACT .................................................................................................................................. VI 
LIST OF TABLES ......................................................................................................................... X 
LIST OF ILLUSTRATIONS ....................................................................................................... XI  
CHAPTER 1 : INTRODUCTION............................................................................................... 1 
Thioamide Properties .................................................................................................................... 2 
Thioamides in Nature: Biosynthesis, Structure, and Function ................................................. 6 
Closthioamide .............................................................................................................................. 6 
YcaO-TfuA-dependent thioamidation ......................................................................................... 10 
Thioamide-Containing Protein: Methyl-Coenzyme M Reductase (MCR) .................................. 13 
Potential for Other Thioamide Natural Products ........................................................................ 15 
Synthetic Thioamide in Peptides and Proteins ......................................................................... 16 
Chemical Synthesis of Thioamide-Containing Peptides ............................................................ 17 
Uses of Synthetic Thioamide Peptides as Fluorescence Quencher Probes ............................. 20 
Synthetic thioamide peptides for other uses .............................................................................. 24 
Thioprotein Semisynthesis ......................................................................................................... 32 
Thioamide Effects in Full Length Proteins. ................................................................................ 35 
Synopsis ....................................................................................................................................... 36  
CHAPTER 2 : IMPROVED FMOC DEPROTECTION METHODS FOR THE 
SYNTHESIS OF THIOAMIDE-CONTAINING PEPTIDES................................................. 38 
2.1 Introduction ............................................................................................................................ 39  
2.2 Results and Discussion ........................................................................................................ 41 
2.3 Conclusion .............................................................................................................................. 46  
2.4 Materials and Methods .......................................................................................................... 47 
viii 
 
CHAPTER 3 : SYNTHESIS, CHARACTERIZATION, AND INCORPORATION OF SIDE-
CHAIN THIOAMIDE DERIVATIVES THIOASPARAGINE, THIOGLUTAMINE, AND 
THIOACETYL LYSINE ............................................................................................................. 53 
3.1 Introduction ............................................................................................................................ 53  
3.2 Results and Discussion ........................................................................................................ 54 
3.3 Conclusion .............................................................................................................................. 59  
3.4 Materials and Methods .......................................................................................................... 59 
CHAPTER 4 : CHEMOSELECTIVE MODIFICATIONS FOR THE TRACELESS 
LIGATION OF THIOAMIDE-CONTAINING PEPTIDES AND PROTEINS .................... 70 
4.1 Introduction ............................................................................................................................ 71  
4.2 Results and Discussion ........................................................................................................ 72 
Selective desulfurization using thioacetamide scavenger ......................................................... 74 
One pot ligation/desulfurization .................................................................................................. 76  
Desulfurization of Cys analogs .................................................................................................. 78 
Synthesis of GB1 protein by ligation/desulfurization .................................................................. 81 
4.3 Conclusion .............................................................................................................................. 83  
4.4 Materials and Methods .......................................................................................................... 84 
CHAPTER 5 : THE EFFECTS OF THIOAMIDE BACKBONE SUBSTITUTION ON 
PROTEIN STABILITY .............................................................................................................. 97 
5.1 Introduction ............................................................................................................................ 98  
5.2 Results and Discussion ...................................................................................................... 101 
Design and semi-synthesis of CaM thioproteins. ..................................................................... 101 
CaM thioprotein folding thermodynamics................................................................................. 102 
Design and synthesis of GB1 thioproteins. .............................................................................. 107 
GB1 thioprotein folding thermodynamics. ................................................................................ 109 
Design and synthesis of collagen model thiopeptides. ............................................................ 112 
Collagen model thiopeptide folding thermodynamics. ............................................................. 114 
5.3 Conclusion ............................................................................................................................ 117  
5.4 Materials and Methods ........................................................................................................ 119 
CHAPTER 6 : IMPROVED SEMI-SYNTHETIC STRATEGY FOR THIOAMIDE-
INCORPORATION INTO PROTEINS ................................................................................ 135 
6.1 Introduction .......................................................................................................................... 135  
ix 
 
6.2 Results and Discussion ...................................................................................................... 136 
Native chemical ligation between Gly9 and Lys10. .................................................................... 137 
Native chemical ligation between Leu12 and Lys13. .................................................................. 142 
6.3 Conclusion ............................................................................................................................ 145  
6.4 Materials and Methods ........................................................................................................ 146 
CHAPTER 7 : SYNTHESIS, CHARACTERIZATION AND ATTEMPTED GENETIC 
INCORPORATION OF NΕ-ALKYL LYSINE AND NΕ-THIOAALKYL LYSINE 
DERIVATIVES ........................................................................................................................ 176 
7.1 Introduction .......................................................................................................................... 176  
7.2 Results and Discussion ...................................................................................................... 179 
7.3 Conclusion ............................................................................................................................ 186  
7.4 Materials and Methods ........................................................................................................ 186 
CHAPTER 8 APPENDIX ....................................................................................................... 199 
Appendix A: Synthesis of flexizyme substrates to probe the ribosomal exit tunnel ......... 199 
Appendix B: Synthesis of flexizyme substrates to study the mechanism of a quadruplet-
codon reader .............................................................................................................................. 207  
BIBLIOGRAPHY .................................................................................................................... 217  
  
x 
 
LIST OF TABLES 
Table 1.1: Summary of the Physicochemical Properties of Thioamides .......................... 4 
Table 2.1: Comparison of Yield and Epimerization between Peptides Synthesized with 
either DBU or Piperidinea. ..............................................................................................43 
Table 2.2: Tested cleavage conditions with peptide 2-8. ................................................51 
Table 2.3: HPLC purification methods and retention times. ...........................................51 
Table 2.4: HPLC gradients used for small molecule/peptide purification. .......................52 
Table 2.5: MALDI-TOF MS Characterization of Purified Peptides. .................................52 
Table 3.1: HPLC purification methods and retention times. ...........................................64 
Table 3.2: Peptide Purification/Characterization Methods and Retention Times. ...........66 
Table 3.3: MALDI-TOF MS Characterization of Purified Peptides. .................................68 
Table 4.1: Peptide Purification Methods and Retention Times. ......................................90 
Table 4.2: HPLC Gradients for Peptide Purification and Characterization. .....................91 
Table 4.3: MALDI-TOF MS Characterization of Peptides. ..............................................93 
Table 5.1: Apo CaM thermodynamic values. ............................................................... 106 
Table 5.2: GB1 thermodynamic values. ....................................................................... 112 
Table 5.3: CMP thermodynamic and kinetic values. .................................................... 115 
Table 5.4: HPLC Gradients for Peptide Purification and Characterization. ................... 128 
Table 5.5: MALDI-TOF MS Characterization of Peptides. ............................................ 129 
Table 6.1: Peptide/Protein Purification Methods and Retention Times. ........................ 173 
Table 6.2: FPLC and HPLC gradients used for Peptide/Protein Purification and 
Characterization. ......................................................................................................... 174 
Table 6.3: MALDI-TOF MS Characterization of Peptides and Proteins. ....................... 175 
Table 7.1: HPLC Gradients used for Small Molecule Purification. ................................ 198 
Table 8.1: HPLC gradients used for compound purification. ........................................ 206 
Table 8.2: Compound purification retention times. ....................................................... 206 
 
 
xi 
 
LIST OF ILLUSTRATIONS 
Figure 1-1: Structures of various thioamidated natural products. The stereochemistries in 
Thioviridamide, Thiohologamide and Thioalbamide have not yet been elucidated. ......... 5 
Figure 1-2: Biosynthesis of Closthioamide. (A) Biosynthetic gene cluster of closthioamide 
from R. cellulolyticum DSM5812. (B). Proposed NRPS biosynthetic pathway for 
closthioamide. (PCP = peptididyl carrier protein; PHBA = p-hydroxybenzoic acid; DAP = 
diamino propane; AANH = α-adenine nucleotide hydrolase) ........................................... 8 
Figure 1-3: (A) Thioviridamide biosynthetic gene cluster from S. olivoviridis NA05001. (B) 
The core region (red) of the precursor peptide TvaA is converted to thioviridamide by the 
downstram biosynthetic enzymes. The stereochemistry has not yet been elucidated. ...10 
Figure 1-4: Comparison of reactions catalyzed by YcaO enzymes. (A) ATP-dependent 
cyclodehydration of cysteine, serine or threonine to thiazoline or (methyl)oxazoline. (B) 
Analogous proposed mechanism for biosynthesis of thioamides on peptidic backbones, 
with an exogenous sulfide source as nucleophile. .........................................................11 
Figure 1-5: View of the MCR active site with the thioglycine involved in several stabilizing 
interactions using the crystal structure of Methanosarcina barkeri (Protein Data Bank 
entry 1E6Y)51. ................................................................................................................13 
Figure 1-6: Site-specific incorporation of thioamides using solid phase peptide synthesis 
(SPPS). (A) Thioacyl-benzotriazole monomers can be synthesized in three steps from 
Fmoc-protected amino acids. (B) The thioacyl-benztriazoles can be used to introduce 
the thioamide during SPPS. ...........................................................................................18 
Figure 1-7: Using thioamides to monitor protease activity. Left: Reaction scheme; Right: 
Fluorescence time courses from activity assays testing various proteases. Green/blue 
trace: oxopeptide in the presence/absence of protease respectively. Red/Orange: 
thiopeptide in the presence/absence of protease respectively. ......................................23 
Figure 1-8: Thioamide containing probes to study O-GlcNAcase. ..................................24 
Figure 1-9: Reaction scheme conventional macrocyclization and silver(I) promoted 
thioamide macrocyclization. ...........................................................................................26 
Figure 1-10: Controlling bioactivity through thioamide photoisomerization. (A) The insect 
kinin-derived thioamide pentapeptide can undergo UV-induced photoisomerization to 
adopt a 1-4 β-turn structure. (B) Titration of isolated cis or trans peptide in an ex vivo 
myotropic contraction assay shows a 4-fold lower EC50 for the cis peptide. ...................27 
Figure 1-11: (A) Incorporation of a thioamide into Glucagon-like peptide 1 (GLP-1) at the 
X1 or X2 position prevents dipeptidyl peptidase 4 (DPP-4) degradation. (B) Image of the 
DPP-4 (cyan) active site with a modeled GLP-1 fragment (based on PDB entry 1R9N)103. 
X1 – X3 carbonyls and their interactions are highlighted. (C) In vitro degradation assay 
shows that thioamide substitution at X1 or X2 but not X3 can effectively prevent 
proteolysis by DPP-4. ....................................................................................................29 
xii 
 
Figure 1-12: (A) Chemical structures of RGD peptide macrocycles, including cilengitide 
and two matched amide/thioamide pairs. (B) NMR structures of the fS (organge), FS 
(cyan) peptides overlaid with structure of cilengitide bound to αvβ3 integrin (PDB entry 
1L5G)112. (C) Summary of serum stability (t1/2) and activity (IC50 for binding to breast 
cancer and glioblastoma cells) ......................................................................................31 
Figure 1-13: Traceless ligation strategy to synthesize thioamide-containing proteins. (A) 
Thioamide-containing thioester peptides (blue) are synthesized from acylhydrazide 
precursors to generate a thioester. (B) N-terminal cysteine fragments (red) are 
synthesized or recombinantly expressed. (C) Ligation can be performed without special 
precautions for the thioamide. (D) Masking of the ligation site can occur through 
desulfurization, Met masking, homoGln masking and Lys masking. ..............................34 
Figure 2-1: Reported pKa values that allows estimation of α-C-H pKa in thioamides ......40 
Figure 2-2: Lys(AcS)-containing peptides used to study byproduct formation under 
piperidine deprotection conditions. MALDI-TOF MS masses of 2-7, 2-8 (using DBU 
deprotection), 2-9 (byproduct of 2-8 using piperidine deprotection), and 2-10 (byproduct 
of 2-8 using morpholine deprotection); Pip. = piperidine, Mor. = morpholine. .................44 
Figure 2-3: Synthesis of the piperidine adduct Boc-Lys(Pip)-OH (2-14). ........................45 
Figure 2-4: 2D correlations from NMR experiments on Boc-Lys(Pip)-OH (2-14). ...........46 
Figure 3-1: Fluorescence quenching by side-chain Nε-thioacetyl lysine. Top: Structure of 
polyproline rulers with various fluorophores. Bottom: Quenching efficiency of peptides 
with various fluorophores (normalized to corresponding oxo peptide). The number of 
proline residues between fluorophore and quencher are indicated by n. ........................55 
Figure 3-2: Distance dependent fluorescence quenching of AsnγS is in good agreement 
with data obtained from Lys(AcS) measurements. Fluorescence intensity is normalized to 
corresponding oxo peptide. Peptides with n=3 and 5 were not synthesized for AsnγS. The 
number of proline residues between fluorophore and quencher are indicated by n. .......56 
Figure 3-3: Direct thionation of Fmoc-Gln with various side-chain protecting groups. 
Analytical HPLC traces shown. # indicates peak with monothionated mass. 
Abbreviations: Dmcp = Dimethylcyclopropyl; Tmob = 2,4,6-Trimethoxybenzyl; Mbh = 
4,4'-dimethyoxybenzhydryl; Xan = Xanthyl; Trt = Trityl. .................................................58 
Figure 4-1: Thioamide Compatibility with different Desulfurization Methods. Top: reaction 
scheme; Bottom: HPLC chromatogram monitored at 325 nm and UV-Vis absorption 
profiles for major peak in each chromatogram. ..............................................................74 
Figure 4-2: Thioacetamide as Small Molecule Scavenger. Top: Reaction scheme; 
Bottom: HPLC chromatogram monitored at 325 nm, and UV-Vis absorption profiles for 
selected peaks in each chromatogram. .........................................................................76 
Figure 4-3: One-Pot Ligation-Desulfurization. Top: Reaction Scheme; Bottom: HPLC 
chromatogram monitored at 325 nm, and UV-Vis absorption profiles for major peaks in 
each chromatogram. ......................................................................................................78 
xiii 
 
Figure 4-4: Desulfurization time-course of Penicillamine containing peptides. Top: 
Reaction scheme; Bottom: HPLC chromatograms monitored at 325 nm at various time 
points.............................................................................................................................80 
Figure 4-5: Synthesis of Thioamide GB1 by Ligation and Desulfurization. Top: reaction 
scheme; Bottom: HPLC chromatograms monitored at 272 nm, and MALDI-TOF MS 
profiles for selected peaks in each chromatogram. ........................................................82 
Figure 4-6: Attempted One-Pot Ligation-Desulfurization is Incompatible with Hydrazide 
Ligation Chemistry. Bottom shows HPLC chromatogram monitored at 272 nm and 
MALDI-TOF MS profile of unidentified by-products after Acidification/Lyophilization. .....83 
Figure 4-7: Synthesis of Nα-Fmoc-L-Thioleucine-nitrobenztriazolide: (i) NMM, IBCF, 4-
nitrobenzene-1,2-diamine, THF; (ii) P4S10, Na2CO3, THF; (iii) NaNO2, 95% AcOH(aq). ....85 
Figure 5-1: Characterization of WT, CysQ135 and thioCaM variants. CD wavelength 
scan of holo (top) and apo (middle) forms of CaM. Bottom: CD thermal melts of apo 
forms plotted as pseudo-Fraction folded (F*f) generated from fitted data. .................... 104 
Figure 5-2: Structural analysis of GB1 thioamide variants. Left: Overall structure of GB1 
with modeled thioamide substitutions. Right: Zoomed in region showing that the LeuS7 
thiocarbonyl is skewed out of the plane of the anti-parallel β-sheet, providing a potential 
explanation for why it is less destabilizing than LeuS5 or IleS6. Structures rendered from 
PDB entry 2QMT189 ..................................................................................................... 108 
Figure 5-3: Characterization of WT and thio-GB1 variants. Top: CD wavelength scan of 
GB1 variants. Bottom: CD thermal melts plotted as Fraction folded (Ff) generated from 
fitted data. ................................................................................................................... 110 
Figure 5-4: Structural analysis of CMP thioamide variants. ProSProGly and ProProGlyS 
have buried and partially buried sulfur atoms, respectively (Top and Middle), accounting 
for the disruptions observed in the CD experiments. The ProProSGly (Bottom) sulfur 
atom is fully solvent exposed and the N–H of the thioamide forms a hydrogen bond with 
the strand shown in grey (inset), accounting for the stabilization observed in the CD 
experiments. Structures rendered from PDB entry 2CUO205. ....................................... 114 
Figure 5-5: Thermal stability of CMP thioamide variants. CD thermal melts of collagen 
plotted as fraction folded (Ff) values. ........................................................................... 116 
Figure 5-6: Synthesis of Thio-Isoleucine nitrobenztriazolide monomer. ....................... 121 
Figure 5-7: Plots generated using the two-state fitting method for GB1 variants. Left: For 
each GB1 variant, a single set of raw data (θMRE) and fits from equations for θfit, θf, and 
θu. Right: The averaged fraction folded plots (1-Fcalc) from two replicated melts........... 132 
Figure 6-1: Semi-synthetic scheme to obtain thioamide labeled GB1. C-terminal 
fragment will be recombinantly expressed while the N-terminal fragment will be 
synthesized on solid phase. After NCL the cysteine at the ligation site will be alkylated 
with 2-bromoethylamine to yield thialysine. .................................................................. 137 
xiv 
 
Figure 6-2: SDS-PAGE (16% Tris-Glycine gel) showing attempted intein cleavage of 
GB1-MxeGyrA-His6 under varying conditions. BME concentrations used were 0.1 M, 
0.25 M, and 0.5 M. Data shown here is for the reaction at pH 9.0. Gel at pH 8.0 looked 
identical. MW: GB1-MxeGyrA-His6: 29.1 kDa; MxeGyrA-His6: 22.9 kDa; GB1: 6.2 kDa.
 .................................................................................................................................... 138 
Figure 6-3: SDS-PAGE (16% Tris-Glycine gel) showing intein cleavage of GB1-
NpuDnaE-His6 under varying conditions. BME concentrations used were 0.1 M, 0.2 M, 
0.5 M and 1.0 M. Data shown here is for the reaction at pH 7.5. Gels at pH 8.0, 8.5, and 
9.0 looked similar. MW: GB1-NpuDnaE-His6: 23.1 kDa; MxeGyrA-His6: 16.9 kDa; GB1: 
6.2 kDa. GB1 stains poorly and runs higher than expected at around 12 kDa. ............ 139 
Figure 6-4: SDS-PAGE (14% Tris-Tricine gel) of intein cleavage test for GB110-56 K10C-
Intein-His6 fusion constructs. All cleavages performed with 1 M BME at 37°C for 48 hrs. 
Inteins: A: NpuDnaE; B: MxeGyrA; C: MxeGyrA(Δ); D: MxeGyrA(Δ, T3C) ................... 141 
Figure 6-5: NCL with ligation site between Gly9 and Lys10. Top: Scheme showing the 
expected vs. observed reaction product. Botton: MALDI-TOF MS of NCL reaction 
showing formation of GB1 dimer with only minimal product formation. ........................ 142 
Figure 6-6: Semi-synthetic scheme to generate thio-GB1. Key difference to the previous 
scheme is the different ligation site to prevent the previously observed dimer formation.
 .................................................................................................................................... 143 
Figure 6-7: Progress of NCL reaction based on MALDI-TOF MS. Traces show reaction 
at the beginning (30 minutes; blue), at completion (72 hours, red), and post HPLC 
purification (green). * denotes MPAA disulfide adducts. .............................................. 145 
Figure 6-8: MALDI-TOF MS of purified GB11-9 LS7-N2H3 (6-1). [M+Na]+: expected: 
1,131.58; observed: 1,131.86. ..................................................................................... 149 
Figure 6-9: Top: MALDI-TOF MS of purified GB11-12 LS7-N2H3 (6-2). [M+H]+: expected: 
1,451.82; observed: 1,452.21. *denotes inseparable product with +104 mass difference. 
Bottom: MS/MS analysis of peak at m/z = 1,556 shows most expected b-ions of 6-2 up 
to b11 but none of the expected y-ions, indicating modification of the C-terminal acyl-
hydrazide. .................................................................................................................... 151 
Figure 6-10: Characterization of GB1 expression. Top: SDS-PAGE (14% Tris-Tricine 
gel) of GB1 (WT) expression/purification. MW: GB1-NpuDnaE-His6: 23.1 kDa; NpuDnaE-
His6: 19.6 kDa; GB1: 6.2 kDa. GB1 runs at a higher than expected molecular weight at 
about 11 kDa. Bottom: MALDI-TOF analysis of GB1. [M+H]+: expected: 6,223.85 
observed: 6,222.37. ..................................................................................................... 163 
Figure 6-11: Characterization of GB1 K10CK (6-5) expression. Top: SDS-PAGE (14% 
Tris-Tricine gel) of expression/purification. MW: GB1 K10C-NpuDnaE-His6: 23.1 kDa; 
NpuDnaE-His6: 19.6 kDa; GB1: 6.2 kDa. GB1 K10C runs at a higher than expected 
molecular weight at about 11 kDa. Bottom: MALDI-TOF analysis of protein before (blue) 
and after (green) labelling. GB1 K10C (6-4): [M+H]+: expected: 6,198.81 observed: 
6,197.30. GB1 K10CK (6-5): [M+H]+: expected: 6,241.88 observed: 6,242.53. .............. 164 
xv 
 
Figure 6-12: Characterization of GB110-56 K10C (6-6) expression. Top: SDS-PAGE (14% 
Tris-Tricine gel) of expression/purification. MW: GB110-56 K10C-MxeGyrA(Δ)-His6: 22.8 
kDa; MxeGyrA(Δ)-His6: 17.7 kDa; GB110-56 K10C: 5.1 kDa. GB110-56 K10C runs at a higher 
than expected molecular weight at about 11 kDa and stains poorly. Bottom: MALDI-TOF 
analysis. GB110-56 K10C (Pyruvate adduct): [M+H]+: expected: 5,207.50 observed: 
5,208.79 ...................................................................................................................... 166 
Figure 6-13: Characterization of GB1 K13C (6-8) expression. Top: SDS-PAGE (14% Tris-
Tricine gel) of expression/purification. MW: GB1 K13C-NpuDnaE-His6: 23.1 kDa; 
NpuDnaE-His6: 19.6 kDa; GB1: 6.2 kDa. GB1 K13C runs at a higher than expected 
molecular weight at about 11 kDa. Bottom: MALDI-TOF analysis. GB1 K13C [M+H]+: 
expected: 6,198.81 observed: 6,198.26. ...................................................................... 167 
Figure 6-14: SDS-PAGE (14% Tris-Tricine gel) following expression and purification of 
Ulp-1 (6-9). The post FPLC band was run on a separate gel with identical composition 
and run conditions. The molecular weight of Ulp-1 is 27.4 kDa. ................................... 169 
Figure 6-15: Characterization of GB113-56 K13C (6-10) expression. Left: SDS-PAGE (14% 
Tris-Tricine gel) following purification of 6-10 from a SUMO fusion protein. MW: His6-
SUMO-GB113-56 K13C: 17.8 kDa; His6-SUMO: 13.0 kDa; GB113-56 K13C: 4.8 kDa. GB113-56 
K13C runs at a higher than expected molecular weight at about 11 kDa. Right: MALDI-
TOF analysis. GB113-56 K13C [M+H]+: expected: 4,795.07 observed: 4,793.57. * denotes 
MPAA adduct. ............................................................................................................. 171 
Figure 7-1: Codon reassignment strategy for the site-specific incorporation of unnatural 
amino acids: An orthogonal synthetase/tRNA pair are responsible for site-specific of the 
unnatural amino acid. Figure adapted from Lei Wang233. ............................................. 178 
Figure 7-2: Attempted incorporation of Lys(Ac) and Lys(AcS) into sfGFP. Left: SDS-
PAGE analysis of cells shows the main product to be truncated protein. Right: 
Fluorescence measurement supports that only a small fraction of Lys(Ac) got 
incorporated to generate fluorescent full-length GFP. .................................................. 180 
Figure 7-3: OD600 (top) and fluorescence (bottom) measurements (in triplicate) of cells 
grown for 24 hours in autoinducing medium. Non-WT expressions contained 10 mM 
Lys(Ac)/Lys(AcS) or 1 mM Lys(Hept)/Lys(HeptS). ......................................................... 182 
Figure 7-4: Result of attempted UAA incorporation using mmchAcK3 synthetase. Top: 
SDS-PAGE of crude cells extract and purified protein for WT (sfGFP) and TAG (sfGFP 
Y151Z) constructs. Expression were performed in the presence of 10 mM UAA. Purified 
WT protein was diluted (1:5) before loading to not overload gel. MW: sfGFP: 27.7 kDa, 
sfGFP1-150: 16.9 kDa. Bottom: MALDI-TOF MS of tryptic digest shows that in both cases 
fragment 141-156 didn’t contain thioamino acid. Expected masses: sfGFP141-156 
Y151K(Ac): 1,934.96; : sfGFP141-156 Y151K(AcS): 1,950.94. observed: 1,935.13 for Lys(Ac) 
incorporation; 1,935.14 for Lys(AcS) incorporation. ...................................................... 184 
Figure 7-5: Result of attempted UAA incorporation using mmOctK synthetase. Top: 
SDS-PAGE of crude cells extract and purified protein for WT (sfGFP) and TAG (sfGFP 
Y151Z) constructs. Expression were performed in the presence of 1 mM UAA. Purified 
WT protein was diluted (1:5) before loading to not overload gel. MW: sfGFP: 27.7 kDa, 
xvi 
 
sfGFP1-150: 16.9 kDa. Bottom: MALDI-TOF MS of tryptic digest shows that in both cases 
fragment 141-156 didn’t contain thioamino acid. Expected masses: sfGFP141-156 
Y151K(Hept): 2,005.04; : sfGFP141-156 Y151K(HeptS): 2,021.02. observed: 2,005.19 for 
Lys(Hept) incorporation; 2,005.25 for Lys(HeptS) incorporation. .................................. 185 
Figure 7-6: Synthetic scheme for the synthesis of Lys(AcS)-OH (7-2). ......................... 188 
Figure 7-7: Synthetic scheme for the synthesis of Lys(Hept)-OH (7-4) and Lys(HeptS)-
OH (7-6). ..................................................................................................................... 189 
Figure 7-8: Plasmid maps showing vector backbones used. Left: pEVOL plasmid 
containing mmchAcK3RS gene (green) under control of araBAD. Right: pET plasmid 
contining sfGFP gene (green) under control of the lac operon. .................................... 196 
Figure 8-1: General synthesis scheme for dinitrobenzyl esters of 
(trialkylammonium)maleimide modified cysteine. i) Boc2O, TEA, H2O; ii) 3,5-
Dinitrobenzylchloride, NaI, DIPEA, DMF; iii) TFA; iv) TCEP, N-ethylmaleimide/2-8a-c, 
H2O, pH 6.0 ................................................................................................................. 200 
Figure 8-2: Synthesis of maleimido-quaternary ammoniums. i) (a) N-
(Bromoethyl)phtalimide, MeCN; (b) HBr (48%); ii) N-methoxycarbonylmaleimide, ¼ sat. 
NaHCO3. ..................................................................................................................... 201 
Figure 8-3: Synthesis of L-Tryptophan cyanomethyl ester. i) NaI, DIPEA, ClCH2CN; ii) 
TFA, CHCl3. ................................................................................................................. 205 
Figure 8-4: Generalized synthesis scheme for Dinitrobenzyl esters. Reagents and 
conditions: i) (3,5)Dinitrobenzyl chloride, NaI, DIPEA, THF; ii) TFA, CHCl3 ................. 207 
Figure 8-5: Synthesis of trans-L-4-Hydroxyproline dinitrobenzyl ester (8-12a). ............ 208 
Figure 8-6:Synthesis of cis-L-4-Hydroxyproline dinitrobenzyl ester (8-12b). ................ 209 
Figure 8-7: Synthesis of 2-Carboxyazetidine dinitrobenzyl ester (8-12c). ..................... 210 
Figure 8-8: Synthesis of Thioproline dinitrobenzyl ester (8-12d). ................................. 211 
Figure 8-9: Synthetic scheme for the synthesis of fMet-Pro-Pro-DBE. ......................... 214 
Figure 8-10: NMR of fMet-Pro-Pro-DBE. ..................................................................... 216 
 
 
  
1 
 
Chapter 1 : Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted and adapted with permission from:  
Wang, Y. J.; Szantai-Kis, D. M.; Petersson, E. J., Semi-synthesis of thioamide containing 
proteins. Organic & Biomolecular Chemistry 2015, 13, 5074-5081. Copyright 2015 The 
Royal Society of Chemistry1 
and 
Mahanta, N.*; Szantai-Kis, D. M.*; Petersson, E. J.; Mitchell, D. A.; Biosynthesis and 
Chemical Applications of Thioamides. ACS Chemical Biology 2019, 14, 142-163. 
Copyright 2019 The American Chemical Society2 
*denotes equal contribution 
  
2 
 
Thioamide Properties 
A thioamide is a single-atom deviation from the canonical amide functional group 
(hereafter also referred to as “oxoamide”), where the carbonyl oxygen is replaced with 
sulfur. In the literature the thioamide functional group has historically been referred to as 
a thionoamide, thioxoamide, endothiopeptide, mercaptoamide, thiopeptide unit, 
thiodepsipeptide, and thiocarboxamide. For the sake of brevity and to be consistent with 
current Organic Chemistry usage patterns, we prefer thioamide. Formally, according to 
IUPAC recommendations, thioamide backbone modifications in peptides and proteins 
should be annotated systematically as ψ[CS-NH]. For brevity, we have previously used a 
superscript S (S) to indicate the presence of a thioamide between two residues. 
Additionally, it should be noted that we use the term thiopeptides to describe thioamide-
containing peptides while this term is often also used to describe thiazole- and thiazolene-
containing natural products such as thiostrepton3.  
The potential benefits of incorporation of thioamide into both natural and synthetic 
compounds result from the at once subtle and dramatic changes to amide interactions that 
can come from this single atom substitution. The physicochemical properties of thioamides 
are summarized in Table 1.1. Thioamides are more reactive with both nucleophiles and 
electrophiles than amides4,5, with a weaker carbonyl bond (130 vs 170 kcal/ mol)6 and 
therefore have been used as chemical synthesis intermediates. Thioamides also have 
greater affinity for certain metals compared to those of amides. For instance, the natural 
product methanobactin (Figure 1-1) exhibits extremely high affinity copper binding7, and 
selective, silver and mercury-catalyzed transformations have been used to convert 
thioamides into other carbonyl derivatives8,9. The differences in amide and thioamide 
geometry govern many of the noncovalent interactions exhibited by thioamide-containing 
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peptides. The thioamide C=S bond (1.71 Å) is one-third longer than the amide C=O bond 
(1.23 Å)10, and sulfur has a van der Waals radius (1.85 Å) one-third larger than that of 
oxygen (1.40 Å)11. Peptide conformational changes can result from the elongated C=S 
bond and the higher rotational barrier for the C−N bond (∼5 kcal/mol)12, which reduces 
conformational flexibility. Additional altered physiochemical properties include (i) 
thioamide N−H groups being more acidic (ΔpKa = −6) than the corresponding amide13, (ii) 
thioamide N−H groups being better hydrogen bond donors14, and (iii) the sulfur lone pairs 
of thioamides being weaker hydrogen bond acceptors relative to oxygen lone pairs in 
amides15. Therefore, thioamides are suitable for evaluating the contribution of single 
hydrogen bonds to protein folding and/or stability. Substitution of an amide with a 
thioamide also imparts significant spectroscopic and electrochemical changes. The 
thioamide C=S bond has an ultraviolet (UV) absorption maximum at 265 ± 5 nm and an 
infrared (IR) stretch at 1120 ± 20 cm−1 , compared to values of 220 ± 5 nm and 1660 ± 20 
cm−1 , respectively, for the amide C=O bond16. Moreover, the 13C nuclear magnetic 
resonance (NMR) chemical shift of the thioamide carbonyl is found 30 ppm downfield 
(200−210 ppm) of the corresponding amide resonance17. The oxidation potential of a 
model thioamide (1.21 eV) is significantly lower than that of the amide (3.29 eV)18, which 
has prompted speculation about a potential role in electron transfer in biological settings. 
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Table 1.1: Summary of the Physicochemical Properties of Thioamides 
Property Amide Thioamide 
van der Waals radius (Å) 1.40 1.8511 
C=X BDEa (kcal/mol) 170 1306 
C=X length (Å) 1.23 1.7110 
C–N rotational barrier (kcal/mol) 17 2212 
Electronegativity of the heteroatom 3.44 2.58 
C=X …H–N hydrogen bond (kcal/mol) 6.1 4.814 
N–H pKa 17 1213 
π→π* absorption (nm) 200 27016 
EOxb (V vs SHE) 3.29 1.2118 
aBDE is the bond dissociation energy. bEOx is the oxidation potential 
vs a standard hydrogen electrode. 
 
The origin of the higher C−N rotational barrier in thioamides has been examined 
by NMR12 and ab initio calculations19. It was found that the amino group of thioformamide 
is more conformationally rigid than in formamide. Additionally, the change in charge 
density at sulfur upon rotation of the amino group in thioformamide is greater than that at 
oxygen in formamide due to a predominant bipolar amide resonance form. The small 
difference in electronegativity between carbon and sulfur (Pauling electronegativities for 
C of 2.55 and for S of 2.58) and the larger size of sulfur are the predominant factors that 
allow charge transfer from nitrogen to sulfur in thioamides. A special feature of the 
thioamide bond arises from the red-shifted absorption bands and the higher barrier for 
cis−trans isomerization. This property allows access to either the cis or trans isomer by 
irradiation with the appropriate UV wavelength. The photoinduced isomerization is efficient 
(30%) and fast (<600 ps), whereas thermal relaxation is comparatively slow (>10 min)16. 
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Hence, thioamide-containing peptides are good candidates for fast photoswitches in 
proteins, either to regulate activity or to initiate conformational transitions for time-resolved 
studies20. The properties mentioned above, allow thioamide modification to affect 
biomolecule function in valuable ways that have led to the evolution of several distinct 
mechanisms for thioamidation in natural products. 
 
Figure 1-1: Structures of various thioamidated natural products. The stereo-
chemistries in Thioviridamide, Thiohologamide and Thioalbamide have not yet been 
elucidated. 
6 
 
Thioamides in Nature: Biosynthesis, Structure, and Function 
Thioamides are exceptionally rare in biology. Most reported natural thioamides are 
of bacterial origin, except for the plant-derived cycasthioamide (Figure 1-1). Among these 
bacterial thioamide products are the ribosomally synthesized and posttranslationally 
modified peptide (RiPP) natural products thioviridamide and its analogues, 
thiohologamide and thioalbamide, methanobactin, and thioamidated thiopeptides as well 
as closthioamide, which is a nonribosomal natural product (Figure 1-1)3,21–23. Known 
thioamide-containing nucleotides include thiouridine, thiocytidine, and thioguanine, which 
will not be discussed in the context of this thesis. Recent identification of the proteins 
responsible for thioglycine formation in the active site of methyl-coenzyme M reductase 
(MCR), the only known thioamidated protein, adds impetus to this area24,25. On the other 
hand, a distinct biosynthetic mechanism has been identified for closthioamide26, which 
shares features of thionated nucleoside biosynthesis27, as well as for methanobactin28. 
Collectively, these revelations suggest that natural thioamidation pathways arose through 
multiple different independent routes24–26. In the context of this thesis I will highlight two 
distinct pathways that lead to thioamidated natural products: The biosynthesis of 
Closthiamide and the YcaO-TfuA-dependent thioamidation as a posttranslational 
modification. 
Closthioamide: Closthioamide, a polythioamide compound, produced by 
Ruminiclostridium cellulolyticum (previously Clostridium cellulolyticum), a strictly 
anaerobic, Gram-positive, soil-dwelling bacterium (Figure 1-1)21. Until recently, no R. 
cellulolyticum natural products had been isolated via standard laboratory cultivation. 
Hertweck and co-workers mimicked the natural environment by adding soil extracts to the 
culture, which led to the production of closthioamide21. Closthioamide is a symmetrical 
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hexathioamide and displays a central diaminopropyl group with four β-alanyl extender 
units and two terminal p-hydroxybenzoyl groups. Closthioamide is growth-suppressive 
toward several human pathogens, including Staphylococcus aureus, Enterococcus 
faecalis, and Neisseria gonorrheae21,29. Replacement of the thioamides with amides 
abolished the antibacterial activity of closthioamide, indicating the importance of thioamide 
moieties in its biological activity21. 
Studies using whole cell-based assays showed that closthioamide inhibits the 
ATPase activity of DNA gyrase and topoisomerase IV, thus effectively blocking DNA 
replication30. Closthioamide also inhibits the relaxation activity of DNA gyrase, which does 
not require ATP hydrolysis and thus may allosterically, rather than directly, interfere with 
the ATPase activity of gyrase. Notably, this mode of action differs from that of the other 
DNA gyrase inhibitors such the fluoroquinolones and aminocoumarins30. The discovery of 
closthioamide from an underexplored anaerobe with a new mode of action holds promise 
that additional, novel antibiotics might be discovered by parallel methods. 
Manipulation of the regulatory elements involved in the global activation of 
secondary metabolism in R. cellulolyticum sustained the production of closthioamide and 
allowed isolation of seven congeners that showed varied levels of bioactivity31. Evaluation 
of the antibacterial activity of the congeners demonstrated the importance of all six 
thioamide moieties, terminal aromatic residues, the modular arrangement of the β-
thioalanyl units, and the distinct length of spacer units for antibacterial activity21,31. 
Moreover, it was also found that closthioamide is a selective Cu(I) chelator akin to 
methanobactin and forms a compact symmetrical dinuclear copper complex7,32. 
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Figure 1-2: Biosynthesis of Closthioamide. (A) Biosynthetic gene cluster of 
closthioamide from R. cellulolyticum DSM5812. (B). Proposed NRPS biosynthetic 
pathway for closthioamide. (PCP = peptididyl carrier protein; PHBA = p-
hydroxybenzoic acid; DAP = diamino propane; AANH = α-adenine nucleotide 
hydrolase) 
Through synthesis and application of deuterium- and fluorine-labeled probes, initial 
insights into closthioamide biosynthesis were obtained, which predicted the involvement 
of an unusual nonribosomal peptide synthetase (NRPS)17,31. A very recent study reported 
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the closthioamide biosynthetic gene cluster (BGC) in R. cellulolyticum and demonstrated 
that closthioamide biosynthesis involves a novel thiotemplated peptide assembly line that 
differs from known NRPSs26,33. Extensive genome editing and isolation of intermediates 
from the knockout mutants revealed that the closthioamide BGC consisted of genes ctaA− 
M (Figure 1-2A), and a preliminary biosynthetic pathway has been proposed (Figure 
1-2B)26. First, p-hydroxybenzoic acid (PHBA) is synthesized from chorismate by 
chorismate lyase CtaA and loaded onto a peptidyl carrier protein (PCP), either CtaE or 
CtaH34. This step is probably catalyzed by either CtaD or CtaI, as both enzymes are 
members of PCP-loading protein families (ATPgrasp and AMP-dependent ligase, 
respectively)35. The second PCP would be loaded with two molecules of β-alanine by the 
iterative action of CtaD/I, which itself could be biosynthesized from L-aspartate by the 
decarboxylase CtaF. Then, the PHBA thioester is proposed to be loaded onto this PCP-
bound β-alanyl dipeptide. CtaG, whose N-terminus is homologous to an amide synthase, 
BtrH from butirosin biosynthesis, is the likely candidate36. The resultant PCP-bound 
product would be converted to the corresponding polythioamide intermediate by CtaC, 
which is homologous to the α-adenine nucleotide hydrolase (AANH) superfamily22. Finally, 
it would be coupled to diamino propane (DAP) by the amide synthase CtaJ and thionated 
by CtaC to yield mature closthioamide26. The biosynthetic intermediate, DAP, could be 
biosynthesized from L-aspartate by the sequential action of CtaK, CtaB, and CtaF37. 
Currently, the source of sulfur is not known26. This is the first example of a thioamidated 
compound that employs a novel NRPS biosynthetic assembly line26. 
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YcaO-TfuA-dependent thioamidation. Thioviridamide (and its derivative JBIR-
140) is a RiPP natural product obtained from Streptomyces olivoviridis NA05001 that 
exhibits activity in several cancer cell lines as well as antibiotic properties38,39. 
Thioviridamide features an N-terminal pyruvyl group (although it is hypothesized to be an 
artifact from extraction40), a β-hydroxy-N1,N3-dimethylhistidinium (hdmHis) residue, and an 
S-(2-aminovinyl)-cysteine (AviCys) residue that forms part of a macrocycle (see Figure 
1-1)38,40,41. Thioviridamide also has five thioamide groups in place of backbone amide 
groups. The thioviridamide (tva) BGC was identified from S. olivoviridis and confirmed by 
heterologous production of thioviridamide in Streptomyces lividans TK2342. 
 
Figure 1-3: (A) Thioviridamide biosynthetic gene cluster from S. olivoviridis 
NA05001. (B) The core region (red) of the precursor peptide TvaA is converted to 
thioviridamide by the downstram biosynthetic enzymes. The stereochemistry has 
not yet been elucidated. 
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This demonstrated the ribosomal origin of this molecule, which is derived from a 12-amino 
acid core peptide at the C-terminus of the TvaA precursor peptide. An additional 11 
proteins encoded by this gene cluster (TvaB−TvaL) are predicted to be involved in the 
maturation of the precursor peptide into thioviridamide, although virtually nothing has been 
reported regarding the individual steps (Figure 1-3)42. Two proteins encoded by the 
thioviridamide BGC have plausible roles in thioamide synthesis. TvaH is a member of the 
YcaO superfamily43, while the second, TvaI, is annotated as a “TfuA-like” protein42. 
Biochemical characterization of YcaO family proteins illustrates that they catalyze ATP-
dependent cyclodehydration of cysteine, serine, and threonine residues to the 
corresponding thiazoline, oxazoline, and methyloxazoline, respectively (see Figure 1-4A, 
cysteine shown), in the biosynthesis of various RiPP natural products3,43.  
 
Figure 1-4: Comparison of reactions catalyzed by YcaO enzymes. (A) ATP-
dependent cyclodehydration of cysteine, serine or threonine to thiazoline or 
(methyl)oxazoline. (B) Analogous proposed mechanism for biosynthesis of 
thioamides on peptidic backbones, with an exogenous sulfide source as 
nucleophile. 
Characterized YcaOs often require a partner protein for efficient cyclodehydration44,45. 
Two types of such partner proteins have been reported so far, with one type resembling 
E1-ubiquitin activating-like enzymes and the other being termed an “ocin-ThiF”44,46 protein. 
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These partner proteins harbor N-terminal RREs47 that bind mostly the N-terminal leader 
peptide region. Once the substrate peptide is bound, the YcaO performs modifications in 
the C-terminal core region43. In contrast, two recently characterized YcaOs from 
bottromycin biosynthesis can catalyze the formation of thiazoline and macrolactamidine 
moieties in vitro in a manner independent of a partner protein43,48,49. On the basis of 
sequence similarity, the TfuA protein encoded adjacent to the YcaO in the thioviridamide 
BGC and in numerous other genomic contexts24 is predicted to assist in the thioamidation 
reaction, although this proposal awaits biochemical validation in thioviridamide 
biosynthesis. However, an exogenous source of a sulfide equivalent will be required for 
thioamide formation (Figure 1-4B). Recently, genetic deletion studies in Methanosarcina 
acetivorans corroborated by in vitro studies of thioglycine formation, a universal post-
translation modification (PTM) in MCR, provide the first evidence for this proposal24,25. 
Potential roles for TfuA include allosteric activation of the YcaO and/or delivery of sulfur 
equivalents, possibly in collaboration with sulfurtransferases. Recent genome-mining 
efforts led to the discovery of several thioviridamide-like compounds with improved 
bioactivities (Figure 1-1). Truman and co-workers reported three such analogues, 
thioalbamide (from Amycolatopsis alba DSM44262), thiostreptamide S4 (from 
Streptomyces sp. NRRL S-4), and thiostreptamide S87 (from Streptomyces sp. NRRL S-
87)40. Of these, thioalbamide possesses nanomolar antiproliferative activity with ∼6-fold 
selectivity for cancer cells40. Around the same time, the groups of Müller and Koehnke 
reported the discovery of thioholgamides A/B from Streptomyces malaysiense (Figure 
1-1)50. Thioholgamide A showed markedly increased activity compared to that of 
thioviridamide with submicromolar activity against several cancer cell lines (30 nM against 
HCT-116 cells) and a potency 10-fold higher than that of thioholgamide B50. The minimal 
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set of responsible biosynthetic genes has been identified; however, the pathways have 
not yet been biochemically evaluated50. 
 
Figure 1-5: View of the MCR active site with the thioglycine involved in several 
stabilizing interactions using the crystal structure of Methanosarcina barkeri 
(Protein Data Bank entry 1E6Y)51. 
Thioamide-Containing Protein: Methyl-Coenzyme M Reductase (MCR). MCR 
is found strictly in methanogenic (methane-producing) and methanotrophic (methane-
consuming) archaea and carries out the reversible conversion of methyl-coenzyme M 
(CoM, 2-methylmercaptoethanesulfonate) and coenzyme B (CoB, 7-thioheptanoyl-
threoninephosphate) to methane and a CoB−CoM heterodisulfide52,53. MCR plays an 
important role in the global carbon cycle by maintaining steady-state levels of atmospheric 
methane, a potent greenhouse gas54. The 300 kDa enzyme is a heterodimer of three 
subunits in an α2β2γ2 arrangement and uses a tightly bound, Ni-containing coenzyme 
F43052,55. The Ni(I) oxidation state of this porphinoid cofactor is crucial for catalysis56. 
14 
 
Notably, the α subunit of MCR (MCRα) has several unusual PTMs, including 3-
methylhistidine, S-methylcysteine, 5-methylarginine, 2-methylglutamine, didehydro-
aspartate, and thioglycine, with varying frequencies of occurrence57–59. Thioglycine is 
present in all of the methanogens analyzed thus far, and MCR is the only protein known 
to biology to bear a thioamide PTM58. Although there have been proposals for thioglycine 
in the MCR catalytic mechanism60–62, recent work has shown that it might instead play a 
structural role in properly organizing the active site24. Thauer originally proposed that 
thioglycine formation in MCR could be similar to thioviridamide biosynthesis38,58. Upon 
elucidation of the thioviridamide BGC, it was then proposed that ycaO−tfuA would be 
involved in MCR thioamidation. Bioinformatics analysis of all available methanogen 
genomes revealed the universal occurrence of ycaO with ∼90% also encoding a tfuA 
gene24. To evaluate any role in thioglycine formation, ycaO and tfuA genes were deleted 
(individually and together) in M. acetivorans24. MCRα peptide fragments from the wild-type 
and deletion strains were analyzed by mass spectrometry, and it was found that each 
variant (i.e., ΔycaO, ΔtfuA, and ΔycaO−tfuA) lacked thioglycine (at Gly465 in MCRα), 
revealing their importance in thioamide installation24. While each variant was viable, they 
were incapable of growth at higher temperatures and displayed marked growth defects 
compared to wild-type M. acetivorans24.This could be due to the increased flexibility of the 
unmodified glycine in the ΔycaO−tfuA strain, which would render the contorted 
conformation of the peptide backbone, otherwise stabilized by several interactions 
involving the thioglycine, in the Gly462−Leu469 region of MCRα considerably less stable 
(Figure 1-5)24. This genetic deletion study was further supported by in vitro thioamidation 
using purified YcaO, TfuA, ATP, and substrate peptides from M. acetivorans MCRα. The 
requisite bisulfide nucleophile was supplied chemically as sodium sulfide or produced 
enzymatically from L-cysteine and M. acetivorans IscS25. The residues encompassing 
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Gly465 that are directly engaged by YcaO were evaluated using biochemical and 
biophysical methods. Structural insights were obtained using thermophilic YcaO 
homologues from Methanopyrus kandleri and Methanocaldococcus jannaschii, which 
confirmed the ATP-binding pocket. Sequence- and structure-guided alanine scanning 
mutagenesis was performed to elucidate the role of residues involved in ATP/Mg2+ and 
possible peptide binding25. According to a mechanistic proposal supported by 
spectroscopic and isotopic labeling experiments (Figure 1-4), upon substrate binding, an 
external source of sulfide will attack the target amide bond (in this case, Gly465) 
generating a tetrahedral intermediate. The amide oxyanion will then attack the γ-
phosphate of ATP, releasing ADP and a phosphorylated thiolate intermediate. This 
thermodynamically favorable step in which ATP cleavage is coupled with C−S bond 
formation could be concerted or stepwise. Finally, the tetrahedral intermediate will 
collapse by releasing phosphate and the thioamidated peptide25. Further studies are 
needed to elucidate the substrate orientation in the active site as well as the role of TfuA, 
which is currently proposed to act as a partner to YcaO that may regulate ATP usage or 
participate in sulfur delivery in collaboration with sulfurtransferases25. 
Potential for Other Thioamide Natural Products. The discoveries of thioamide 
biosynthesis pathways and the assignments of thioamide-specific functions in 
polypeptides reveal the potential that this backbone modification might be widely used in 
nature to confer evolutionarily valuable properties that presumably cannot be attained 
through side chain modification. However, one is then left to wonder why natural 
thioamides are not more prevalent. Studies of MCR, thioviridamide-like molecules, and 
thioamidated thiopeptides have identified biosynthetic signatures of such compounds, 
which surveys predict to be considerably more numerous than currently appreciated23–25. 
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Indeed, given that a thioamide containing peptide is ∼16 Da heavier than the 
corresponding amide, the mass change can easily be misinterpreted as oxidation. This 
may explain why some thioamide-containing natural products have gone undetected, 
although thioamidation may still represent a relatively rare PTM. Bioinformatics-driven 
searches based on the presence of ycaO and tfuA genes are already aiding in the 
discovery of thioamide-containing molecules and will undoubtedly help to resolve such 
misassignments. As more thioamide-containing compounds are discovered, the ability to 
synthetically introduce thioamides will be important to define the functional role of the 
thioamide. This knowledge can be applied by exogenously introducing thioamides to 
confer new functions on peptides and proteins. 
Synthetic Thioamide in Peptides and Proteins 
Studies of the roles of natural thioamides are enhanced by the ability to site-
specifically incorporate thioamides to generate biosynthetic precursors, probe molecules, 
or natural product analogues. This is well-illustrated in the studies of closthioamide by 
Hertweck and co-workers noted above30,32. In addition to testing the activity of synthetic 
closthioamide63, they prepared closthioamide variants with some or all of the thioamides 
replaced by amides, variants that had been observed in R. cellulolyticum extracts32. Using 
these compounds, amide variants were not converted to thioamide variants, but thioamide 
variants were hydrolyzed to form the amide variants. Thus, it appeared that thioamide 
incorporation occurred during closthioamide backbone synthesis, not through downstream 
modification of amides. In the second study, the motifs that are crucial to the antibiotic 
properties of closthioamide were investigated by modulating, among other things, the 
number and position of thioamides30. Removal of even one thioamide caused a >100-fold 
decrease in potency toward methicillin-resistant S. aureus and vancomycin-resistant 
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Enterococcus faecalis. As these studies make clear, the ability to insert thioamides at 
specific locations allows one to interrogate the biosynthesis and mechanism of action of 
thioamide containing natural products. 
Chemical Synthesis of Thioamide-Containing Peptides. Site-specific 
installation of a thioamide into a peptide of interest is readily accomplished by 
incorporating a thioamide precursor during peptide synthesis rather than attempting a 
selective transformation of a specific amide bond. Various routes have been investigated, 
including activation of thioacids with phosphonium-based reagents like benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP)30 or the synthesis of 
thioacyl-benzimidazolinones64. However, these reactions suffered from low yields and 
racemization of the thioamide residue. An improved route was devised based on thioacyl-
benzotriazoles, which are sufficiently reactive that they can thioacylate amines in the 
presence of a base with no other activating reagent65. While tert-butyloxycarbonyl (Boc)- 
protected precursors were synthesized in the initial report, the methods have been shown 
to be compatible with fluorenylmethyloxycarbonyl (Fmoc)-protected amino acids66, which 
are more commonly used. These precursors have become widely used; the route to their 
synthesis and incorporation is illustrated in Figure 1-6: Site-specific incorporation of 
thioamides using solid phase peptide synthesis (SPPS). (A) Thioacyl-benzotriazole 
monomers can be synthesized in three steps from Fmoc-protected amino acids. (B) The 
thioacyl-benztriazoles can be used to introduce the thioamide during SPPS.. The 
synthesis starts with Fmoc protected amino acids, which are commercially available in 
most cases, with typical yields of 40% over the three steps. So far, thioamide versions of 
15 of the 20 common proteinogenic amino acids (Ala67, Arg68, Asp69, Cys68, Glu70, Gly68, 
Ile71, Leu72, Lys68, Phe73, Pro73, Ser68, Trp68, Tyr71, and Val74), as well as hydroxyproline71, 
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have been reported. While the aforementioned benzotriazole synthesis can be used for 
Boc- or Fmoc-based precursors, thioamides are incompatible with the harsh HF cleavage 
used in Boc-based solid phase peptide synthesis (SPPS). However, thioamides are 
compatible with the conditions and reagents used in Fmoc based SPPS, including various 
activating reagents (for the other amino acids), bases, cleavage additives, capping 
solutions, and strong acids like trifluoroacetic acid (TFA) that are used in cleavage 
reactions. Fmoc-based SPPS using thioacyl-benzotriazole building blocks has been used 
to routinely prepare thioamide-containing peptides of 20−40 amino acids on a 
multimilligram scale71,75. 
 
Figure 1-6: Site-specific incorporation of thioamides using solid phase peptide 
synthesis (SPPS). (A) Thioacyl-benzotriazole monomers can be synthesized in 
three steps from Fmoc-protected amino acids. (B) The thioacyl-benztriazoles can 
be used to introduce the thioamide during SPPS. 
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There are several side reactions that must be considered during SPPS and 
cleavage. First, prolonged exposure (>30 min) to strongly acidic conditions [95% TFA] 
typically used during peptide cleavage can lead to an Edman-degradation type reaction 
that results in backbone cleavage at the n + 1 site76. Therefore, one must limit TFA 
concentrations and deprotection times to achieve a delicate balance between full removal 
of all acid-labile side chain protecting groups while also maintaining the integrity of the 
thioamide. Second, thioamide precursors can react with residual amounts of water during 
coupling reactions, resulting in an S-to-O exchange reaction to yield the corresponding 
amide. Fortunately, the use of anhydrous methylene chloride during thioamide coupling 
can greatly reduce the level of this side reaction68. Last, thioamides can undergo 
epimerization during peptide synthesis. While there have been few studies in peptides, 
studies of model compounds consistently show that the pKa of the thioamide Cα proton is 
∼5 units lower than that of the corresponding amide, equating to a pKa of 12−13 in 
peptides. A more detailed analysis can be found in chapter 2 and elsewhere77. Therefore, 
prolonged exposure to base during Fmoc deprotection steps can lead to peptide 
epimerization. Although there have been various approaches to this problem70,77, the use 
of a 2% (v/v) solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) seems to give the best 
combination of high deprotection efficiency and minimal epimerization. This is particularly 
important for the synthesis of peptides containing multiple adjacent thioamides72,78, motifs 
found in the thioviridamide family of compounds. While alternate methods such as recently 
developed ynamide-based couplings may lead to further improvements79, with these 
considerations, the thioacyl-benzotriazoles can be used to access many thioamide 
containing peptides. 
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Uses of Synthetic Thioamide Peptides as Fluorescence Quencher Probes.  
The use of thioamides as spectroscopic labels, particularly as circular dichroism 
(CD) probes or fluorescence quenchers, has limited utility in complex biological 
environments but has been successfully been used in in vitro experiments. Thioamides 
have been employed as CD probes due to their unique signature at 270 nm80, which is 
based on their π→π* transition81. Furthermore, thioamides have been successfully used 
as fluorescence quencher probes by our lab and others. Their versatility comes from the 
ability to quench a wide range of fluorophores through two commonly employed ways of 
energy transfer: The first one is Förster Resonance Energy Transfer (FRET), a non-
radiative energy transfer mechanism that relies on spectral overlap of the fluorophore 
emission with the thioamide absorption spectrum. FRET is a distance dependent energy 
transfer mechanism and FRET pairs are in general described by the Förster radius (R0), 
which is the distance at which energy transfer is half-maximal. R0 can be calculated using 
the so called Förster equation shown in Equation 1, where κ2 is a factor to describe the 
orientation of the interacting transition dipoles of the donor and acceptor, Φ is the donor 
quantum yield, J is the spectral overlap integral, n is the refractive index and NA is 
Avogadro’s number82. 
 
Equation 1: Equation to calculate Förster distance. 
The spectral overlap integral is defined by Equation 2, where fD(λ) is the normalized 
donor emission spectrum and εA(λ) is the normalized acceptor emission spectrum. As 
evident from Equation 1 and Equation 2, there is a strong wavelength dependence on the 
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Förster distance R0, so the choice of acceptor/donor and their excitation/emission 
wavelengths influence the range in which distances can accurately be determined. 
 
Equation 2: Calculation of the spectral overlap integral J. 
The calculated R0 can be used to calculate the distance between two fluorophores 
using Equation 3.  
 
Equation 3: Linking Quenching efficiency to distance. 
For thioamides, the distance that can accurately be measured is usually in the 
range of approximately 10-30 Å83,84. For shorter distances, a different quenching 
mechanism can be exploited. Due to their lowered oxidation potential (see Table 1.1), 
thioamides are able to quench fluorescence through photoinduced electron transfer 
(PET). Compared to FRET, the distance dependence of PET quenching is more 
complicated, so PET is only able to provide rough distance information and in most cases 
van der Waals contact between the fluorophore/quencher pair is required84. Whether PET 
is able to occur or not can be rationalized by calculating the free energy transfer of electron 
transfer using the Rehm-Weller Equation show in Equation 4, where Eox(D) and Ered(A) 
are the oxidation and reduction potentials of donor and acceptor respectively, ΔG00 is the 
zero-vibrational electronic excitation energy85. The last term describes the coulombic 
attraction energy experienced by the pair post electron transfer with ε being the dielectric 
constant of the solvent and d being the distance. However, the last term is usually small 
enough to be neglected in aqueous buffers84. 
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Equation 4: Rehm-Weller Equation to calculate the free energy of electron transfer. 
 While ΔG is able to predict if an electron transfer will occur or not, the magnitude 
of ΔG is not correlated with the quenching efficiency EQ. While Marcus Theory could be 
applied to calculate the rate of electron transfer, detailed knowledge of all photophysical 
rates would be required. Therefore, currently experimental determination of EQ is the most 
straightforward way. In most cases where fluorescence quenching by thioamides was 
observed, thioamides were assumed to act as donor while the fluorophores were assumed 
to act as electron acceptor86. However, it is possible that in some cases a reversed role 
could be possible. However, electrochemical data to calculate this order of reaction is not 
yet available. 
Our group and others have exploited the use of thioamides as fluorescence 
quenchers in various ways. In an early work from our lab, thioamides have been used to 
monitor protease activity87. Substrate peptides were designed to where one terminus had 
a thioamide, while 7-methoxycoumarinylalanine was attached to the other. In the initial 
state the fluorescence is quenched. Upon cleavage of the substrate the two fragments are 
able to diffuse away from one another, resulting in an increase of fluorescence. This 
increase in fluorescence is directly correlated to protease activity and kinetic parameters 
derived from the assays agreed well with reported literature values. Furthermore, our lab 
demonstrated that this method works for a variety of different proteases, including serine-, 
cysteine-, carboxyl- and metallo-protases such as trypsin, chymotrypsin, pepsin, 
thermolysin, papain and calpain. 
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Figure 1-7: Using thioamides to monitor protease activity. Left: Reaction scheme; 
Right: Fluorescence time courses from activity assays testing various proteases. 
Green/blue trace: oxopeptide in the presence/absence of protease respectively. 
Red/Orange: thiopeptide in the presence/absence of protease respectively. 
While these results demonstrate that thioamides can be used for this application, 
questions about the influence on activity with regards to positioning the thioamide in 
reference to the scissile bond remained. Our lab has conducted follow-up experiments for 
serine- and cysteine proteases in this regard and the results will be published soon. 
Another similar utility of thioamides was demonstrated by the Vocadlo lab in their 
study of O-linked N-acetylglucosamine (O-GlcNAc) modifying enzymes. Specifically, they 
are interested in studying activity of human O-GlcNAcase (hOGA). For this purpose they 
synthesized probes where Resorufin or 4-Methylcoumarin was O-linked at the anomeric 
position of GlcNAc and a thioamide was appended to the 2’ or 4’ position88,89. The 
quenching efficiency was determined by comparing fluorescence signals of equimolar 
solutions of the probes with or without the thioamide at the 2’ position. The average 
quenching efficiency was >90% for the 4-Methylcoumarin modified GlcNAc and ~50% for 
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Resorufin modified one. Quenching efficiencies for probes with thioamides attached at the 
4’ position varied based on linked chemistry but were in the same range as for the 2’ 
attachment. All of the probes worked with hOGA and were specific. Unfortunately, all of 
the thioamide modified probes reduced the enzyme efficiency kcat/Km. Depending on the 
linker and point of attachment there was a 20-1000 -fold decrease in enzyme 
efficiency88,89. 
 
Figure 1-8: Thioamide containing probes to study O-GlcNAcase. 
While these are only two examples, they demonstrate how thioamides can be used 
to develop enzymatic turn-on probes as a mean to study enzyme kinetics. However, they 
also demonstrate that careful consideration of thioamide placement is crucial to not impact 
enzyme efficiency. 
Synthetic thioamide peptides for other uses. The prospects of using the nearly 
isosteric thioamide to intentionally modify the physical properties of the peptide backbone 
have long intrigued biochemists. As noted above, these properties can be roughly 
categorized into four categories: increased reactivity with nucleophiles, electrophiles, and 
soft metals; altered conformational properties; altered hydrogen bonding propensity; and 
altered photophysical or electrochemical properties. All of these properties have been 
exploited for various purposes. The first biochemical study of a synthetic thioamide 
containing peptide was published by Nobel laureate Vincent du Vigneaud in 197390. This 
study focused on the C-terminal amide of the cyclic 9-mer peptide hormone oxytocin. It 
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was known that the C-terminal amide was crucial for biological activity, but none of the 
previously studied analogues altered the carbonyl moiety. Thioamide substitution at this 
site reduced the biological activity to ≤6% of oxytocin in all assays tested. This study 
demonstrated that although it is nearly isosteric with an amide and retains functional 
groups capable of donating and accepting hydrogen bonds, a thioamide modification can 
have significant effects on biological signaling. Since this pioneering work, thioamides 
have been used in biophysical studies of protein folding, as spectroscopic labels, as 
probes of hydrogen bonding in protein interactions, and as synthetic intermediates in the 
synthesis of other carbonyl modifications. For example, Boger’s laboratory used 
thioamides both as synthetic tools and as probes of hydrogen bonding interactions with a 
backbone carbonyl in vancomycin8. Through the introduction of thioamides as useful 
intermediates, synthetic chemists have been able to synthesize analogues that have 
different hydrogen bonding patterns and test the derivatives with model target substrates 
to confirm the assumed mechanism of action8 and to develop more potent variants of 
vancomycin91,92. 
Another very recent example is the Ag(I) promoted macrocyclization of peptides 
using N-terminal thioamides93. The Hutton laboratory was able to demonstrate that 
protected peptides with N-terminal thioamides can be cyclized as demonstrated in Figure 
1-9. After subsequent deprotection the resulting macrocyclic peptide contains a canonical 
oxoamide. Compared to other methods, their method is fast (1 hr), high yielding (80-90% 
with >90% purity) and without epimerization. They successfully synthesized various sized 
macrocycles with 5-10 amino acids.  
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Figure 1-9: Reaction scheme conventional macrocyclization and silver(I) promoted 
thioamide macrocyclization. 
The use of thioamides as spectroscopic labels, particularly as circular dichroism 
probes or fluorescence quenchers, has limited utility in complex biological environments, 
but they have found other uses in cell-based or in vivo experiments. One photophysical 
property that has a demonstrated utility in biological systems is the ability to use 
thioamides as photoswitches. Excitation at 270 or 340 nm (π → π* or n → π* transition, 
respectively)16, allows for selective photoswitching of the thioamide between the trans and 
cis isomers. Additionally, the metastable photoinduced cis state has a slow thermal 
relaxation rate (k < 1 × 10−3 s−1)94 and can populate up to 50% of the photostationary 
state95. Two studies illustrate the use of thioamide photoswitching in biological contexts. 
Kiefhaber and Fischer investigated the enzymatic activity of ribonuclease S96. This 
cleaved enzyme requires the S-protein and complementary S-peptide for activity. 
Incorporation of a thioamide moiety into the helical S-peptide at central positions had no 
significant effect on enzyme activity as measured by hydrolysis of cytidine 2′,3′- cyclic 
monophosphate (cCMP). However, UV irradiation induced 30% isomerization of the 
peptide to the cis state, correlating with a 30% decrease in enzyme activity without 
dissociation of the protein−peptide complex. This indicated that switching the thioamide 
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into the cis state led to a conformational change that abolished enzyme activity. In another 
study, the conformation−activity relationship of a C-terminal pentapeptide activator of 
insect kinin was investigated95. NMR and molecular modeling studies were inconclusive 
as to whether a 1−4 or 2−5 β-turn was the active conformation of the peptide97. In a 
cockroach hindgut myotropic activity assay, the photoswitched thioamide peptide in the 
cis conformation had a 4-fold lower EC50 compared to that of the native peptide or trans 
thioamide peptide, confirming that a 1−4 turn was necessary for bioactivity (Figure 1-10)95. 
These examples show that thioamide photoswitching can regulate peptide activity in cell 
lysates and similar systems, providing a backbone switch with much less structural 
perturbation than an azobenzene replacement98. 
 
Figure 1-10: Controlling bioactivity through thioamide photoisomerization. (A) The 
insect kinin-derived thioamide pentapeptide can undergo UV-induced photoiso-
merization to adopt a 1-4 β-turn structure. (B) Titration of isolated cis or trans 
peptide in an ex vivo myotropic contraction assay shows a 4-fold lower EC50 for the 
cis peptide. 
The distinct properties of thioamides have also been exploited in studies involving 
proteases. Most investigations have centered on the effects of thioamides in short peptide 
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substrates of various proteases, with the intention of developing inhibitors and 
investigating the protease mechanism (e.g., favored interactions with soft metals 
substituted in the active sites of metalloproteases)99. For example, Fischer and co-workers 
investigated thioalanine-proline-p-nitroaniline (AlaS-Pro-pNA) as a substrate for dipeptidyl 
peptidase 4 (DPP-4), where the enzyme hydrolyzes the bond between Pro and pNA100. 
They found a 1100-fold decrease in kcat/Km compared to that of the amide, which they 
attributed to the decrease in kcat caused by the increased rotational barrier of the 
thioamide. Recently, these results were extended by introducing thioamide substitutions 
in glucagonlike peptide 1 (GLP-1)75, a natural substrate of DPP-4 that stimulates the 
release of insulin while suppressing glucagon release101. However, GLP-1 is rapidly 
degraded (t1/2 = 2 min) in vivo by DPP-4, which cleaves the two N-terminal amino acids 
and renders GLP-1 inactive102 (see Figure 1-11A). Injection of DPP-4- resistant GLP-1 
variants has become a common treatment for type II diabetes102. The single-atom 
thioamide substitution at either of the two terminal positions increased the peptide halflife 
in an in vitro proteolysis assay from 2 min to 12 h (Figure 1-11C). Competition experiments 
with an alternate DPP-4 substrate revealed that thioamide GLP-1 was not a competitive 
inhibitor, seemingly in conflict with the finding of a primary kcat effect. This may be due to 
the fact that the 36-residue GLP1 peptide cannot be repositioned in the active site to 
accommodate the thioamide, whereas the AlaS-Pro-pNA can but in a way that is not 
optimal for catalysis. Examination of the crystal structure of DPP-4 with a peptide 
substrate103 reveals bifurcated hydrogen bonds with the carbonyls of the two N-terminal 
amino acids (Figure 1-11B). Thioamide incorporation at either site leads to DPP-4 
resistance, a finding that can be explained on the basis of weakened hydrogen bond 
acceptance by the thioamide (although the rotational barrier may still play a role). 
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Figure 1-11: (A) Incorporation of a thioamide into Glucagon-like peptide 1 (GLP-1) 
at the X1 or X2 position prevents dipeptidyl peptidase 4 (DPP-4) degradation. (B) 
Image of the DPP-4 (cyan) active site with a modeled GLP-1 fragment (based on 
PDB entry 1R9N)103. X1 – X3 carbonyls and their interactions are highlighted. (C) In 
vitro degradation assay shows that thioamide substitution at X1 or X2 but not X3 can 
effectively prevent proteolysis by DPP-4. 
Rats injected with the thioamide-containing version of GLP1 had a significantly 
reduced blood glucose spike in an oral glucose tolerance test compared to that of rats 
injected with GLP-1 or the vehicle control, showing that DPP-4 resistance was retained in 
vivo. In cell-based receptor activation assays, thioamide GLP-1 had a comparable potency 
for cyclic AMP activation (which controls insulin release) but a substantially lower potency 
for activation of β-arrestin 1 and 2 (which has been correlated with effects of GLP-1 on 
appetite)104,105. While a detailed analysis of this bias effect was not possible at the time of 
publication of the thioamide GLP-1 study, subsequent disclosure of a cryo-electron 
microscopy structure of the GLP-1 receptor (PDB entry 6B3J) could be used as a basis 
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for modeling to explain both the signal bias and the thioamide positional effects106. These 
studies illustrate how thioamide substitution has the potential to influence interactions of 
peptides with other proteins, preventing proteolytic cleavage and eliciting subtle changes 
in receptor activation. While thioamide substitution has been used to confer protease 
resistance in several other in vivo studies107,108, we highlight the DPP-4 work because of 
the level of mechanistic understanding available. 
A recent publication by Chatterjee and co-workers nicely illustrates how the altered 
conformational properties of thioamides can be exploited in medicinal chemistry 
applications for macrocyclic peptides109. Because of their large surface area per molecular 
weight, easy variability of functional groups, and improved bioavailability compared to that 
of linear congeners, peptide macrocycles are primed to be used as protein−protein 
interaction inhibitors110. However, in spite of their cyclic constraint, macrocycles can exhibit 
significant conformational flexibility, often making them low-affinity or nonspecific binders 
in vivo. NMR experiments, including 13C spin−lattice relaxation time and temperature 
coefficient measurements, were used to show that introduction of a thioamide into a 
peptide macrocycle narrowed the breadth of the conformational ensemble, limiting the 
macrocycle to a single observable conformation. After initial investigation of model peptide 
macrocycles, the authors turned to bioactive RGD peptides. RGD peptides are known 
antagonists of proangiogenic integrins and represent attractive drug targets110 for cancer 
and other indications. Cilengitide, an N-methylated cyclic peptide that reached Phase III 
clinical trials against glioblastoma, was used as a reference for in vitro and in cellulo 
binding assays111. Some of the thioamide-containing RGD peptides bound more tightly to 
integrins than cilengitide did, and computational docking of their solution NMR structures 
aligned well to a bound cilengitide molecule in an integrin receptor cocrystal structure 
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(Figure 15)112. These docking studies allowed them to identify the basis for the increased 
affinity in the optimal thioamide RGD macrocycle as stabilization of a certain ring 
conformation. Interestingly, ex vivo metabolic stability assays in human serum over 72 h 
revealed that all tested thioamide RGD macrocycles were more stable than cilengitide, 
independent of the position of the thioamide. Like the thioamide GLP-1 molecules, these 
RGD analogues show strong prospects as injectable therapeutics or vehicles for imaging 
probes.  
 
Figure 1-12: (A) Chemical structures of RGD peptide macrocycles, including 
cilengitide and two matched amide/thioamide pairs. (B) NMR structures of the fS 
(organge), FS (cyan) peptides overlaid with structure of cilengitide bound to αvβ3 
integrin (PDB entry 1L5G)112. (C) Summary of serum stability (t1/2) and activity (IC50 
for binding to breast cancer and glioblastoma cells) 
Together, these studies show that thioamides can profoundly modulate the 
biological activity of peptides. Their unique combination of easy installation and amide 
mimicry with distinct physical properties allows targeted manipulation of various systems 
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to tune protein interactions. These provide valuable tools for basic science or translational 
research and help to shed light on the roles of thioamides in natural peptides. 
Thioprotein Semisynthesis. SPPS is largely sufficient to synthesize thioamide 
analogues of peptide hormones or natural product derivatives. However, to investigate the 
role of thioamides in proteins like MCR or to use them as probes in full-sized proteins, 
other methods are necessary. To the best of our knowledge, the longest directly 
synthesized thioamide peptide/small protein was a thioleucine-modified version of the 56-
amino acid B1 domain from protein G (GB1)71. However, the isolated yield of this GB1 
variant was very low (1%), showing the size limitations of SPPS for generating thioamide 
proteins. This problem has been rectified using native chemical ligation (NCL). NCL allows 
the ligation of two peptides or protein fragments together at low millimolar concentrations 
under neutral pH, aqueous conditions, resulting in a native amide bond113. The main 
requirement and/or limitation of this method is that proteins must be able to refold into their 
native structure after ligation in a denatured state. For this reaction to occur, the C-terminal 
fragment requires an N-terminal Cys or a β-, γ-, or δ-thiol-containing amino acid derivative, 
and the N-terminal fragment requires a C-terminal thioester. While the generation of C-
terminal peptide fragments containing thioamides is straightforward, the generation of N-
terminal fragments is complicated by the need to generate a C-terminal thioester. It was 
once speculated that ligation of thioamide-containing peptides was “not suitable because 
the presence of [thioamide] bonds is not compatible with the subsequent synthesis of the 
thioester moiety.”96. Since then, thioamides have been shown to be compatible with 
various peptide activation methods to generate C-terminal thioesters. Such methods 
include conventional solution phase PyBOP activation114 and more recent in situ 
thioesterification strategies making use of latent thioesters, such as CbPGo (N-to-S acyl 
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shift) 114,115, ChB (O-to-S acyl shift)116,117, and Nbz, which promotes thioester formation by 
activating the C-terminal carbonyl114,118. Many of these older methods suffer from low 
yields, slow reactions, or racemization. Currently, the fastest and most effective way of 
generating C-terminal thioesters in thioamide-containing peptides makes use of acyl 
hydrazide methods, for which detailed procedures are available119. The acyl hydrazide 
modification is stable to most purification conditions and latent until activation using 
sodium nitrite at pH 4.0, which converts it to an acyl azide. Readjustment of the pH to 7.0 
and addition of an aromatic thiol generates a thioester that can be immediately used in 
NCL reactions. Thioamide-containing peptides have been shown to be compatible with 
this activation reaction with no observed side reactions and have been used to generate 
proteins with thioamides near the N-terminus120. 
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Figure 1-13: Traceless ligation strategy to synthesize thioamide-containing 
proteins. (A) Thioamide-containing thioester peptides (blue) are synthesized from 
acylhydrazide precursors to generate a thioester. (B) N-terminal cysteine fragments 
(red) are synthesized or recombinantly expressed. (C) Ligation can be performed 
without special precautions for the thioamide. (D) Masking of the ligation site can 
occur through desulfurization, Met masking, homoGln masking and Lys masking. 
Another concern in the field of NCL is that the requirement for a Cys residue at the 
ligation site forces one to ligate long fragment sequences or results in semisynthetic 
proteins with non-native Cys residues included. There are two general approaches to 
circumventing this issue, and both have been demonstrated to be compatible with 
thioamides (see Figure 1-13). The first strategy involves masking the cysteine or analogue 
thereof, resulting in a mimic of another amino acid. For example, homocysteine can be 
used as a ligation handle and treated with methyl iodide after ligation to convert it to 
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methionine69. Alternatively, cysteine can be treated with alkyl halide reagents like 
iodoacetamide or 2-bromoethylamine, which converts it to thioether mimics of 
(homo)glutamine or lysine, respectively. The second strategy, radical desulfurization, 
converts cysteine to alanine and converts β-, γ-, or δ-thiol analogs of various amino acids 
to their respective canonical amino acids121. Desulfurization of thioamide-containing 
peptides using classical Raney nickel procedures results in undesired backbone cleavage 
at the thioamide position120. The more recently developed VA-044, a water-soluble diazo 
compound that acts as a radical initiator, has been shown to be compatible with backbone 
thioamides, provided that thioacetamide is used as a scavenger to suppress an S-to-O 
exchange side reaction120. With this combination of methods, thioamides can be 
incorporated into essentially any protein that is amenable to synthesis by NCL. At the 
millimolar concentrations typically used in NCL, reactions proceed in a few hours for 
ligations of short peptides and in 1−2 days for ligations with at least one large protein 
fragment (>60 residues). The limiting reagent in this process is the amount of purified 
thioamide-containing peptide, which usually is obtained in a 20−50% yield relative to 
SPPS of the corresponding all-amide peptide. 
Thioamide Effects in Full Length Proteins. With the possibility of incorporating 
thioamides as spectroscopic probes into full length proteins73, the question of their 
influence on protein stability has emerged. Because of their increased size and altered 
hydrogen bonding properties, they can stabilize or destabilize protein folds. While several 
older studies had focused on the effects of thioamide on the stability of peptide models of 
α-helical and β-sheet secondary structure67,122, two recent publications have investigated 
their effects in full-sized proteins71,123. First, Raines and co-workers investigated the 
influence of thioamides on the thermal stability of collagen model peptides and identified 
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thioamides as the first backbone modification that does not compromise the thermal 
stability of these peptides. A separate team of investigators conducted a more 
comprehensive investigation, examining thioamide substitutions in three different protein 
model systems each representing a different class of secondary structure71. Taken 
together, the two studies indicate that thioamides can have a slight stabilizing effect in α-
helices and polyproline type II (PPII) helices, if the additional steric bulk of the thiocarbonyl 
is accommodated and the thioamide acts primarily as a hydrogen bond donor. However, 
in a sterically crowded environment, thioamides can be destabilizing. All tested (internal) 
β-sheet positions, as well as some positions in a PPII helix, had a significant negative 
impact on protein stability (see Chapter 5). Destabilizing effects in α-helices, however, 
were comparatively mild, and some of the destabilizing effects in αhelices can be 
“rescued” with the incorporation of a second thioamide78. While Raines and others have 
shown that thioamides can exert stabilizing effects in model peptide systems by increasing 
the strength of n → π* interactions between i and i + 1 carbonyls, these have not obviously 
contributed to the stabilizing effects observed to date in protein systems72,124,125. However, 
many of the observed effects cannot fully be rationalized using crystal structures of the 
native proteins. Determining high-resolution structures of the thioamide proteins 
themselves will benefit the field substantially. Combining structural information with 
biophysical studies should help to provide guidelines for thioamide placement beyond 
simple rules of avoiding steric clashes of the longer thiocarbonyl and taking advantage of 
stronger thioamide hydrogen bond donation. 
Synopsis  
Thioamides are a unique modification of canonical amide bonds. Although they 
only differ by a single Oxygen to Sulfur substitution, their physicochemical properties are 
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dramatically different from regular amides. Thioamides have been observed in various 
natural products with potential therapeutic properties. Over the last few decades, synthetic 
chemists and peptide chemists have exploited the unique properties of thioamides for 
various different purposes. However, their use in proteins is still very limited. The 
Petersson laboratory has created some of the first (semi-)synthetic thioamide labeled 
proteins (thioproteins). In this thesis, I will describe my efforts towards improving various 
aspects of thioprotein semi-synthesis and characterization. First, I will demonstrate how 
optimization of thiopeptide synthesis can increase isolated yield. Next, I will show that 
moving the thioamide motif to the side-chain of certain amino acids is synthetically feasible 
and that side-chain thioamides retain their fluorescence quenching ability. Furthermore, I 
will demonstrate how traceless ligation methods can be modified to be compatible with 
thiopeptides and thioproteins. This will be followed by an analysis of thioamides in different 
secondary protein structures and the influence of thioamides on protein stability. I will then 
demonstrate a novel semi-synthetic scheme for thioproteins that allows us to obtain mg 
quantities of protein, needed for high-resolution structural analysis. I will finish by 
describing my attempt of genetically incorporating thioamides into proteins. Together, 
these studies will aid the effort of developing thioamides as a probe that cannot only be 
used in peptides, but also in proteins. 
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Chapter 2 : Improved Fmoc Deprotection Methods for the 
Synthesis of Thioamide-Containing Peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted and adapted with permission from: Szantai-Kis, D. M.; Walters, C. R; Barrett, T. 
M.; Hoang, E. M.; Petersson, E. J., Thieme Chemistry Journals Awardees – Where Are 
They Now? Improved Fmoc Deprotection Methods for the Synthesis of Thioamide-
Containing Peptides and Proteins. Synlett 2017, 28, 1789-1794. Copyright 2017 Georg 
Thieme Verlag Stuttgart New York77. 
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2.1 Introduction 
Thioamides have traditionally been incorporated using adaptations of standard 
fluorenylmethyloxycarbonyl (Fmoc)-based solid phase peptide synthesis (SPPS) 
conditions, wherein monomers are introduced as pre-activated thioacyl compounds and 
deprotections are accomplished using 20% (v/v) piperidine in dimethylformamide (DMF) 
for Fmoc deprotections. However, we observed two different side-reactions while using 
this strategy for Fmoc deprotections. One of the side-reactions is epimerization at the α-
carbon of the thioamino acid. Prolonged exposure to base during Fmoc deprotection can 
catalyze this epimerization reaction. The other undesired reaction observed during SPPS 
is the formation of a covalent adduct when incorporating Nε-thioacetyl lysine, or Lys(AcS). 
While we only observed this adduct during syntheses involving Lys(AcS), we hypothesize 
that transient formation of this adduct with backbone thioamides may also lead to S-to-O 
exchange of the thioamide in the presence of water. Both of these side-reactions are 
detrimental to the yields of our thioamide peptides, and we therefore sought to understand 
their origins and eliminate them. 
We primarily attribute epimerization at the α-carbon to the lowered pKa of the α-C-
H bond. While there have been only a limited number of measurements of the pKas of 
protons in thioamide bonds and peptides, a survey of small molecule and peptide literature 
values for N-H and α-C-H pKa values allows us to make reasonable estimates of the 
corresponding values in thioamide containing peptides (see Figure 2-1; all values in 
DMSO unless otherwise notes)126–129. In general, the α-C-H of thioamides is about 5 pH 
units lower than for the corresponding oxoamides and therefore the α-C-H pKa of 
thioamides in peptides can be estimated to be around 12-13. The pKa for the acidic form 
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of the bases used in SPPS is usually around the same value or higher, making base-
catalyzed epimerization a reasonable pathway for the observed racemization. 
While the formation of piperidine adducts during thioamide SPPS had not 
previously been reported, studies from Boger and coworkers had established the 
susceptibility of thioamides to reactions with amine nucleophiles8. Even in the absence of 
the silver catalysts used by Boger, it is not surprising that amidine adducts can form when 
using high concentrations of piperidine. 
 
Figure 2-1: Reported pKa values that allows estimation of α-C-H pKa in thioamides 
 
Previously, it was reported that lowering the concentration of piperidine and 
shortening Fmoc deprotection times to one minute resulted in less epimerization of 
thioamides70. However, since the half-life of the Fmoc group under these conditions is 20–
45 seconds, this approach significantly decreases the yield of isolated protein130. We 
sought to test alternative deprotection solutions to reduce both observed side reactions. 
Other commonly used Fmoc deprotections solutions are 50% (v/v) Morpholine in DMF 
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and 2% (v/v) 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). Unlike piperidine and 
morpholine, DBU is a non-nucleophilic base and is not able to scavenge the reactive 
dibenzofulvene group resulting from the Fmoc deprotection. Therefore, either a 
nucleophilie needs to be added as a scavenger, or reaction times must be kept short and 
the resin washed extensively after deprotection131. The non-nucleophilic nature of DBU 
also reduces its likelihood of forming amidines by reaction with thioamides.  Therefore, we 
evaluated the use of DBU for deprotection of Fmoc groups in thioamide-containing 
peptides to address both epimerization and adduct formation issues observed with 
piperidine. 
2.2 Results and Discussion 
We designed a set of model peptides containing a mixture of nonpolar (Phe and 
Ala) and polar (Lys and Glu) amino acids. For each sequence, 7-methoxycoumarin-4-
ylalanine (Mcm or μ) was installed as the first amino acid on 2-chlorotrityl resin. This 
chromophore has an absorption maximum at 325 nm and allows for facile tracking of the 
peptides by analytical HPLC. Thioamides also have a shifted absorption maximum (272 
nm) relative to oxoamides (215 nm), which can be used to characterize the thiopeptides. 
To discriminate between genuine L-thiaomino acid peptides and their D-epimers, we 
synthesized both L and D-thionitrobenzotriazolide monomers (Fmoc-alaS-NBt and Fmoc-
pheS-NBt, using the lower-case letter convention for D-amino acids) for inclusion into the 
model peptides. The retention times for the authentic D-thioamino acid peptides were used 
as standards for each of the first four sets of thiopeptides. Additionally, a separate assay 
was performed to assess how each condition affected yield. In these experiments, 7-
methoxycoumarin-4-acetic acid (Mca) was added to each peptide sample to a final 
concentration of 500 μM, representing the maximum theoretical yield of peptide in each 
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HPLC sample. The integration value of this standard peak was compared to the integration 
of the product peak in each chromatogram (at 325 nm) to calculate the yield. These 
experiments, including synthesis and characterization of peptides and small molecules 
were carried out by C. R. Walters and T. M. Barrett and a detailed description can be 
found elsewhere77. The results are summarized in Table 2.1 and show that the use of DBU 
reduced epimerization in all cases and therefore increased overall purity and yield of the 
corresponding peptide. 
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Table 2.1: Comparison of Yield and Epimerization between Peptides Synthesized 
with either DBU or Piperidinea. 
 
Peptideb Base used Epimerization 
(%) 
Purity 
(%)c 
Yield (%) 
KAFSAKµ (2-1) 
Piperidine 16.1 56.2 29.9 
DBU 5.0 61.1 35.9 
FSAKAKµ (2-2) 
Piperidine 1.0 89.0 44.3 
DBU 0.0 88.5 51.3 
FASKAKµ (2-3) 
Piperidine 3.2 68.5 44.0 
DBU 1.0 67.3 44.7 
FAESAKµ (2-4) 
Piperidine 5.6 71.5 18.2 
DBU 1.0 71.6 22.7 
CVNYSEEFVQMMTAK (2-5) 
Piperidine 49.9 8.6 n/dd 
DBU 9.3 12.3 n/dd 
CVNYEEFSVQMMTAK (2-6) 
Piperidine 28.1 25.0 n/dd 
DBU 4.5e 22.0e n/dd 
a Graph: Example chromatogram for epimer quantification and yield determination. L 
and D denote epimers respectively, # denotes KAAKµ (product of failed FS coupling), 
S denotes Mca standard used for yield quantification 
b Peptides in one-letter code. Superscript S denotes thioamino acids; µ = 7-
methoxycoumarin-4-yl-alanine 
c Purity calculations based on HPLC peak are of desired product. 
d No external standard added for yield quantification. 
e Average of two experiments. 
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We are also interested in incorporating sidechain thioamides as probes for 
fluorescence quenching studies or protein interactions and as mimics of post-translational 
modifications.  Thus, we attempted to synthesize peptide 2-8 (Figure 2-2) containing the 
sidechain thioamide Lys(AcS). However, during this synthesis, we encountered a +51 
mass product. This product was not observed while synthesizing the corresponding 
oxopeptide 2-7 (Figure 2-2), which contained Nε-acetyl-lysine, or Lys(Ac). This implied that 
the modification must have been part of the thioamide motif. To investigate this, we tested 
several different cleavage solutions to cleave the peptide from the resin (See Table 2.2). 
However, all tested cleavage conditions still resulted in the +51 mass adduct, leading us 
to believe that this side product was not formed during peptide cleavage. 
 
 
Figure 2-2: Lys(AcS)-containing peptides used to study byproduct formation under 
piperidine deprotection conditions. MALDI-TOF MS masses of 2-7, 2-8 (using DBU 
deprotection), 2-9 (byproduct of 2-8 using piperidine deprotection), and 2-10 
(byproduct of 2-8 using morpholine deprotection); Pip. = piperidine, Mor. = 
morpholine. 
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We hypothesized that the +51 mass corresponded to piperidine adduct 2-9.  As 
noted above, thioamides have been used previously to prepare amidines, as in Boger’s 
syntheses of vancomycin derivatives8. This was confirmed with several experiments.  We 
synthesized peptide 2-8 using either 50% (v/v) morpholine in DMF or 2% (v/v) DBU in 
DMF as deprotection solutions.  We observed a +53 mass when Fmoc-deprotections were 
performed with morpholine, which we believe corresponds to peptide 2-10.  No side-
product was observed in the peptide synthesized with DBU.  We also synthesized peptide 
2-11 (Figure 2-2), where Nα-Boc-Nε-thioacetyl-lysine, or Boc-Lys(AcS), was installed at the 
N-terminus of the peptide and no +51 side product was observed after cleavage (TFA only 
to cleave Boc group, no base required). 
 
Figure 2-3: Synthesis of the piperidine adduct Boc-Lys(Pip)-OH (2-14). 
 
To further verify adduct formation, we dissolved Boc-Lys(AcS) (2-13) in 50% (v/v) 
piperidine in DMF and isolated lysyl amidine (2-14) by HPLC (Figure 2-3). NMR, UV/VIS 
spectroscopy, and high-resolution mass spectrometry confirmed the identity of (2-14). 
Specifically, we observed cross peaks in a nuclear Overhauser effect spectroscopy 
(NOESY) experiment between the CH3 group on the side-chain with the piperidinyl-ring 
as well as the protons attached to the δ-Carbon of the Lys sidechain.  Additionally, we 
46 
 
observed correlations of that same methyl group with two nitrogen atoms using proton-
nitrogen heteronuclear multi-bond correlation (HMBC) spectroscopy. An illustration of the 
observed correlations is shown in Figure 2-4 (only clearly distinguishable signals shown; 
only one set off 1H-13C HMBC correlations on Boc group shown to reduce complexity).  
These amino acid and peptide studies confirm the necessity of using DBU in Fmoc-
deprotections when synthesizing Lys(AcS) containing peptides. 
 
Figure 2-4: 2D correlations from NMR experiments on Boc-Lys(Pip)-OH (2-14). 
   
2.3 Conclusion 
With the preparation of each backbone thiopeptide system, we have demonstrated 
reduction of epimerization at the thioamino acid α-carbon by performing Fmoc 
deprotection reactions with DBU in the place of piperidine. Although only four different 
amino acids were tested (AlaS, PheS, GluS, and TyrS), the positional and sequence 
variability with which this effect is demonstrated provides strong evidence that this result 
is general. Furthermore, we demonstrated that in at least one sidechain thioamide case, 
47 
 
the use of DBU as the deprotection reagent was superior to piperidine or morpholine. 
While we have not yet observed a piperidine adduct in a backbone thioamide, it may occur 
at sterically-accessible sites such as GlyS residues. Such adducts would presumably not 
be stable, but could lead to Edman-type degradation, as well as hydrolysis of the peptide 
backbone or oxoamide formation by reaction with water under the acidic resin cleavage 
conditions. All of these side reactions would be avoided by using DBU for Fmoc-
deprotections during peptide synthesis. We expect that these synthetic developments will 
help to improve the accessibility of thioamide containing peptides and proteins, further 
enabling the broad spectrum of biophysical and biochemistry experiments made possible 
by this versatile functional group. 
2.4 Materials and Methods 
General Information. Nα-Fmoc-4-cyanophenylalanine was purchased from 
PepTech (Burlington, MA, USA). Nα-Fmoc-7-methoxycoumarin-4-yl-alanine (Mcm) was 
purchased from Bachem (Basel, Switzerland). Piperidine was purchased from 
AmericanBio (Natick, MA). Triisopropylsilane (TIPS) was purchased from Santa Cruz 
Biotechnology (Dallas, TX, USA). All other Fmoc protected amino acids and peptide 
synthesis reagents were purchased from EMD Millipore (Billerica, MA, USA). All other 
reagents and solvents were purchased from Fisher Scientific (Waltham, MA, USA) or 
Sigma-Aldrich (St. Louis, MO, USA) and used without further purification unless otherwise 
specified. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, 
USA). Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on 
a Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
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mass spectrometer. UV-Vis absorption spectra were acquired on a Hewlett-Packard 
8452A diode array spectrophotometer (currently Agilent Technologies; Santa Clara, CA, 
USA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker DRX 500 
MHz instrument (Billerica, MA, USA). Matrix assisted laser desorption/ionization with time-
of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex III 
instrument. Analytical HPLC was performed on an Agilent 1100 Series HPLC system. 
Preparative HPLC was performed on a Varian Prostar HPLC system (currently Agilent 
Technologies). HPLC columns were purchased from W. R. Grace & Company (Columbia, 
MD, USA) or Phenomenex (Torrence, CA, USA). 
Synthesis of N2-(((9H-fluoren-9-yl)methoxy)carbonyl)-N6-ethanethioyl-L-
lysine (Fmoc-Lys(AcS)-OH) Synthesis based on published procedure132. Briefly, Fmoc-
Lys-OH (368 mg, 1.00 mmol, 1.0 equiv) was suspended in 2.2 mL EtOH and 2.0 mL 10% 
(w/v) Na2CO3 solution added. Ethyl-dithioacetate (126 μL, 1.10 mmol, 1.1 equiv) added 
and stirred overnight. Next day the solvent was removed in vacuo and redissolved in 10 
mL H2O. Reaction mixture was acidified with 3M HCl until solution became milky white 
(~pH 2). Aqueous phase extracted 3 times with 10 mL CHCl3 each. The combined organic 
phase was dried over Na2SO4 and the solvent was removed in vacuo. The product yielded 
as off-white foam in high yield (423 mg, 0.99 mmol, 99.3%). 1H NMR (500 MHz, 
Chloroform-d) δ 9.60 (s, 1H), 7.97 (s, 1H), 7.71 (d, J = 7.6 Hz, 2H), 7.53 (t, J = 8.1 Hz, 
2H), 7.35 (td, J = 7.5, 2.9 Hz, 2H), 7.25 (td, J = 6.5, 5.7, 3.1 Hz, 2H), 5.77 (d, J = 8.2 Hz, 
1H), 4.38 – 4.23 (m, 3H), 4.14 (t, J = 7.1 Hz, 1H), 3.60 – 3.46 (m, 2H), 2.45 (s, 3H), 1.84 
(d, J = 10.5 Hz, 1H), 1.73 – 1.52 (m, 3H), 1.46 – 1.34 (m, 2H). ESI+-HRMS: calculated for 
C23H27N2O4S+: 427.1692; found [M + H]+: 427.1705. 
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Synthesis of N2-(tert-butoxycarbonyl)-N6-ethanethioyl-L-lysine (Boc-
Lys(AcS)-OH) (2-13) Synthesis was performed the same way as for the corresponding 
Fmoc protected compound. Briefly, Boc-Lys-OH 2-12 (369 mg, 1.50 mmol, 1.0 equiv) was 
suspended in 4.4 mL EtOH and 4.0 mL 10% (w/v) Na2CO3 solution added. Ethyl-
dithioacetate (189 μL, 1.65 mmol, 1.1 equiv) added and stirred overnight. Next day the 
solvent was removed in vacuo and redissolved in 10 mL H2O. Reaction mixture was 
acidified with 3M HCl until solution became milky white (~ pH 2). Aqueous phase extracted 
3 times with 10 mL CHCl3 each. The combined organic phase was dried over Na2SO4 and 
the solvent was removed in vacuo. The product yielded as yellow foam in high yield (423 
mg, 1.39 mmol, 92.4%). 1H NMR (500 MHz, Chloroform-d) δ 10.88 (s, 1H), 8.37 (s, 1H), 
5.35 (d, J = 7.7 Hz, 1H), 4.07 (d, J = 75.4 Hz, 1H), 3.52 (s, 2H), 2.50 – 2.34 (m, 3H), 1.77 
(s, 1H), 1.69 – 1.49 (m, 3H), 1.42 – 1.23 (m, 11H). ESI+-HRMS: calculated for 
C13H25N2O4S+: 305.1535; found [M + H]+: 305.1556. 
Synthesis of Piperidine adduct (2-14) Boc-Lys(AcS)-OH 2-13 (133 mg, 0.438 
mmols) was dissolved in 2 mL of 50% (v/v) piperidine in DMF. After stirring for 5 hours, 
reaction mixture was diluted with 0.1% TFA in H2O and purified by reverse phase HPLC 
using gradient 2A on a Grace Vydac C18 Prep column with a flow rate of 15 mL/min 
(retention times for the product 2-14 and starting material 2-13 are 23.8 min and 27.8 min 
respectively). Fractions containing product 2-14 or unreacted starting material 2-13 were 
collected separately and lyophilized. After lyophilization starting material 2-13 was 
dissolved in 50% (v/v) piperidine in DMF and, after 5 hours the reaction was purified as 
before. This procedure was repeated one more time until enough product was collected 
for NMR analysis (1.90 mg, 4.05 μmols, 0.9 %). 1H NMR (500 MHz, DMSO-d6) δ 12.58 (s, 
1H), 8.68 (s, 1H), 7.05 (d, J = 7.8 Hz, 1H), 3.84 (td, J = 8.8, 4.6 Hz, 1H), 3.57 (s, 4H), 3.32 
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(s, 2H), 2.28 (s, 3H), 1.67 – 1.54 (m, 8H), 1.49 (dt, J = 13.3, 7.0 Hz, 2H), 1.37 (s, 9H), 1.36 
– 1.28 (m, 2H). 13C NMR (126 MHz, DMSO) δ 174.28, 162.44, 155.65, 78.02, 53.36(+), 
49.45(-), 46.48(-), 43.89(-), 30.38(-), 28.86(-), 28.25(+), 25.64(-), 24.74(-), 23.06(-), 
22.65(-), 14.35(+). ESI+-HRMS: calculated for C23H27N2O4S+: 356.2549; found [M+H]+: 
356.2558. Additional 2D NMR correlations shown in Figure 2-4(only clearly distinguishable 
signals shown; only one set off 1H-13C HMBC correlations on Boc group shown to reduce 
complexity). 
Synthesis of (thio)acetyl lysine containing peptides Peptides 2-7 – 2-11 were 
synthesized on 2-chlorotrityl resin (100-200 mesh, 10 μmol scale) in 3 mL fritted syringes. 
The resin was swelled in DMF for 20 minutes. All amino acids (5 equiv.) were dissolved in 
2 mL DMF along with HBTU (5 equiv.) and DIPEA (10 equiv.), except for the first amino 
acid of each peptide, for which HBTU was omitted. Amino acid couplings were carried out 
as single couplings for 30 minutes. Fmoc deprotections were carried out with either 2% 
(v/v) DBU in DMF (3 x 2 min), 20% (v/v) piperidine in DMF (2 x 10 min) or 50% (v/v) 
morpholine in DMF (2 x 10 min). After complete synthesis, the resin was washed with 
DCM and dried under vacuum before being cleaved off. The standard cleavage solution 
contained DCM/TFA/TIPS/H2O (10:8:1:1), although other cleavage conditions were tested 
as well (see Table 2.2). After cleavage for 45 minutes, the solvent was removed in vacuo. 
The crude peptide was dissolved in 1 mL of 50% (v/v) MeCN in H2O and either analyzed 
directly by MALDI-MS or purified by HPLC. 
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Table 2.2: Tested cleavage conditions with peptide 2-8. 
Entry Cleavage Condition 
1 AcOH / TFE / DCM (1:1:8) 
2 AcOH / TFE / DCM (2:2:6) 
3 0.5% (v/v) TFA in DCM 
4 1% (v/v) TFA + 5% (v/v) TIPS in DCM 
5 5% (v/v) TFA + 5% (v/v) TIPS in DCM 
AcOH = acetic acid; TFE = Trifluoroethanol; DCM = 
Dichloromethane; TFA = Trifluoroacetic acid; TIPS = 
Triisopropylsilane 
 
 
 
 
Table 2.3: HPLC purification methods and retention times. 
Peptide/Compound Gradient 
Retention 
Time 
Column 
Boc-Lys(AcS)-OH (2-13) 2A 27.8 min Vydac C18 Prep 
Boc-Lys(Pip)-OH (2-14) 2A 23.8 min Vydac C18 Prep 
F*PPK(Ac)-OH (2-7) 2B 18.9 min Vydac C18 Semiprep 
F*PPK(AcS)-OH (2-8) 2C 18.1 min Vydac C18 Semiprep 
F* = 4-Cyanophenylalanine; Lys(Pip) = Piperidine adduct 
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Table 2.4: HPLC gradients used for small molecule/peptide purification. 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
2A 0:00 5 2B 0:00 2 2C 0:00 2 
5:00 5 3:00 2 3:00 2 
10:00 20 10:00 12 10:00 18 
31:00 26 25:00 22 25:00 28 
32:00 100 28:00 100 28:00 100 
35:00 100 31:00 100 31:00 100 
37:00 5 33:00 2 33:00 2 
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
 
 
 
Table 2.5: MALDI-TOF MS Characterization of Purified Peptides. 
Peptide 
[M+H]+ 
Calculated Found 
F*PPK(Ac)-OH (2-7) 555.29 555.41 
F*PPK(AcS)-OH (2-8) 571.27 571.39 
F*PPK(Pip)-OH (2-9) 622.37 ([M]+) 622.50 ([M]+) 
F*PPK(Mor)-OH (2-10) 624.35 ([M]+) 624.69 ([M]+) 
K(AcS)PPF*-OH (2-11) 571.27 571.59 
F* = 4-Cyanophenylalanine; K(Pip) = Piperidine adduct; K(Mor) = Morpholine adduct 
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Chapter 3 : Synthesis, Characterization, and Incorporation of 
Side-chain Thioamide derivatives Thioasparagine, 
Thioglutamine, and Thioacetyl Lysine 
 
3.1 Introduction 
While substitution of amide linkages in backbones has been pursued for 
decades90, the incorporation of thioamides into side-chains of amino acids is a newer 
endeavor. Synthesis of side-chain bearing thioamides is synthetically more challenging 
and wasn’t reported until 2000133. One could exploit the natural amide-containing amino 
acids asparagine or glutamine as starting point to create side-chain thioamide versions of 
asparagine (AsnγS) or glutamine (GlnδS). Alternatively, the synthesis of Nε-thioacetyl lysine 
(Lys(AcS)) as a thioamide version of a posttranslationally modified amino acid would be 
possible132. These side-chain thioamides could be used in cases where backbone 
thioamides have been been shown to be disruptive71. 
The synthetic incorporation of Lys(AcS) into peptides using solid phase peptide 
synthesis (SPPS) and its effect on deacetylation have been described previously in the 
literature132. It has been shown that Lys(AcS) can act as non-hydrolyzable analogue of Nε-
acetyl lysine (Lys(Ac)) for Sirtuins, which represent the class III or NAD-dependent histone 
deacetylase family of proteins. The synthesis and incorporation of the other two side-chain 
thioamides is more challenging. Fmoc-protected precursors of AsnγS for SPPS have been 
synthesized previously, but not successfully incorporated into peptides133. Synthesis of 
Fmoc-protected GlnδS has been attempted but was not successful.133 
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Here we investigate whether the fluorescence quenching behavior observed in 
backbone thioamides would be similar with the side-chain thioamide Lys(AcS). 
Furthermore, we report the first successful incorporation of AsnγS into peptides and the 
first successful synthesis of Fmoc-protected precursors of GlnδS. 
3.2 Results and Discussion 
We wanted to confirm that the fluorescence quenching behavior observed in 
backbone thioamides would hold up with the side-chain thioamide Lys(AcS). We 
synthesized Fmoc-Lys(AcS)-OH as previously described132. We synthesized rigid 
polyproline ruler peptides, where Lys(AcS) was incorporated on the C-terminus and a 
fluorophore was incorporated on the N-terminus. Based on the different quenching 
mechanisms of thioamides, we chose three different fluorophores: First, we chose p-
Cyanophenylalanine (pCNF) because it has a significant spectral overlap with thioamides 
and is mostly quenched through Förster Resonance Energy Transfer (FRET), a non-
radiative form of energy transfer. Our second fluorophore of choice was Tryptophan, since 
it has some spectral overlap, but can also be quenched through photoinduced electron 
transfer (PET). Lastly, we also incorporated (7-Methoxymcoumarinyl-)2-alanine (Mcm), 
since it has no spectral overlap with thioamides and all quenching is based upon PET. 
We synthesized our peptides mostly using standard solid-phase peptide synthesis 
(SPPS) conditions. One of the crucial differences was the use of 1,8-Diazabicyclo[5.4.0]-
undec-7-ene as base during Fmoc deprotections to suppress unwanted byproducts77. For 
all peptides we synthesized a thio version, containing Lys(AcS), as well as an oxo version 
containing Lys(Ac). We measured fluorescence spectra of the various peptides and were 
able to observe distance dependent quenching (see Figure 3-1). The strongest quenching 
can be observed for Trp, which can be quenched through FRET and PET based 
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mechanisms. Closer analysis of the data along with computational modelling are currently 
underway. 
 
Figure 3-1: Fluorescence quenching by side-chain Nε-thioacetyl lysine. Top: 
Structure of polyproline rulers with various fluorophores. Bottom: Quenching 
efficiency of peptides with various fluorophores (normalized to corresponding oxo 
peptide). The number of proline residues between fluorophore and quencher are 
indicated by n. 
 Furthermore, we wanted to synthesize Fmoc-protected thioamide precursors of 
AsnγS and GlnδS. We followed the synthesis described by Findlay et al.133 to synthesize 
xanthyl protected Fmoc-AsnγS(Xan)-OH. Similar to their observation, we were not able to 
synthesize the corresponding Fmoc-GlnδS(Xan)-OH, which we attribute to decomposition 
during xanthyl protection. Unlinke Findlay et al., we were actually successful in 
incorporating AsnγS into peptides. While they were able to demonstrate that the amino acid 
was incorporated into the peptide on resin, they were unable to isolate the resin using 
standard cleavage conditions with 95% trifluoroacetic acid (TFA). We have previously 
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observed with backbone thioamides that reducing the TFA concentration to 50% or lower 
and reducing cleavage time to <1 hour can significantly increase the isolated yield of 
thioamide containing proteins. We cleaved our peptides using lower TFA concentrations 
and were able to cleave thioamide containing peptides off of resin.  
We wanted to demonstrate that these peptides are still capable of quenching 
fluorescence. We synthesized a small series of peptides similar to the ones above, where 
Cnf was the N-terminal residue and Asn or AsnγS was the C-terminal residue. The two 
residues were separated by 2, 4, or 6 Pro residues. Fluorescence measurements of 
concentration matched peptides showed that AsnγS is indeed capable of quenching 
fluorescence in a distance dependent manner that tracks well with Lys(AcS) (see Figure 
3-2). Further analysis of the data along with computational modeling are currently 
underway. 
 
Figure 3-2: Distance dependent fluorescence quenching of AsnγS is in good 
agreement with data obtained from Lys(AcS) measurements. Fluorescence 
intensity is normalized to corresponding oxo peptide. Peptides with n=3 and 5 
were not synthesized for AsnγS. The number of proline residues between 
fluorophore and quencher are indicated by n. 
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Lastly, we were wondering if Fmoc-protected GlnδS might be obtained through 
direct thionation with phosphorous pentasulfide (P4S10) of commercially available 
derivatives as this would drastically reduce the number of steps needed to synthesize 
precursors. We hypothesized that the size of the side-chain protecting group might have 
an influence of thionation as large protecting groups might sterically obstruct the thionation 
site. We set out to attempt direct thionation of five differently protected Gln derivatives. 
Small scale reactions were set up and analyzed after 20 hours. As shown in Figure 3-3, 
direct thionation was successful with all tested derivatives. While 2,4,6-trimethoxybenzyl- 
(Tmob) and 4,4'-dimethyoxybenzhydryl-protected (Mbh) Fmoc-Gln showed the highest 
rate of conversion, they also showed additional peaks that had masses corresponding to 
species with multiple thionations. Since the presence of methoxy groups is the main 
chemical difference, we hypothesize that these groups can undergo thioetherification 
upon prolonged exposure of P4S10. While the presence of the thioether should not affect 
coupling or cleavage if one were to use these compounds, careful characterization by 
NMR spectroscopy is necessary to ensure that the desired thioamide moiety is present, 
as it cannot be determined by HPLC in combination with MS. 
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Figure 3-3: Direct thionation of Fmoc-Gln with various side-chain protecting groups. 
Analytical HPLC traces shown. # indicates peak with monothionated mass. 
Abbreviations: Dmcp = Dimethylcyclopropyl; Tmob = 2,4,6-Trimethoxybenzyl; Mbh 
= 4,4'-dimethyoxybenzhydryl; Xan = Xanthyl; Trt = Trityl. 
Based on these results, we decided to proceed and set up a larger scale synthesis 
with a trityl (Trt) side-chain protecting group. We chose Trt because it had similar clean 
conversion as xanthyl- (Xan) protected Gln, but had better solubility. While the isolated 
yield was rather low, it is the first successful synthesis of a Fmoc protected precursor for 
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GlnδS. Attempts to incorporate GlnδS into peptides will be performed shortly. Furthermore, 
we are currently trying to apply the same direct thionation to Asn derivatives with various 
side-chain protecting groups. 
3.3 Conclusion 
We wanted to see if the fluorescence quenching behavior observed in backbone 
thioamides would hold up with the side-chain thioamide Lys(AcS). We were able to 
demonstrate that Lys(AcS) is indeed able to quench fluorescence of various fluorophores 
in a distance dependent manner. 
Previous attempts at precursor synthesis and peptide incorporation of AsnγS and 
GlnδS.have failed at various stages: A precursors for SPPS of AsnγS was previously 
synthesized in 4 steps, but incorporation into peptides ultimately failed, while synthesis of 
a GlnδS SPPS precursor failed. We successfully repeated the reported synthesis of the 
AsnγS precursor. We were successful in incorporating AsnγS into peptides and demonstrate 
that similar to Lys(AcS) it is able to quench Cnf fluorescence. Furthermore, we tested direct 
thionation of Gln with various side-chain protecting groups. We were able to show that all 
derivatives can get thionated. The scale-up of one of the Gln derivatives yielded the first 
isolated GlnδS precursor for SPPS. Attempts for direct thionation of Asn and incorporation 
of GlnδS into peptides are currently underway.  
3.4 Materials and Methods 
General Information. Nα-Fmoc-4-cyanophenylalanine was purchased from 
PepTech (Burlington, MA, USA). Nα-Fmoc-7-methoxycoumarin-4-yl-alanine (Mcm) was 
purchased from Bachem (Basel, Switzerland). Piperidine was purchased from 
AmericanBio (Natick, MA). Triisopropylsilane (TIPS) was purchased from Santa Cruz 
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Biotechnology (Dallas, TX, USA). Fmoc-Lys(AcS)-OH132 and Fmoc-AsnγS(Xan)-OH133 
were synthesized as previously described. was All other Fmoc protected amino acids and 
peptide synthesis reagents were purchased from EMD Millipore (Billerica, MA, USA). All 
other reagents and solvents were purchased from Fisher Scientific (Pittsburgh, PA, USA) 
or Sigma-Aldrich (St. Louis, MO, USA) and used without further purification unless 
otherwise specified. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, 
USA). Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on 
a Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
mass spectrometer. UV-Vis absorption spectra were acquired on a Hewlett-Packard 
8452A diode array spectrophotometer (currently Agilent Technologies; Santa Clara, CA, 
USA). Fluorescence data was acquired on a Photon Technologies International (PTI) 
QuantaMaster40 fluorometer (currently Horiba Scientific, Edison, NJ, USA). Nuclear 
magnetic resonance (NMR) spectra were obtained on a Bruker DRX 500 MHz instrument 
(Billerica, MA, USA). Matrix assisted laser desorption/ionization with time-of-flight detector 
(MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex III or Microflex LRF 
instrument. Reverse-phase purification of small molecules was performed on a Biotage 
Isolera System on Biotage SNAP Ultra C18 columns (Charlotte, NC, USA). Analytical 
HPLC was performed on an Agilent 1260 Infinity II series UHPLC system (Agilent, Santa 
Clara, CA, USA). Preparative HPLC was performed on an Agilent 1260 Infinity II Prep 
HPLC system. HPLC columns were purchased from Phenomenex (Torrance, CA, USA). 
HPLC columns used were Analytical (150 x 4.6 mm), Semiprep (250 x 10 mm), and Prep 
size (250 x 21.2 mm) Luna® Omega 5 µm PS C18 100 Å columns from Phenomenex. 
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Synthesis of (thio)acetyl lysine containing peptides Peptides were 
synthesized on 2-chlorotrityl resin (100-200 mesh, 10 μmol scale) in 3 mL fritted syringes. 
The resin was swelled in DMF for 20 minutes. All amino acids (5 equiv.) were dissolved in 
2 mL DMF along with HBTU (5 equiv.) and DIPEA (10 equiv.), except for the first amino 
acid of each peptide, for which HBTU was omitted, and Mcm, for which only 2 equiv. amino 
acid/HBTU and 4 equiv. DIPEA were used. Amino acid couplings were carried out as 
double couplings for 30 minutes. Fmoc deprotections were carried out with 2% (v/v) DBU 
in DMF (3 x 2 min), After complete synthesis, the resin was washed with DCM and dried 
under vacuum before being cleaved off. The standard cleavage solution contained 
DCM/TFA/TIPS/H2O (10:8:1:1). After cleavage for 45 minutes, the solvent was removed 
in vacuo. The crude peptide was dissolved in 1 mL of 50% (v/v) MeCN in H2O purified by 
HPLC. Fractions containing pure peptide were combined and lyophilized. 
Synthesis of (thio)asparagine containing peptides Peptides were synthesized 
on 2-chlorotrityl resin (100-200 mesh, 10 μmol scale) The resin was swelled in DMF for 
20 minutes. All amino acids (5 equiv.) were dissolved in 2 mL DMF along with HBTU (5 
equiv.) and DIPEA (10 equiv.), except for the first amino acid of each peptide, for which 
HBTU was omitted, and Fmoc- AsnγS(Xan)-OH, for which only 2 equiv. amino acid and 4 
equiv. DIPEA were used. Amino acid couplings were carried out as double couplings for 
30 minutes. Fmoc deprotections were carried out with 20% (v/v) Piperidine in DMF (2 x 
10 min), After complete synthesis, the resin was washed with DCM and dried under 
vacuum before being cleaved off. The cleavage solution contained 75% DCM, 10% TFA, 
5% TIPS, 5% EDT and 5% thioanisole (all percentages are v/v). After cleavage for 30 
minutes, the solvent was removed in vacuo. The crude peptide was dissolved in 1 mL of 
50% (v/v) MeCN in H2O purified by HPLC. 
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Fluorescence measurements. Peptide stocks were dissolved in 500 µL and 
dissolved in phosphate buffered saline (10 mM Na2HPO4, 150 mM NaCl, pH 7.0, sterile 
filtered) and quantified. Measurements were performed as triplicates at 10 µM 
concentration with the following settings: Cnf: excitation: 240 nm; emission: 260-400 nm; 
5 nm slit widths; Trp: excitation: 278 nm; emission: 300-450 nm; 5 nm slit widths; Mcm: 
excitation: 325 nm; emission: 340-500 nm; 5 nm slit widths. 
Small scale synthesis of Fmoc-Gln derivatives. Synthesis for all derivatives 
was performed on a 50 μmol scale. A thionation solution was prepared by suspending 
P4S10 (134 mg, 300 μmoles) and Na2CO3 (31.8 mg, 300 μmoles) in 9 mL anhydrous 
tetrahydrofuran in an oven-dried 20 mL scintillation vial. The thionation mixture was stirred 
for 1 hour at room temperature under argon atmosphere. In the meantime, reagents were 
weighed out in 1 dram vials. After the thionation mixture has stirred for 1 hour, 1.5 mL 
thionation solution (equals 1 equiv. of P4S10) was added to each vial. The solution was 
stirred for 1 minute to dissolve amino acids and a sample was taken for HPLC analysis 
(10 μL sample added to 1 mL MeOH). Reactions were blanketed with Argon before being 
closed, sealed with parafilm and stirred for 20 hours. After 20 hours, another sample was 
taken and was analyzed by HPLC and LCMS. HPLC analysis was done using 20 μL 
injections on a Luna Omega analytical column using gradient 3O. 
Synthesis of Fmoc-GlnδS(Trt)-OH.  P4S10 (233 mg, 0.5 mmoles) and Na2CO3 
(53.0 mg, 0.5 mmoles) were suspended in 10 mL anhydrous tetrahydrofuran. The solution 
was stirred under argon atmosphere for 1 hour. Fmoc-Gln(Trt)-OH (122 mg, 0.2 mmoles) 
were added and the reaction was stirred under argon atmosphere overnight. The next day 
the solvent was removed in vacuo. Crude product was redissolved in 1 mL MeOH and 
purified on Biotage system using a SNAP Ultra C18 column (12g) on a gradient from 50%-
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100% Solvent B (0.1% TFA in acetonitrile) over 20 column volumes. Fractions containing 
product were lyophilized and product yielded as white powder in low yield (22.0 mg, 35.1 
μmoles, 17.6%). 1H NMR (500 MHz, Chloroform-d) δ 7.77 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 
7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.34 – 7.29 (m, 8H), 7.29 – 7.27 (m, 2H), 7.26 (d, J 
= 2.8 Hz, 1H), 7.26 – 7.21 (m, 6H), 6.84 (s, 1H), 6.02 (d, J = 7.6 Hz, 1H), 4.57 (dd, J = 
10.6, 6.8 Hz, 1H), 4.36 (dd, J = 10.7, 7.2 Hz, 1H), 4.30 – 4.21 (m, 2H), 2.52 – 2.39 (m, 
2H), 2.22 (d, J = 15.3 Hz, 1H), 2.04 – 1.83 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 200.28, 
171.33, 156.40, 144.50, 143.90, 141.47, 128.78, 128.18, 127.89, 127.87, 127.31, 127.27, 
125.27, 120.12, 71.03, 67.31, 61.84, 47.36, 33.18, 27.30. ESI+-HRMS calculated for 
C39H35N2O4S+: 627.2318; found: [M+H]+: 627.2313. 
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Table 3.1: HPLC purification methods and retention times. 
Peptide/Compound Gradient 
Retention 
Time 
Column 
F*PPK(Ac)-OH 3A 19.0 Vydac C18 Semiprep 
F*PPPK(Ac)-OH 3A 19.2 Vydac C18 Semiprep 
F*PPPPK(Ac)-OH 3A 21.4 Vydac C18 Semiprep 
F*PPPPPK(Ac)-OH 3A 22.3 Vydac C18 Semiprep 
F*PPPPPPK(Ac)-OH 3B 16.0 Vydac C18 Semiprep 
F*PPK(AcS)-OH 3C 19.2 Vydac C18 Prep 
F*PPPK(AcS)-OH 3C 19.6 Vydac C18 Prep 
F*PPPPK(AcS)-OH 3D 18.2 Vydac C18 Prep 
F*PPPPPK(AcS)-OH 3D 18.4 Vydac C18 Prep 
F*PPPPPPK(AcS)-OH 3D 18.4 Vydac C18 Prep 
WPPK(Ac)-OH 3E 21.5 Vydac C18 Prep 
WPPPK(Ac)-OH 3F 19.6 Vydac C18 Prep 
WPPPPK(Ac)-OH 3D 17.4 Vydac C18 Prep 
WPPPPPK(Ac)-OH 3D 18.0 Vydac C18 Prep 
WPPPPPPK(Ac)-OH 3D 18.0 Vydac C18 Prep 
WPPK(AcS)-OH 3G 20.5 Vydac C18 Prep 
WPPPK(AcS)-OH 3G 20.7 Vydac C18 Prep 
WPPPPK(AcS)-OH 3G 20.4 Vydac C18 Prep 
WPPPPPK(AcS)-OH 3G 20.3 Vydac C18 Prep 
WPPPPPPK(AcS)-OH 3G 20.7 Vydac C18 Prep 
µPPK(Ac)-OH 3H 22.2 Vydac C18 Prep 
µPPPK(Ac)-OH 3H 22.3 Vydac C18 Prep 
µPPPPK(Ac)-OH 3H 25.2 Vydac C18 Prep 
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Table 3.1 continued. 
Peptide/Compound Gradient Retention Time Column 
µPPPPPK(Ac)-OH 3H 25.2 Vydac C18 Prep 
µPPPPPPK(Ac)-OH 3H 26.4 Vydac C18 Prep 
µPPK(AcS)-OH 3I 21.8 Vydac C18 Prep 
µPPPK(AcS)-OH 3I 23.0 Vydac C18 Prep 
µPPPPK(AcS)-OH 3I 22.9 Vydac C18 Prep 
µPPPPPK(AcS)-OH 3I 22.9 Vydac C18 Prep 
µPPPPPPK(AcS)-OH 3I 22.7 Vydac C18 Prep 
F*PPN-OH 3J 16.7 Vydac C18 Semiprep 
F*PPPPN-OH 3K 19.5 Vydac C18 Semiprep 
F*PPPPPPN-OH 3L 14.6 Vydac C18 Semiprep 
F*PPNγS-OH 3M 25.3 Vydac C18 Semiprep 
F*PPPPNγS-OH 3M 25.0 Vydac C18 Semiprep 
F*PPPPPPNγS-OH 3N 27.2 Vydac C18 Semiprep 
F* = 4-Cyanophenylalanine; µ = 7-Methoxycoumarin-4-yl-alanine 
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Table 3.2: Peptide Purification/Characterization Methods and Retention Times. 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
3A 0:00 2 3B 0:00 2 3C 0:00 2 
3:00 2 3:00 2 3:00 2 
10:00 12 12:00 23 10:00 18 
25:00 22 25:00 32 25:00 28 
28:00 100 28:00 100 30:00 100 
31:00 100 31:00 100 31:00 100 
33:00 2 33:00 2 33:00 2 
3D 0:00 2 3E 0:00 2 3F 0:00 2 
3:00 2 3:00 2 3:00 2 
10:00 20 10:00 15 10:00 18 
25:00 30 25:00 30 25:00 25 
30:00 100 30:00 100 30:00 100 
31:00 100 31:00 100 31:00 100 
33:00 2 33:00 2 33:00 2 
3G 0:00 2 3H 0:00 2 3I 0:00 2 
3:00 2 5:00 2 5:00 2 
10:00 20 10:00 15 10:00 22 
25:00 35 30:00 30 30:00 40 
30:00 100 32:00 100 32:00 100 
31:00 100 37:00 100 37:00 100 
33:00 2 40:00 2 40:00 2 
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Table 3.2 continued 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
3J 0:00 2 3K 0:00 2 3L 0:00 2 
3:00 2 3:00 2 3:00 2 
10:00 8 10:00 10 10:00 15 
24:00 16 24:00 16 24:00 21 
28:00 100 28:00 100 28:00 100 
31:00 100 31:00 100 31:00 100 
33:00 2 33:00 2 33:00 2 
3M 0:00 2 3N 0:00 2 3O 0:00 5 
3:00 2 3:00 2 10:00 5 
35:00 20 35:00 25 105:00 100 
36:00 100 36:00 100 110:00 100 
41:00 100 41:00 100 111:00 5 
44:00 2 44:00 2   
      
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
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Table 3.3: MALDI-TOF MS Characterization of Purified Peptides. 
Peptide 
[M+H]+ 
Calculated Found 
F*PPK(Ac)-OH 555.29 555.27 
F*PPPK(Ac)-OH 652.35 652.56 
F*PPPPK(Ac)-OH 749.41 749.56 
F*PPPPPK(Ac)-OH 846.47 846.61 
F*PPPPPPK(Ac)-OH 943.53 943.73 
F*PPK(AcS)-OH 571.35 571.38 
F*PPPK(AcS)-OH 668.41 668.45 
F*PPPPK(AcS)-OH 765.47 765.52 
F*PPPPPK(AcS)-OH 862.53 862.63 
F*PPPPPPK(AcS)-OH 959.59 959.71 
WPPK(Ac)-OH 569.31 569.60 
WPPPK(Ac)-OH 666.37 666.70 
WPPPPK(Ac)-OH 763.43 763.79 
WPPPPPK(Ac)-OH 860.49 860.88 
WPPPPPPK(Ac)-OH 957.55 957.94 
WPPK(AcS)-OH 585.37 585.51 
WPPPK(AcS)-OH 682.43 682.59 
WPPPPK(AcS)-OH 779.49 779.67 
WPPPPPK(AcS)-OH 876.55 876.73 
WPPPPPPK(AcS)-OH 973.61 973.83 
µPPK(Ac)-OH 628.30 628.93 
µPPPK(Ac)-OH 725.36 725.83 
µPPPPK(Ac)-OH 822.42 822.92 
µPPPPPK(Ac)-OH 919.48 919.81 
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Table 3.3 continued 
Peptide 
[M+H]+ 
Calculated Found 
µPPPPPPK(Ac)-OH 1,016.54 1,017.06 
µPPK(AcS)-OH 644.36 644.65 
µPPPK(AcS)-OH 741.42 741.74 
µPPPPK(AcS)-OH 838.48 838.39 
µPPPPPK(AcS)-OH 935.54 935.41 
µPPPPPPK(AcS)-OH 1,032.60 1,033.06 
F*PPN-OH 499.23 499.21 
F*PPPPN-OH 693.34 693.34 
F*PPPPPPN-OH 887.44 887.42 
F*PPNγS-OH 515.21 515.21 
F*PPPPNγS-OH 709.31 709.30 
F*PPPPPPNγS-OH 903.42 903.41 
F* = 4-Cyanophenylalanine; µ = 7-Methoxycoumarin-4-yl-alanine 
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Chapter 4 : Chemoselective Modifications for the Traceless 
Ligation of Thioamide-Containing Peptides and Proteins 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted and adapted with permission from: Wang, Y. J.; Szantai-Kis, D. M.; Petersson, 
E. J., Chemoselective modifications for the traceless ligation of thioamide-containing 
peptides and proteins. Organic & Biomolecular Chemistry 2016, 14, 6262-6269120. 
Copyright 2016 The Royal Society of Chemistry 
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4.1 Introduction 
In our previous work, we showed that thioamides can also quench the fluorescence 
of a variety of fluorophores in a distance-dependent manner. The quenching takes place 
either through a Förster resonance energy transfer (FRET) mechanism for UV range 
fluorophores83,134, or through a photoinduced electron transfer (PET) mechanism for red-
shifted fluorophores86,135. We further demonstrated the utility of various 
fluorophore/thioamide pairs in monitoring protein thermal unfolding, protein substrate 
binding and protease activities87. To apply the fluorophore/thioamide dual labeling method 
to full-length proteins, we developed a semi-synthesis strategy to incorporate thioamides 
into proteins. As a backbone modification, the thioamide functional group can only be 
installed onto small molecules through solution phase thionation, or short peptides by 
fluorenylmethyloxycarbonyl (Fmoc) based solid phase peptide synthesis (SPPS)65,68. We 
extended this synthetic approach to full-length proteins by adopting native chemical 
ligation (NCL), where a small thioamide-containing fragment was first prepared by SPPS 
and then conjugated to an expressed protein fragment. NCL, as pioneered by Kent et 
al.136,137, joins a C-terminal thioester and an N-terminal Cys through transthioesterification, 
after which an S-to-N acyl shift takes place to form a native amide bond at the junction. 
We showed that the thioamide can be placed in either the thioester or N-terminal Cys 
fragment, and successfully prepared several constructs of thioamide-labeled α-synuclein 
(αS), a 140 aa protein implicated in Parkinson’s disease69,73,114. The detailed synthetic 
methodology has also been reviewed1. We note that while an in vitro translation strategy 
incorporating a thioamide-containing dipeptide was recently demonstrated138, the NCL 
method is more general in terms of sequence and produces higher protein yields. One 
inherent limitation of the conventional NCL reactions used in our initial studies is the 
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necessity of a Cys at the ligation site. Cys is among the least abundant amino acids (2.4% 
in the human proteome139), and readily forms disulfide bonds under ambient conditions. 
For protein targets without a native Cys in their sequences (or at the desired ligation sites), 
NCL would leave an artifact of residual Cys in the ligated product, undermining the utility 
of the thioamide as a minimalist probe and introducing complications during biophysical 
studies. To circumvent the Cys limitation, various groups have developed traceless NCL 
methods by either masking or “erasing” the side chain thiol121,140. Masking techniques 
utilize alkyl halides to convert Cys into Lys/Glu/Gln analogs, or homocysteine (Hcs) into 
Met after ligation141–144. Alternatively, the side chain thiol can be “erased” by RANEY® 
nickel or radical initiated desulfurization, where either a Cys or a thiol analog of another 
amino acid is converted into the native residue (Ala in the case of Cys)145–147. Thus far, 
synthetic β- or γ-thiol analogs of 12 native amino acids have been reported148–150. The 
radical initiated method may also be extended to selenolcontaining residues such as 
selenocysteine (Sec) or β-selenophenylalanine, where the mild tris(2-
carboxyethyl)phosphine (TCEP) initiated deselenization could preserve Cys residues in 
the sequence148,151,152. Having briefly explored the compatibility of thioamides with Hcs 
masking69, we sought to further expand the scope of thioamide incorporation with the 
desulfurization/deselenization approach. 
4.2 Results and Discussion 
We started with a systematic evaluation of the compatibility of thioamides with 
various desulfurization/deselenization methods, namely TCEP assisted radical 
deselenization, 2,2′- azobis[2-(2-imidazolin-2-yl)propane] (VA-044) initiated radical 
desulfurization and RANEY® nickel desulfurization. Yanxin Wang performed all the work 
on radical deselenization and a detailed description can be found elsewhere120. We were 
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delighted to find that both the ligation and deselenization proceeded smoothly and 
chemoselectively. The positive results prompted us to further investigate selective 
desulfurization with VA-044 as radical initiator. When the Cys/thioamidecontaining model 
peptide 4-1 was treated with VA-044, the desired Ala peptide 4-2 was generated as the 
major product, which also preserved the characteristic absorption of the thioamide. In 
contrast, when the same peptide was treated with RANEY® nickel, a cleavage product 4-
1* was observed instead (see Figure 4-1). These results suggest that the radical initiated 
mechanisms are key to their thioamide compatibility. Consistent with our prior knowledge 
that a thioamide can function as an acceptor for PET (where a single electron is transferred 
from thioamide to a paired fluorophore, generating a transient thioamide radical cation in 
the process)86,135, thioamides appeared to be stable in the radical-rich environment of the 
desulfurization/deselenization mixture. On the contrary, RANEY® nickel is well-
established for its broad substrate scope where thiols, thioethers and thionoesters 
(thiocarbonyl esters) are all effectively desulfurized153; although the cleavage side reaction 
we observed in aqueous solution was somewhat different from the reductive 
desulfurization to an amine reported in organic solvent154,155, it was not surprising that this 
metal–sulfur affinity based reaction resulted in desulfurization of the thioamide. Given that 
Cys and β-thiol analogs are much easier to synthesize and handle than Sec or β-selenol 
compounds, we decided to pursue VA-044 initiated desulfurization as the primary method 
for our traceless NCL incorporation of thioamides, and reserve TCEP assisted 
deselenization for applications where additional selectivity against Cys is needed. 
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Figure 4-1: Thioamide Compatibility with different Desulfurization Methods. Top: 
reaction scheme; Bottom: HPLC chromatogram monitored at 325 nm and UV-Vis 
absorption profiles for major peak in each chromatogram. 
Selective desulfurization using thioacetamide scavenger. To further 
characterize the VA-044 initiated desulfurization reaction, we systematically varied key 
parameters to identify the optimal conditions. We found that a high TCEP concentration 
(empirically above 40 mM) was necessary to avoid disulfide bond formation, which likely 
resulted from the collisional quenching of thiol radicals and was reversed by TCEP 
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reduction. We also observed that the reaction was tolerant to a wide range of VA-044 
concentrations; above a critical amount (empirically 10 equivalents), the desulfurization 
reaction proceeded smoothly with no complications for as high as 1000 equivalents of VA-
044, which is consistent with our current understanding that VA-044 merely served as a 
radical initiator and that propagation primarily occurred via the thiol additive t-BuSH. Under 
optimal conditions, the reaction completed in less than 10 min, with no major complications 
for up to 4 h. In addition, we showed that dissolved oxygen – which may function as 
collisional radical quencher – was well-tolerated, with only minor alterations in reaction 
kinetics. Denaturants such as guanidinium (Gdn) and urea (which may become necessary 
for proteins or long peptides) were also shown to be compatible with the radical initiated 
desulfurization. When investigating the robustness of the chemoselectivity, we observed 
a small amount of desulfurization of the thioamide, resulting in the accumulation of the 
thioamide-to-oxoamide conversion side product 4-5 after prolonged treatment with VA-
044. Although 4-5 only represented a 6% side reaction after 2 h, it became significant after 
18 h (15–20% side product formation). Although the thioamide C=S bond is much stronger 
than the Cys C–S bond, increased stability of the thioamide allylic-type radical may 
contribute to its susceptibility to desulfurization. We therefore turned to thioacetamide as 
a “suicide scavenger” to prevent desulfurization of the thioamide in the peptide. When the 
model peptide 4-4′ (prime symbols denote genuine peptide standards to distinguish them 
from species identified in reactions) was treated with VA-044 in the absence of 
thioacetamide, side product 4-5 was generated at 16% by 18 h; in the presence of 
thioacetamide, 4-4′ was fully stable over the same time period. When we applied this 
additive to the Cys/thioamide peptide 4-3, the same suppression was observed, improving 
the yield of desired product 4-4 from 58% to 88% after an 18 h reaction (Figure 4-2). As a 
further validation, we demonstrated that thioacetamide was effective over a wide range of 
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concentrations as a scavenger, and that the oxygen and denaturant tolerance was 
unaltered by its addition. It is worth noting that the residual peak at 21.8 min represents a 
2–3% Cys-to-Ser conversion byproduct 4-6 (based on MALDI-TOF MS). The formation of 
the isomeric dethioamidated peptide 4-7 was not observed. These studies were carried 
out together with Yanxin Wang. 
 
Figure 4-2: Thioacetamide as Small Molecule Scavenger. Top: Reaction scheme; 
Bottom: HPLC chromatogram monitored at 325 nm, and UV-Vis absorption profiles 
for selected peaks in each chromatogram. 
One pot ligation/desulfurization. Having established a robust method for 
selective Cys desulfurization in the presence of thioamides, we next sought to apply this 
method in traceless NCL, where two peptide fragments are first joined through a Cys, 
which is subsequently “erased” to form an Ala peptide. In particular, we were interested in 
achieving one-pot ligation-desulfurization without an intermediate purification step to 
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isolate the ligated Cys product. The major hurdle was aromatic thiol additives such as 
thiophenol, which was used to accelerate the NCL reaction156, but may also function as a 
radical quencher to sequester subsequent desulfurization157. For large proteins, one may 
simply remove the residual PhSH by dialysis after ligation; for small proteins and peptides, 
however, a different strategy must be devised. Knowing that the pKa of PhSH is 6.5, we 
hypothesized that we could remove PhSH by lyophilization after NCL if the pH was kept 
sufficiently low to maintain its protonated form (vapor pressure 1.8 mBar158). In contrast, if 
the ligation mixture (at neutral or basic pH) was lyophilized directly, the majority of the 
PhSH would exist as non-volatile thiophenolate, and interfere with the desulfurization. 
Indeed, when we acidified a neutral PhSH solution to pH 1.6 and subjected it to 
lyophilization, we observed a significant reduction in residual PhSH concentration. Using 
thioester 4-8a and Cys-containing peptide 4-8b, we demonstrated that one-pot ligation-
desulfurization can be successfully performed in the presence of PhSH as an aromatic 
thiol additive, by adopting the simple procedure of acidification and lyophilization (see 
Figure 4-3). As a further validation, we compared the desulfurization product 5 to the 
authentic peptide standard 5′, and found them to be perfect matches in both mass and 
UV-Vis absorption profiles. With thioacetamide present as a scavenger, no thioamide-to-
oxoamide conversion was observed. One-pot ligation-desulfurization experiments were 
carried out together with Yanxin Wang. 
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Figure 4-3: One-Pot Ligation-Desulfurization. Top: Reaction Scheme; Bottom: HPLC 
chromatogram monitored at 325 nm, and UV-Vis absorption profiles for major peaks 
in each chromatogram. 
Desulfurization of Cys analogs. To further expand the scope of traceless NCL 
for thioamide incorporation, we also investigated the desulfurization of β-thiol amino acid 
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analogs, selective deselenization in the presence of both thioamide and Cys residues, as 
well as the incorporation of Sec into expressed proteins. Similar to the conversion of Cys 
into Ala, synthetic β- or γ-thiol analogs of other amino acids may also be used as ligation 
handles and then “erased” to form the native residues. As a proof-of-concept example, we 
performed the VA-044 initiated desulfurization reaction on Pen-containing peptide 4-9 
(Pen = penicillamine). Pen is the β-thiol analog of Val159; we chose it because its 
desulfurization involves the formation of a tertiary carbon radical close to the peptide 
backbone, and is thus the most sterically demanding of all β-thiol analogs. Upon treatment 
with VA-044 in the presence of thioacetamide, 4-9 was converted to desired 4-4 in 83% 
yield, with its thioamide intact (Figure 4-4). The reaction was somewhat slower than Cys 
desulfurization, presumably due to the steric constraints near the reaction center. The 
successful expansion of the VA-044 initiated radical desulfurization to include Pen clearly 
demonstrated the versatility of this method for thioamide incorporation, providing a 
gateway to other synthetic β- or γ-thiol analogs. 
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Figure 4-4: Desulfurization time-course of Penicillamine containing peptides. Top: 
Reaction scheme; Bottom: HPLC chromatograms monitored at 325 nm at various 
time points. 
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Synthesis of GB1 protein by ligation/desulfurization. We then applied the 
ligation–desulfurization method to the synthesis of a thioamide-containing version of the 
B1 domain of Streptococcal protein (GB1)160. GB1 is small protein, but has been studied 
extensively as a model biophysical system and has been used in protein engineering 
efforts involving both natural and unnatural amino acids161–166. Therefore, we are 
interested in synthesizing thioamide analogs of GB1 as part of a longer term effort to study 
the impact of thioamides on the folding and function of proteins. To synthesize GB1 using 
NCL and desulfurization, we chose a central Ala residue as a point of disconnection. The 
GB1 N-terminus was synthesized as an acyl hydrazide (GB11–23 LS5-N2H3, 4-10a) and 
converted to the phenyl thioester in situ using Liu’s method (GB11–23LS5-SPh, 4-10b)119,167. 
The GB1 C-terminus was synthesized by conventional SPPS with an Ala-to-Cys mutation 
at its N-terminus (GB124–56 A24C-OH, 4-11). Ligation under standard conditions lead to 
quantitative conversion to form full length GB11–56 LS5A24C- OH (4-12a), which was isolated 
by HPLC purification and desulfurized using VA-044 to give GB11–56LS5-OH (4-12b) in 71% 
yield (see Figure 4-5). 
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Figure 4-5: Synthesis of Thioamide GB1 by Ligation and Desulfurization. Top: 
reaction scheme; Bottom: HPLC chromatograms monitored at 272 nm, and MALDI-
TOF MS profiles for selected peaks in each chromatogram. 
 We note that attempts to acidify the reaction and desulfurize after lyophilizing gave 
a number of byproducts which we attribute to the reactivity of residual NaNO2 (from acyl 
hydrazide activation) in highly acidic media (see Figure 4-6). Therefore, the one pot 
lyophilization/desulfurization procedure may not be applicable to the products of ligations 
using the Liu method, and other additives such as trifluoroethanethiol should be 
considered157. 
83 
 
 
Figure 4-6: Attempted One-Pot Ligation-Desulfurization is Incompatible with 
Hydrazide Ligation Chemistry. Bottom shows HPLC chromatogram monitored at 
272 nm and MALDI-TOF MS profile of unidentified by-products after 
Acidification/Lyophilization. 
 
4.3 Conclusion 
We have devised a method for the traceless incorporation of thioamides into 
peptides and proteins using chemoselective desulfurization/deselenization in combination 
with NCL. We demonstrated that Cys can be selectively converted into Ala using VA-044 
as a radical initiator in the presence of a backbone thioamide, and that thioacetamide can 
be used as an additive to improve the robustness of this chemoselectivity. We also showed 
that by acidifying the ligation mixture, PhSH can be effectively removed by lyophilization, 
enabling one-pot ligation–desulfurization that had not previously been achieved. As a 
proof-of-concept example, we synthesized thioamidecontaining GB1 through traceless 
NCL at a Leu site. We will use the methods developed here to synthesize other thioamide 
variants of GB1 in order to better understand the impact of thioamide incorporation on this 
small, well-folded protein. We note that Liu’s acyl hydrazide method gave high yields of 
the thioester protein fragment with no degradation of the thioamide and we will explore 
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this method in the context of other thioamide ligations. To expand the scope of ligation 
sites, we also showed the selective desulfurization of β-thiol analogs using conversion of 
Pen into Val as an example, demonstrated selective deselenization in the presence of 
both Cys and a thioamide, and devised a chemoenzymatic approach to incorporate 
ligation handles other than Cys onto the N-termini of expressed proteins. With these 
methods, we are now able to perform traceless ligation at sites other than Cys for 
thioamide-containing peptides and proteins, making thioamide incorporation by semi-
synthesis fully general. 
4.4 Materials and Methods 
General Information VA-044 was purchased from Wako Pure Chemical 
Industries (Osaka, Japan). Fmoc protected amino acids and peptide synthesis reagents 
were purchased from EMD Millipore (Billerica, MA, USA). Nα-Fmoc-L-(S-Trityl)-
Penicillamine (Fmoc-Pen(Trt)-OH) was purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Nα-Fmoc-L-Thioalanine-benztriazolide (Fmoc-AlaS-Bt) was synthesized by Yanxin 
Wang. Hydrazine Hydrate solution was purchase from Oakwood Chemical (Estill, SC, 
USA). GB124-56 A24C-OH was purchased from Genscript (Piscataway, NJ, USA) and was 
supplied as lyophilized powder. Amicon Ultra centrifugal filter units (3k Da MWCO) were 
purchased from EMD Millipore. All other reagents and solvents were purchased from 
Fisher Scientific or Sigma-Aldrich unless otherwise specified. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, 
USA). Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on 
a Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
mass spectrometer. UV-Vis absorption spectra were acquired on a Hewlett-Packard 
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8452A diode array spectrophotometer (currently Agilent Technologies; Santa Clara, CA, 
USA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker DRX 500 
MHz instrument (Billerica, MA, USA). Matrix assisted laser desorption/ionization with time-
of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex III 
instrument. Analytical HPLC was performed on an Agilent 1100 Series HPLC system. 
Preparative HPLC was performed on a Varian Prostar HPLC system (currently Agilent 
Technologies). HPLC columns were purchased from W. R. Grace & Company (Columbia, 
MD, USA). 
Nα-Fmoc-L-Thioleucine-nitrobenztriazolide (Fmoc-LeuS-Nbt) synthesis: 
 
Figure 4-7: Synthesis of Nα-Fmoc-L-Thioleucine-nitrobenztriazolide: (i) NMM, IBCF, 
4-nitrobenzene-1,2-diamine, THF; (ii) P4S10, Na2CO3, THF; (iii) NaNO2, 95% AcOH(aq). 
Nα-Fmoc-L-Leucine-2-amino-5nitroanilide (4-13a): Fmoc-Leu-OH (2.82g, 8.0 
mmoles) were dissolved in 70 mL anhydrous THF. N-methylmorpholine (1.76 mL, 16.0 
mmoles) was added and the reaction was cooled to -10°C while the flask was purged with 
Argon. Isobutylchloroformate (1.04 mL, 8.00 mmoles) were added dropwise under stirring. 
Upon complete addition the reaction mixture was stirred for 15 min at -10°C and 4-
nitrobenzene-1,2-diamine (1.22 g, 8.00 mmoles) was added. The reaction was stirred 
under Argon for 2 hours at -10°C, then at room temperature overnight. After removing the 
solvent in vacuo, the residue was dissolved in 50 mL DMF. Upon addition of 250 mL sat. 
aqueous KCl solution and 250 mL Milli-Q water, a yellow solid precipitated. The solid was 
filtered, washed with Milli-Q water and dried under vacuum. The title compound was 
isolated in quantitative yield and 94.9% purity, as determined by HPLC. 
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1H NMR (500 MHz, DMSO-d6) δ 9.57 (s, 1H), 8.24 (d, J = 2.2 Hz, 1H), 7.91 – 7.84 
(m, 3H), 7.79 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, 
J = 7.5 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.56 (s, 2H), 4.37 – 4.21 (m, 3H), 1.76 – 1.65 (m, 
1H), 1.67 – 1.56 (m, 1H), 0.95 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.5 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ 172.13, 156.22, 149.19, 143.85, 143.73, 140.70, 
135.45, 127.61, 127.03, 125.31, 122.97, 121.54, 121.29, 120.07, 113.67, 65.68, 53.73, 
46.69, 40.25, 24.33, 23.03, 21.56. 
HRMS (ESI): [M+H]+ calc.: 489.2138, obs.: 489.2148 
Nα-Fmoc-L-Thioleucine-2-amino-5nitroanilide (4-13b): Anhydrous Na2CO3 
(334 mg, 3.15 mmoles) and P4S10 (1.40 g, 3.15 mmoles) were suspended in anhydrous 
THF in an oven-dried round bottom flask and stirred under Argon atmosphere for 30 
minutes until solution became clear. Compound 4-13a (2.05 g, 4.20 mmoles) added and 
reaction stirred over night at room temperature under Argon atmosphere. The next day 
the solution was removed in vacuo. The resulting residue was resuspended in EtOAc and 
filtered over a pad of Celite to remove insoluble P4S10 adducts. The filtrate was washed 
twice with 5% NaHCO3 and once with brine. The aqueous layer was backextracted with 
once with EtOAc. The combined organic layers were dried over MgSO4, filtered and the 
solvent was removed in vacuo. The crude product was redissolved in CH2Cl2 and purified 
over silica to afford pure product as a yellow solid in 68.4% yield. Rf = 0.5 in 
EtOAc/Hexanes (1:1) 
1H NMR (500 MHz, Chloroform-d) δ 9.65 (s, 1H), 7.99 (s, 1H), 7.92 (dd, J = 9.0, 
2.6 Hz, 1H), 7.72 (t, J = 6.9 Hz, 2H), 7.48 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 
7.40 – 7.30 (m, 2H), 7.29 – 7.18 (m, 2H), 6.56 (d, J = 9.0 Hz, 1H), 5.69 (d, J = 7.5 Hz, 1H), 
4.66 (d, J = 8.5 Hz, 1H), 4.61 (s, 2H), 4.26 (d, J = 7.3 Hz, 2H), 4.11 (t, J = 7.2 Hz, 1H), 
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1.87 – 1.80 (m, 1H), 1.79 – 1.72 (m, 2H), 0.99 (t, J = 6.0 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 206.93, 157.20, 148.61, 143.37, 143.28, 141.29, 141.23, 138.18, 128.00, 
127.93, 127.36, 127.22, 125.57, 124.92, 124.85, 122.27, 120.20, 120.14, 115.17, 67.57, 
60.45, 46.92, 44.28, 25.05, 22.80, 22.27. HRMS (ESI): [M+H]+ calc.: 505.1910, obs.: 
505.1916 
Nα-Fmoc-L-Thioleucine-nitrobenztriazolide (4-13c): Compound 4-13b (1.46 g, 
2.89 mmoles) were dissolved in 25 mL of 95% glacial acetic acid(aq). The solution got 
cooled to 0°C and NaNO2 (299 mg, 4.34 mmoles) were added slowly. Upon complete 
addition, the reaction mixture was stirred for 30 min at 0°C, after which 125 mL of cold 
Milli-Q water was added. The precipitating orange solid was filtered, washed with cold 
Milli-Q water and dried in vacuo. The resulting crude product was afforded in 85.9% yield. 
The product can be used crude or purified on a silica column to afford pure product. Rf = 
0.17 in CH2Cl2. 
1H NMR (500 MHz, Chloroform-d, major rotomer only) δ 9.66 (s, 1H), 8.44 (dd, J 
= 8.9, 2.1 Hz, 1H), 8.31 (d, J = 8.9 Hz, 1H), 7.82 – 7.71 (m, 2H), 7.61 (d, J = 7.5 Hz, 2H), 
7.40 (t, J = 5.6 Hz, 2H), 7.32 (q, J = 7.2 Hz, 2H), 6.37 – 6.24 (m, 1H), 5.63 (d, J = 9.6 Hz, 
1H), 4.54 (dd, J = 10.8, 6.7 Hz, 1H), 4.40 (dd, J = 10.9, 6.9 Hz, 1H), 4.22 (t, J = 6.8 Hz, 
1H), 1.96 – 1.86 (m, 1H), 1.86 – 1.65 (m, 2H), 1.26 (s, 2H), 1.13 (d, J = 6.4 Hz, 3H), 0.97 
(d, J = 6.6 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 210.70, 156.05, 149.70, 149.14, 143.74, 
141.48, 132.04, 127.87, 127.20, 125.19, 125.09, 122.31, 121.61, 120.13, 112.94, 67.06, 
47.40, 46.05, 25.87, 23.45, 21.45. HRMS (ESI): [M+Na]+ calc.: 538.1525, obs.: 538.1535 
Synthesis and Purification of model peptides Peptides were synthesized using 
standard Fmoc solid phase peptide synthesis (SPPS) procedure on either Rink Amide or 
2-chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). For coupling, 5 
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equiv of amino acid and 5 equiv of HBTU were dissolved in dimethylformamide (DMF), 
pre-activated for 1 min in the presence of 10 equiv of N,N-diisopropylethylamine (DIPEA), 
and then stirred with the resin for 30 min at room temperature. For deprotection, 20% 
piperidine in DMF was stirred with the resin for 20 min. Thioalanine (denoted AlaS or AS) 
was introduced through activated benzotriazole precursors (S4); 2 equiv of the precursor 
was dissolved in anhydrous CH2Cl2, and stirred with the resin for 45 min in the presence 
of 2 equiv DIPEA. For N-terminally acetylated peptides, an acetylation cocktail of 1:1:8 
acetic anhydride/N-methylmorpholine/DMF was stirred with the resin twice, each for 10 
min, after the last deprotection. Upon completion of SPPS, resins were rinsed thoroughly 
with CH2Cl2 and dried under vacuum. 
For cleavage, resins were treated with a cleavage cocktail (12:1:1:26 trifluoroacetic 
acid/triisopropylsilane/H2O/CH2Cl2) for 30 min. The solution was then collected by 
filtration, and dried by rotary evaporation. For purification, the crude residues were brought 
up in 1:10 MeCN/H2O, and then purified by reverse phase HPLC with acidified (with 0.1% 
trifluoroacetic acid) MeCN/H2O gradients. Individual fractions were characterized by 
MALDI-TOF MS, and dried by lyophilization. 
Synthesis and Purification of GB11-23 LeuS5-N2H3 (4-10a) Hydrazide resin for 
peptide synthesis was prepared according to Liu and coworkers119. For coupling, 5 equiv 
of amino acid and 5 equiv of HBTU were dissolved in DMF, pre-activated for 1 min in the 
presence of 10 equiv of DIPEA, and then stirred with the resin for 30 min at room 
temperature. For deprotection, 2% (v/v) 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) in 
DMF was stirred with the resin three times for 2 min each. Thioleucine (denoted LeuS or 
LS) was introduced through activated nitrobenztriazole precursor; 2 equiv of the precursor 
was dissolved in anhydrous CH2Cl2, and stirred with the resin for 45 min in the presence 
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of 2 eq DIPEA. Upon completion of SPPS, resin was rinsed thoroughly with CH2Cl2 and 
dried under vacuum. For cleavage, resin was treated with a cleavage cocktail (6:1:1:12 
trifluoroacetic acid/triisopropylsilane/H2O/CH2Cl2) for 30 min. The solution was then 
collected by filtration, and dried by rotary evaporation. For purification, the crude residues 
were brought up in 1:1 MeCN/H2O, diluted with H2O, and then purified by reverse phase 
HPLC using gradient 4G. Individual fractions were characterized by MALDI-TOF MS, and 
dried by lyophilization. 
Purification of GB124-56 A24C-OH (4-11) Crude peptide was purchased from 
Genscript and received as a lyophilized white powder. Crude product was dissolved in 1:1 
MeCN/H2O and purified by reverse phase HPLC using gradient 4H. Individual fractions 
were characterized by MALDI-TOF MS, and dried by lyophilization. 
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Table 4.1: Peptide Purification Methods and Retention Times. 
Peptide/Compound Gradient Retention Time Column 
Ac-LASAKAGCAKµAG-NH2 (4-1) 4A 23.1 min Vydac C18 Semiprep 
Ac-LASAKAGAAKµAG-NH2 (4-2) 4A 22.3 min Vydac C18 Semiprep 
Ac-µTTEAVDACTASAK-NH2 (4-3) 4B 16.0 min Vydac C18 Semiprep 
Ac-µTTEAVDAATASAK-NH2 (4-4) 4C 21.6 min Vydac C18 Semiprep 
Ac-µTTEAVDAATAAK-NH2 (4-5) 4C 19.9 min Vydac C18 Semiprep 
Ac-µTTEAVDASTASAK-NH2 (4-6) 4C 19.7 min Vydac C18 Semiprep 
Ac-µTTEAVDACTAAK-NH2 (4-7) 4C 21.2 min Vydac C18 Semiprep 
Ac-µTTEAVDA-SC2H4COOCH3 
(4-8a) 4D 17.6 min 
YMC-Pack Pro C8 
Semiprep 
CTASAK-NH2 (4-8b) 4E 12.8 min Vydac C18 Semiprep 
Ac-µTTEAVDAψTASAK-NH2 (4-9) 4F 34.6 min Vydac C18 Prep 
GB11-23 LS5-N2H3 (4-10a) 4G 21.9 min Vydac C18 Prep 
GB124-56 A24C-OH (4-11) 4H 22.3 min Vydac C18 Prep 
GB1 LS5 (4-12b) 4I 21.3 min Vydac C18 Semiprep 
µ = 7-methoxycoumarinylalanine; ψ = penicillamine 
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Table 4.2: HPLC Gradients for Peptide Purification and Characterization. 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
4A 0:00 2 4B 0:00 2 4C 0:00 2 
5:00 2 5:00 2 5:00 2 
10:00 15 10:00 25 10:00 20 
25:00 30 25:00 40 25:00 35 
30:00 100 30:00 100 30:00 100 
35:00 100 35:00 100 35:00 100 
40:00 2 40:00 2 40:00 2 
4D 0:00 2 4E 0:00 2 4F 0:00 5 
5:00 2 5:00 2 5:00 5 
10:00 25 10:00 10 15:00 22 
30:00 45 20:00 20 45:00 28 
35:00 100 25:00 100 50:00 100 
40:00 100 30:00 100 55:00 100 
45:00 2 35:00 2 60:00 5 
4G 0:00 5 4H 0:00 2 4I 0:00 2 
5:00 5 5:00 2 10:00 2 
10:00 20 10:00 23 15:00 30 
25:00 30 45:00 35 35:00 50 
27:00 100 48:00 35 37:00 50 
30:00 100 50:00 100 39:00 100 
32:00 5 53:00 100 43:00 100 
  55:00 2 45:00 2 
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Table 4.2 continued. 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
4J 0:00 2 4K 0:00 2 4L 0:00 2 
5:00 2 8:00 2 15:00 2 
10:00 20 10:00 10 20:00 20 
25:00 50 30:00 50 50:00 50 
30:00 100 35:00 100 55:00 100 
35:00 100 40:00 100 60:00 100 
40:00 2 45:00 2 65:00 2 
4M 0:00 2       
5:00 2     
10:00 25     
40:00 40     
45:00 100     
50:00 100     
55:00 2     
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
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Table 4.3: MALDI-TOF MS Characterization of Peptides. 
Peptide 
[M+H]+ 
Calculated Found 
Ac-LASAKAGCAKµAG-NH2 (4-1) 1262.59 1262.63 
AKAGAAKµAG-NH2 (4-1*) 988.53 988.46 
Ac-LASAKAGAAKµAG-NH2 (4-2) 1230.62 1230.78 
Ac-µTTEAVDACTASAK-NH2 (4-3) 1482.62 1482.42 
Ac-µTTEAVDACStBuTASAK-NH2 (4-3b) 1570.65 1570.74 
Ac-µTTEAVDAATASAK-NH2 (4-4) 1450.64 1450.80 
Ac-µTTEAVDAATAAK-NH2 (4-5) 1434.67 1434.81 
Ac-µTTEAVDASTASAK-NH2 (4-6) 1466.64 1466.74 
Ac-µTTEAVDACTAAK-NH2 (4-7) 1466.64 1466.80 
Ac-µTTEAVDA-SC2H4COOCH3 (4-8a) 1117.40 ([M+Na]+) 1117.45 ([M+Na]+) 
CTASAK-NH2 (4-8b) 508.23 508.37 
Ac-µTTEAVDAψTASAK-NH2 (4-9) 1482.62 1482.56 
GB11-23 LS5-N2H3 (4-10a) 2512.89 2512.25 
GB11-23 LS5-SPh (4-10b) 2591.01 2591.31 
GB124-56 A24C-OH (4-11) 3749.01 3748.85 
GB1 LS5A24C-OH (4-12a) 6228.84 6229.73 
GB1 LS5 (4-12b) 6196.78 6196.39 
µ = 7-methoxycoumarinylalanine; ψ = penicillamine 
 
 
Desulfurization for Thioamide Compatibility Studies    Initial compatibility 
studies for desulfurization of thioamide containing peptides were carried out by Yanxin 
Wang with Peptide 4-1 (10 nmol, ε325 = 12,000 M-1 cm-1). Peptides were either desulfurized 
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by using VA-044 or RANEY-Nickel and results were analyzed by analytical RP-HPLC on 
a Luna C8 analytical column using gradient 4J. A more detailed description can be found 
elsewhere120. 
VA-044 Desulfurization for Condition Optimization    Yanxin Wang performed 
condition optimization for VA-044 based desulfurization with regards to TCEP 
concentration, VA-044 concentration, oxygen tolerance, denaturant tolerance and side-
reaction suppression. A detailed description of the experiments can be found 
elsewhere120. Peptide 4-3 (10 nmol, ε325 = 12,000 M-1 cm-1) was used for all optimizations 
and reactions were analyzed by reverse phase HPLC on a Luna C8 analytical column 
using gradient 4K. Fractions were collected, and then analyzed by MALDI-TOF MS and 
UV-Vis absorption spectroscopy. Yield was quantified by integrating peak areas in the 
HPLC chromatograms. The optimized standard condition is as follows: Peptide 4-3 was 
dissolved in 80 µL of argon-purged 1.25x buffer stock (50 mM TCEP, 125 mM 
thioacetamide, 125 mM Na2HPO4, pH 7.0). 10 µL of t-BuSH was added, followed by 10 
µL of freshly prepared 10x VA-044 stock (100 mM in argon-purged water). The reaction 
was allowed to proceed at 37 °C under argon atmosphere. Upon completion the reaction 
was quickly quenched by chilling to 0 °C on ice. Excess t-BuSH was removed by a stream 
of argon, and then the crude mixture was diluted into H2O for HPLC analysis or purification. 
Desulfurization of Pen/Thioamide-Containing Peptide. Reaction was 
conducted using standard desulfurization procedure with thioacetamide. Briefly, Peptide 
4-9 (10 nmol, ε325 = 12,000 M-1 cm-1) was dissolved in 80 µL of argon-purged 1.25x buffer 
stock (50 mM TCEP, 125 mM thioacetamide, 125 mM Na2HPO4, pH 7.0). 10 µL of t-BuSH 
was added, followed by 10 µL of freshly prepared 10x VA-044 stock (100 mM in argon-
purged water). The reaction was allowed to proceed at 37 °C for 10-60 min under argon 
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atmosphere. Upon completion the reaction was quickly quenched by chilling to 0 °C on 
ice. Excess t-BuSH was removed by a stream of argon, and then the crude mixture was 
diluted into H2O and analyzed by reverse phase HPLC on a Luna C8 analytical column 
using gradient 4M, and characterized by MALDI-TOF MS. After 60 minutes the reaction 
was complete as shown in Figure 4-4. 
Native Chemical Ligation to obtain GB1 LS5 A24C-OH (4-12a). GB124-56 A24C-OH 
(4-11) and GB11-23 LS5-N2H3 (4-10a) were aliquoted in 50 nmol aliquots using ε280 = 8,480 
M-1 cm-1 and ε274 = 11,569 M-1 cm-1, the sum of contributions from the thioamide (ε274 = 
10,169 M-1 cm-1) and tyrosine (ε274 = 1,400 M-1 cm-1), respectively. Activation buffer (200 
mM Na2HPO4, 6 M GnHCl, pH 3.0) and ligation buffer (200 mM Na2HPO4, 6 M GnHCl, pH 
7.0) were degassed by purging with argon for 15 min. C-terminal fragment 4-11 was 
dissolved in 48 µL ligation buffer and 2 µL thiophenol added. N-terminal hydrazide peptide 
4-10a was dissolved in 45 µL activation buffer and stirred at -15°C for 5 min. 5 μL of a 0.5 
M NaNO2 solution in activation buffer was added and stirred at -5°C. After 15 min reaction 
allowed to warm to room temperature for 1 min, C-terminal peptide added and pH was 
adjusted to 7.0. Reaction was stirred overnight at room temperature for 19 h. Analytical 
HPLC runs were performed on a Luna C8 column using gradient 4L. 
Desulfurization to obtain GB1 LS5–OH (4-12b). To the crude ligation reaction, 
400 μL degased desulfurization buffer (200 mM Na2HPO4, 6 M GnHCl, 500 mM TCEP, 
250 mM Thioacetamide, pH 7.0) were added and spin-concentrated to about 80 μL using 
a Millipore Amincon Ultracel 3K Spin Filter Unit at 13.2k rpm for 60 min at 4°C. This 
procedure was repeated one more time. To 80 µL of buffer exchanged ligation product 4-
12a, 10 µL t-BuSH and 10 µL of a 0.5 M VA-044 solution in desulfurization buffer were 
added. The reaction was allowed to proceed at 37°C and was monitored by MALDI-TOF 
96 
 
MS (Table 4-3), since the desulfurized product 4-12b has the same retention time as 4-
12a. After 23 h the reaction was complete, and the crude reaction mixture was diluted to 
3 mL with 0.1% TFA in H2O and purified by reverse phase HPLC using gradient 4I. 
Analytical HPLC runs were performed on a Luna C8 column using gradient 14. The 
product yield (71%) was determined from UV/Vis spectra of isolated products using ε274 = 
19,736 M-1 cm-1, the sum of contributions from the thioamide (ε274 = 10,169 M-1 cm-1), 
tryptophan (ε274 = 5,357 M-1 cm-1), tyrosine (ε274 = 1,400 M-1 cm-1) and phenylalanine (ε274 
= 5 M-1 cm-1). 
GB1 Sequences 
Full Length Thioamide GB1 (GB11-56 LS5-OH, 4-12b) 
DTYKLSILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
TFTVTE-OH 
Thioamide GB1 N-Terminus Hydrazide (GB11-23 LS5-N2H3, 4-10a) 
DTYKLSILNGK TLKGETTTEA VDA-N2H3 
Thioamide GB1 N-Terminus Thioester (GB11-23 LS5-SPh, 4-10b) 
DTYKLSILNGK TLKGETTTEA VDA-SPh 
GB1 C-Terminus (GB124-56 A24C-OH, 4-11) 
CTAEKVFKQY ANDNGVDGEW TYDDATKTFT VTE-OH 
Full Length Thioamide GB1 Cys24 (GB1 LS5A24C-OH, 4-12a) 
DTYKLSILNGK TLKGETTTEA VDACTAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE-OH 
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Chapter 5 : The Effects of Thioamide Backbone Substitution on 
Protein Stability 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted and adapted with permission from: Walters, C. R.; Szantai-Kis, D. M.; 
Zhang, Y.; Reinert, Z. E.; Horne, W. S.; Chenoweth, D. M.; Petersson, E. J., The effects 
of thioamide backbone substitution on protein stability: a study in α-helical, β-sheet, and 
polyproline II helical contexts. Chemical Science 2017, 8, 2868-287771. Copyright 2017 
The Royal Society of Chemistry  
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5.1 Introduction 
The incorporation of functional molecules for monitoring and manipulating protein 
folding has greatly facilitated studies of biochemical phenomena168. The optimal choice of 
modification to a protein of interest depends on the type of process to be tracked, 
disrupted, strengthened, or isolated. Recently, there has been an emerging interest in 
making subtle alterations to the protein backbone to provide additional means to probe 
and mimic dynamic protein movements and interactions165,169–172. In particular, substituting 
a thioamide peptide linkage at single or multiple positions provides a small but powerful 
means to influence and/or monitor protein dynamics or function. 
Thioamides (a.k.a. thionoamides, thioxoamides) have distinct properties from 
oxoamides, including a larger van der Waals radius, red shifted π → π* and n → π* 
transitions, lower oxidation potential, lower infrared (IR) stretching frequency and lower 
N–H pKa10,11,18,173,174. These properties have allowed thioamides to be leveraged as 
photoswitches, Förster resonance energy transfer (FRET) acceptors, and photoinduced 
electron transfer quenchers, as well as IR and circular dichroism (CD) spectroscopic 
probes in biochemical systems66,67,80,83,86,96,134,175,176. Although thioamides have already 
proven to be valuable multifaceted probes, few studies have sought to elucidate the 
energetic impacts they have on peptide or protein folding. This consideration is of the 
utmost importance in assessing the thioamide's potential as a “minimalist” spectroscopic 
label. 
Previous structural studies of thioamide substitutions largely relied upon short, 
isolated protein motifs in the absence of a tertiary structure context. In fact, when we began 
this work, there were no published studies of thioamides in proteins of defined tertiary 
structure. Fischer, Kiefhaber, and coworkers provided the most complete study of the 
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effects of thioamides in α-helices, using model helical polyalanine peptides bearing 
thioalanine (AlaS) substitutions96. Their analysis revealed that the thioamide disrupts the 
helix if substituted at a central position, but is less destabilizing at the N-terminus. Their 
results suggest that the thioamide is similar to a glycine substitution at the same position 
in terms of helix disruption. Thioamides have also been incorporated into the 15-mer S 
peptide, which forms an α-helix upon binding to ribonuclease S122. Substitutions were 
made throughout the helix and were destabilizing at every position, with varying ΔΔG 
values in comparison to the WT complex (0.6–4.7 kcal mol-1). However, in a different 
study, Miwa and coworkers observed that a LeuS substitution in the central region of an α-
helical coiled-coil dimer gave a similarly helical structure to the oxoamide counterpart (as 
observed by CD) and increased the melting temperature by 10°C80. This discrepancy, 
which likely arises from subtle geometric differences between an isolated α-helix and that 
in a coiled coil177, implies that tertiary structure may serve to lessen or even reverse 
destabilization by a thioamide. 
In an alternate secondary structure context, the thioamide was found to be 
tolerated between residues i + 2 and i + 3 in a type II’ β-turn66. Here, the thiocarbonyl is 
solvent-exposed, and the interior of the turn does not require any reorganization to 
accommodate the larger sulfur atom. Thioamide substitutions have been made in a 
tryptophan-rich β-hairpin to interrogate the role of hydrogen bond formation in the folding 
transition state67. However, the results of this study may not be general to all β-sheets due 
to the highly engineered sequence of the tryptophan zipper peptide. Most recently, Raines 
and coworkers made thioamide substitutions in collagen model peptides (CMPs) to assess 
their impact in the Pro-Pro-Gly (PPG) repeats of an all PPG polyproline type II (PPII) 
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helix123. It was found that incorporation of GlyS (i.e., PPGS) was significantly destabilizing, 
whereas substitution with ProS (i.e., PPSG) was slightly stabilizing to the triple helix. 
Taken together, the above studies present a limited understanding about where 
thioamides can be utilized most efficiently in biological systems. Thioamides are likely to 
have much more nuanced effects in proteins with complex tertiary folds and dynamic 
regions. Thus far, only three full-length thioamide proteins have been described in the 
literature: the semi-synthetic constructs a-synuclein and dihydrofolate reductase, and the 
natural protein methyl-coenzyme M reductase52,114,138. Consequently, there have been no 
systematic studies of thioamides in folded proteins, which will be essential to guiding their 
future use as spectroscopic probes or as modulators of protein structure and function. 
Herein, we describe an in-depth study of the effects of thioamide backbone 
substitution in three benchmark protein systems: (1) the C-terminal loop and helix of 
calmodulin (CaM), an α-helical protein; (2) the β-sheet of the B1 domain of protein G 
(GB1), a compact α/β tertiary structure; and (3) the PPII helix of a Pro-Hyp-Gly (POG) 
based CMP. For each protein, we performed CD spectroscopy studies to elucidate the 
structural and thermodynamic stability changes resulting from thioamide insertion. The 
first two systems represent new hosts for examination of the effects of thioamides on 
protein secondary structure in a tertiary fold context. In CMPs, our results build on prior 
published work through complete positional scanning substitutions in both PPG and POG 
subunits. Overall, the findings reported here lay the groundwork for the rational 
implementation of thioamides as biophysical probes in diverse protein systems. 
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5.2 Results and Discussion 
Design and semi-synthesis of CaM thioproteins. CaM is a 148 amino acid, a-
helical calcium signaling protein that is ubiquitous in eukaryotes. It is comprised of two 
structurally similar domains (N- and C-terminal), each containing two calcium binding 
sites178. Upon binding calcium, CaM undergoes a conformational change to expose a 
trans-domain helix, which acts as a binding platform for many of its regulatory target 
proteins179,180. Previously, a semi-synthesis of CaM was performed to modify the C-
terminal EF-hand181. Since these authors observed some destabilization of CaM, we 
decided to limit thioamide substitutions in our investigations to the C-terminal loop and 
helix, near the highest affinity calcium binding site. Thus, we performed native chemical 
ligation (NCL) reactions between the expressed fragment CaM1–134 and the synthetic 
fragment CaM135–148. The native residue at position 135 in CaM is a Gln. Therefore, Cys 
at this position was masked after NCL to mimic Gln (denoted as CysQ) by iodoacetamide 
treatment. All CaM (thio)proteins were expressed, synthesized, purified, characterized, 
and analyzed by Christopher R. Walters. Details on purification are described elsewhere71. 
Positions for thioamide substitutions were selected with three criteria in mind: 
importance to local secondary structure, functional importance for Ca2+ binding, and ease 
of synthesis of peptides and thioamide precursors. Of particular interest were residues in 
the C-terminal helix of Ca2+-bound CaM (Tyr138, Glu139, Glu140, Phe141, and Val142). Glu140 
is functionally important as it undergoes significant conformational change from the apo 
protein in order to directly chelate a Ca2+ ion in the holo protein179. Tyr138, Glu139, Phe141, 
and Val142 reside in the N-terminal and central portions of the helix. We hypothesized that 
thioamide substitution at these sites would be destabilizing due to the weaker hydrogen 
bond acceptor capacity of the thiocarbonyl. Two additional sites were chosen to assess 
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the impact of substitutions in loops and solvent exposed areas proximal to this helix (Val136 
and Ala147, the penultimate residue in CaM). Proteins bearing each of these thioamide 
substitutions were synthesized by semi-synthesis using NCL. Wild-type (WT) CaM and a 
Cys135 mutant were expressed in E. coli as controls for proper refolding of the thioproteins. 
The Cys135 mutant was subjected to denaturing NCL conditions similar to the thioproteins 
and subsequently underwent the same purification and capping reaction. 
CaM thioprotein folding thermodynamics. Each CaM variant was characterized 
by CD spectroscopy under two different buffer conditions: one for the calcium-bound holo 
protein (10 mM Tris pH 7.5, 2 mM CaCl2) and another for the calcium-free apo form (10 
mM Tris pH 7.5, 0.5 mM ethylenediaminetetraacetic acid, EDTA). CaM CD spectra show 
a prototypical α-helical signature with minima at 208 and 222 nm. Spectra for the 
thioprotein variants include a small minimum between 260 and 280 nm resulting from the 
thioamide π→π* transition. This peak is weaker than the comparable transition observed 
in GB1 and collagen, or in previous reported small thiopeptides66,80,96. The attenuation of 
the thiocarbonyl CD signal is likely an environmental and concentration-based effect, as 
the thioamide in CaM is a small fraction of the overall amide content and the region 
containing the thioamide is destabilized in several variants. The thioamide n→π* transition 
at 340 nm is not visible in any of the CaM CD spectra (see Figure 5-1). 
Among the holo proteins, the spectrum of CysQ135 is similar in shape and 
magnitude to that of WT CaM, indicating the side chain modification necessary to enable 
NCL has no significant effect on the fold. Most of the thioamide substitutions appear well 
tolerated in the holo protein; however, the TyrS138 and PheS141 modifications considerably 
alter the folded state, with a nearly three-fold decrease in molar residue ellipticity (MRE, 
[θ) at 222 and 208 nm. These mutants show a similar helical signature to the N-terminal 
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truncation mutant CaM1–71, suggesting that the C-terminal domain may be completely 
disordered as a result of thioamide incorporation. To understand more about the nature of 
each thioamide substitution, we subjected the CaM variants to thermal denaturation. Like 
WT CaM, each of the thioamide variants and the CysQ135 oxo control have melting 
temperatures greater than 80°C in the presence of Ca2+ and did not reach a plateau that 
allowed detailed analysis. 
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Figure 5-1: Characterization of WT, CysQ135 and thioCaM variants. CD wavelength 
scan of holo (top) and apo (middle) forms of CaM. Bottom: CD thermal melts of apo 
forms plotted as pseudo-Fraction folded (F*f) generated from fitted data. 
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Upon the removal of calcium by EDTA, CaM reverts to the apo structure, which 
lacks the stable transdomain helix and open EF hands observed in the holo form182,183. 
We hypothesized that the substantial structural differences between the apo and holo folds 
may lead a thioamide at a given site to have distinct effects in those two contexts. Thus, 
we carried out an analogous series of CD experiments to characterize folding in the apo 
CaM variants. Surprisingly, the CysQ135 modification appears to be significantly perturbing 
to the apo form, reducing helicity by half relative to apo WT CaM. While the origins of the 
effect of side chain modification at residue 135 are not clear, we used the data observed 
for the CysQ135 oxo control as a benchmark to probe the impact of thioamide incorporation 
on the apo fold. 
Each of the apo proteins show complete unfolding transitions over the temperature 
range of 5 to 95°C. Initial apo thermal melts were performed on WT CaM and the CysQ135 
control. The melting temperature for our WT CaM sample is lower than values previously 
reported in literature184–187, likely due to different buffer conditions. Although we attempted 
to fit our data to a two-state model, we ultimately chose to analyze our results using a 
three-state model as it is well established that CaM unfolding proceeds through a semi-
stable intermediate187. We therefore report thermodynamic data as ΔGU, which is the sum 
of the individual unfolding free energies for each transition at 25°C (see Table 5.1). For 
comparison of three-state CaM unfolding to the two-state unfolding of GB1 and CMPs, we 
generated pseudo fraction folded (F*f) plots based on this three-state model, where the 
intermediate state makes a weighted contribution to the total fraction of folded protein. We 
denote the half-point of these weighted unfolding curves as T*M. Using this fitting model, 
we determined that CysQ135 CaM is slightly less stable than WT CaM in T*M and ΔGU; 
however, this minor change in stability should not prevent it from serving as an appropriate 
106 
 
control to study the effects of the thioamide substitutions. A more detailed list including 
thermodynamic data for each transition (TM1, ΔH1, TM2, and ΔH2) can be found 
elsewhere71.  
Table 5.1: Apo CaM thermodynamic values. 
CaM variant T*Ma (°C) ΔT*M (°C) ΔGUb (kcal mol-1) ΔΔGU (kcal mol-1) 
WT 46.8 ± 0.3 ― 6.4 ± 0.2 ― 
CysQ135 Oxo 45.5 ± 0.4 ― 5.9 ± 0.1 ― 
ValS136 48.6 ± 0.7 + 3.2 6.5 ± 0.1 + 0.6 
TyrS138 39.3 ± 0.8 - 6.2 4.1 ± 0.2 - 1.8 
GluS139 47.0 ± 0.1 + 1.6 6.4 ± 0.1 + 0.5 
GluS140 40.4 ± 0.8 - 5.1 3.9 ± 0.2 - 2.0 
ValS142 44.0 ± 0.7 - 1.5 5.8 ± 0.2 - 0.1 
AlaS147 43.7 ± 0.7 - 1.8 5.5 ± 0.2 - 0.3 
aMelting temperature weighted for contributions from the unfolding of each domain. 
bΔGU calculated from TM1, ΔH1, TM2, and ΔH2 as described elsewhere71.  
 
Using the CysQ135 protein as a basis for comparison, we see that AlaS147 slightly 
destabilizes the apo fold, lowering ΔGU by 0.3 kcal mol-1. In agreement with the CD 
spectra, TyrS138 and GluS140 appear to be the most destabilizing mutations, decreasing 
ΔGU by 1.8 and 2.0 kcal mol-1, respectively. ValS142 is well-tolerated, giving rise to a ΔGU 
within error of the oxoamide. Unexpectedly, both ValS136 and GluS139 show elevated melting 
temperatures and an increase of ΔGU by ~0.5 kcal mol-1. The unstable PheS141 construct 
was prone to aggregation during thermal denaturation, precluding rigorous 
thermodynamic analysis. Nevertheless, the thioamide substitutions that we could study 
span a range of thermodynamic effects, which we can interpret in terms of known 
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structures. A detailed discussion and analysis of the observed effects on thioamide 
substitutions can be found elsewhere71. 
Design and synthesis of GB1 thioproteins. The immunoglobulin-binding B1 
domain of protein G from Streptococcus bacteria is 56 amino acids in length and has a 
tertiary structure comprised of three of the most common secondary structural motifs in 
proteins160. The compact GB1 fold consists of a protein-spanning α-helix packed against 
a four-stranded β-sheet with both parallel and anti-parallel strands, making it an ideal 
model to study local folding dynamics in a tertiary structure context. Indeed, NMR, X-ray 
crystallography, and an array of computational studies have been used to great effect in 
understanding the order in which individual secondary structure elements fold to form the 
final tertiary structure of GB1188,189. More recently, various unnatural backbone 
substitutions have been examined in GB1166,190–192. While these substitutions were 
thermodynamically destabilizing to the folded state, many of the proteins showed a native-
like fold by X-ray crystallography and CD. Given these precedents, GB1 is an excellent 
platform to examine effects of thioamides on folding in a β-sheet, a structural motif not yet 
studied in detail with thioamide substitutions.  
GB1 and three thioamide variants were synthesized using a combination of 
automated and manual SPPS, followed by NCL. We originally intended to synthesize 
thioamide GB1 through SPPS only, but encountered low yields due to suboptimal coupling 
reactions after thioamide insertion and Edman degradation-type cleavage of the amide 
bond C-terminal to the thioamide under acidic deprotection conditions. Thioprotein 
production by NCL allowed us to work with shorter thiopeptide fragments where the 
number of couplings subsequent to thioamide insertion and the length of the deprotection 
reaction can be limited. In the synthesis of GB1 and variants, we performed a ligation 
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between a thioamide containing GB11–23 thioester and GB124–56Cys24. After desulfurization 
of Cys24 using VA-044 and sacrificial thioacetamide, we obtained the thioamide GB1 
constructs with no trace of the ligation point and yields ranging between 10 and 20%120. 
 
Figure 5-2: Structural analysis of GB1 thioamide variants. Left: Overall structure of 
GB1 with modeled thioamide substitutions. Right: Zoomed in region showing that 
the LeuS7 thiocarbonyl is skewed out of the plane of the anti-parallel β-sheet, 
providing a potential explanation for why it is less destabilizing than LeuS5 or IleS6. 
Structures rendered from PDB entry 2QMT189 
Using this NCL and desulfurization strategy, we synthesized three GB1 variants 
with single thioamide substitutions at Leu5, Ile6, or Leu7. The Leu5 residue acts as a 
hydrogen bond acceptor in an anti-parallel β-sheet interaction and as a hydrogen bond 
donor in a parallel β-sheet interaction. In contrast, Ile6 acts as a hydrogen bond acceptor 
in a parallel β-sheet interaction and as a hydrogen bond donor in an anti-parallel β-sheet 
interaction. The hydrogen bonding pattern of Leu7 is similar to that of Leu5 (anti-parallel 
acceptor, parallel donor), but the carbonyl points outward slightly, increasing the hydrogen 
bond distance by 0.2 Å and placing it out of plane with respect to its partner in the sheet. 
Thus, we anticipated that the increased size and C=X bond length of the thiocarbonyl 
might be better accommodated at Leu7 than at Leu5 or Ile6. These three substitutions, 
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while not comprehensive, provide examples of how thioamides may be accommodated 
into both types of β-sheet folds within the context of a complex tertiary domain. 
GB1 thioprotein folding thermodynamics. GB1 CD spectra typically contain a 
broad minimum between 208 and 222 nm with few defined features in this range due to 
the combination of the α-helical and β-sheet contributions to the signal. The LeuS5 and 
IleS6 substitutions have nearly identical spectra and maintain similar curve features as the 
GB1 Oxo control, but with significantly reduced MRE values. It is likely that the internal 
hydrogen bonding networks are perturbed by these substitutions, leading to a disruption 
in the packing of the tertiary structure. LeuS7 seems to be the most tolerated thioamide 
substitution with a CD signature closest in magnitude to the control at 208 nm. However, 
the MRE values are still significantly reduced across the entire set of spectra. 
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Figure 5-3: Characterization of WT and thio-GB1 variants. Top: CD wavelength 
scan of GB1 variants. Bottom: CD thermal melts plotted as Fraction folded (Ff) 
generated from fitted data. 
For GB1, the thermal denaturation curves fit well to a two-state unfolding model. 
The TM of GB1 Oxo is 78.2 C and includes a sharp unfolding transition that is preceded 
by only a modest initial unfolding event occurring gradually between 5 and 65°C. The 
thermodynamic differences for each thioamide substitution track with the changes in signal 
observed in the wavelength scans. IleS6 leads to a 9.5°C destabilization in melting 
temperature while LeuS5 leads to an even greater destabilization of 12.6°C. LeuS7 is the 
least destabilizing thioamide substitution with a melting temperature only 2.3°C lower than 
WT GB1. The corresponding unfolding free energies (ΔΔGU calculated according to 
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Equation 5193) show that LeuS7 is destabilized by only 0.5 kcal mol-1. Thus, we see that the 
precise context of thioamide substitution is also important for β-sheet systems. 
 
Equation 5: Equation used to calculate ΔΔGU193. 
In GB1, the thermodynamic and structural changes from thioamide incorporation 
can be readily rationalized based on existing structural data (PDB entry 2QMT)189. LeuS5 
thiocarbonyl substitution likely disrupts the hydrogen bond with the N–H of Thr16, altering 
packing of only the outer strand of the β-sheet (see Figure 5-3). The LeuS5 thioamide N–
H should maintain the hydrogen bond to the Phe52 carbonyl in the core parallel β-sheet 
interface and might even strengthen this interaction. Computational modeling indicates 
that Leu5 forms part of the folding nucleus of GB1188, so perhaps it is not surprising that 
the Leu5 substitution has the most significant effect on the TM and reduced the 
cooperativity of the folding transition. IleS6 reverses this hydrogen bonding pattern, 
maintaining the N–H hydrogen bond to the carbonyl of Gly14 in the outer strand and 
disrupting hydrogen bonding with the Val54 amide N–H in the core strand. Disturbance of 
the core of the β-sheet region would explain why the IleS6 substitution induces such a 
significant change in the TM. LeuS7 causes almost no disruption in folding as determined 
by CD. It seems that the longer hydrogen bond distance (3.1 Å to ˚ the Lys13/Gly14 amide 
N) and out-of-plane orientation of the Leu7 carbonyl are permissive of the sulfur 
substitution, as we anticipated. If there is any minor disturbance, it could be compensated 
for by the increased strength of the LeuS7 thioamide N–H hydrogen bond with the carbonyl 
of Val54. Taken together, these analyses reinforce our observation that the effects of 
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thioamide incorporation in β-sheets can depend dramatically on the location of the 
substitution (see Table 5.2 for detailed thermodynamic values). 
Table 5.2: GB1 thermodynamic values. 
GB1 variant TM (°C) ΔTM (°C) ΔΔGUa (kcal mol-1) 
WT 78.2 ± 0.0 ― ― 
LeuS5 65.6 ± 1.6 - 12.6 - 2.5 ± 0.3 
IleS6 68.7 ± 0.5 - 9.5 - 1.9 ± 0.1 
LeuS7 75.9 ± 1.2 - 2.3 - 0.5 ± 0.2 
aChange in unfolding free energy ΔΔGU, calculated from ΔTM using Equation 5193. 
 
Design and synthesis of collagen model thiopeptides. Collagen provides an 
opportunity to explore the thioamide's potential as a modulator of key stabilizing hydrogen 
bonds and n→π* interactions. The protein is comprised of three monomeric left-handed 
PPII helices that are made up of XaaYaa-Gly repeats. These monomers anneal to one 
another to form the native structure, a right-handed triple helix194. Although, ProProGly 
(PPG) is one of the most prevalent repeat elements in collagen, nearly every other amino 
acid has been observed in the Xaa or Yaa position195. Within this PPG unit, a variety of 
substitutions have been made on the 4 position of the pyrrolidine ring196–201. The most 
common alteration found physiologically is (2S,4R)-4-hydroxyproline (Hyp) at the Yaa 
position (Pro-Hyp-Gly, POG)195. Backbone ester, alkene, and aza-glycine substitutions 
have also been incorporated to modify and study the PPII triple helix202–204. Recently 
Raines et al. reported the effects of thioamide incorporation in two positions (ProProSGly 
and ProProGlyS) by thermal denaturation in a PPG based CMP123. Here, we build on this 
precedent by providing detailed kinetics and thermodynamics for single substitutions in all 
Xaa, Yaa, and Gly positions in a 21-mer POG host peptide system. 
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To probe the effect of the thioamide on CMP self-assembly, we installed the moiety 
near the central positions of the 21-mer host system Ac-(POG)3(XYG)(POG)3-NH2. 
Peptides were synthesized through SPPS, coupling Fmoc-POG-OH trimers at all but the 
central POG subunit. Here, individual residues were installed, including the suitable 
building block for incorporation of the thioamide. Typical yields of completed thioamide 
CMPs range between 4–6%. To analyze the thioamide impact on structure, 
thermodynamics, and kinetics of folding, we subjected each CMP variant to CD scans, 
thermal melts, and kinetic refolding experiments. All experiments with CMPs were 
performed by Yitao Zhang in the Chenoweth Lab at the University of Pennsylvania. 
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Figure 5-4: Structural analysis of CMP thioamide variants. ProSProGly and 
ProProGlyS have buried and partially buried sulfur atoms, respectively (Top and 
Middle), accounting for the disruptions observed in the CD experiments. The 
ProProSGly (Bottom) sulfur atom is fully solvent exposed and the N–H of the 
thioamide forms a hydrogen bond with the strand shown in grey (inset), accounting 
for the stabilization observed in the CD experiments. Structures rendered from PDB 
entry 2CUO205. 
Collagen model thiopeptide folding thermodynamics. CD scans of each 
thioamide variant display a characteristic collagen spectrum with a minimum at 198 nm 
and maximum around 225 nm, along with a broad minimum centered around 265 nm, 
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representing the π→π* contribution from the thioamide. The magnitude of the minima at 
198 nm and 265 nm depend upon the position of the thioamide, with the PSPG substitution 
leading to the greatest loss in MRE signal. Unsurprisingly, the PSPG replacement 
massively destabilizes the protein (Figure 5-5 and Table 5.3), likely because the sulfur 
points inward towards the core of the trimer, imposing a steric obstacle to the packing of 
the strands (see Figure 5-4). Additionally, the lower electronegativity of the elongated 
carbon–sulfur bond weakens key interchain H-bonding between the glycine N–H and the 
C=O of the Xaa proline. The PPSG modification shows a stabilization of the triple helix with 
a significant increase in TM and 0.4 kcal mol-1 increase in ΔGU, while PPGS shows a 
moderate destabilization, in agreement with previous studies123. Hysteresis studies 
showed that the free energy differences are in good agreement with the melting 
temperature profiles. Additionally, each thioamide CMP folded on a similar timescale to 
the PPG control, demonstrating that the kinetics of folding are not altered by thioamide 
substitution. Folding kinetics were carried out by Yitao Zhang in the Chenoweth Lab using 
CD spectroscopy. 
Table 5.3: CMP thermodynamic and kinetic values. 
Collagen variant TM (°C) t1/2 (min) ΔGUa (kcal mol-1) ΔΔGUa (kcal mol-1) 
Pro-Pro-Gly Oxo 36.7 ± 0.4 32.5 ± 2.0 10.8 ― 
ProS-Pro-Gly 11.0 ± 0.9 25.0 ± 4.5 5.1 - 5.7 
Pro-ProS-Gly 38.5 ± 0.5 35.3 ± 5.2 11.2 + 0.4 
Pro-Pro-GlyS 30.3 ± 0.5 40.3 ± 7.6 9.2 - 1.6 
Pro-Hyp-Gly Oxo 39.9 ± 0.5 24.0 ± 4.5 12.0  ― 
Pro-HypS-Gly 41.0 ± 0.2 17.7 ± 4.0 12.6 + 0.6 
Pro-Hyp-GlyS 34.5 ± 0.0 23.8 ± 2.8 11.1 - 0.9 
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To assess thioamide backbone compatibility with substitutions at the 4 position of 
the pyrrolidine ring in proline, we incorporated Hyp into the Yaa position. This POG mutant 
is well known to stabilize collagen triple helices through stereoelectronic effects and 
hydrogen bonding206–210. Results show that peptides POSG and POGS exhibit TM increases 
of 2.5 and 4.2°C, respectively, relative to their corresponding Pro congeners. Interestingly, 
the stabilizing effects from the Hyp substitution and thioamide appear additive when 
compared to appropriate PPG and POG controls. Thioamide substitution at the central 
Yaa position contributes about 0.5 kcal mol-1 of stability and Hyp substitution contributes 
about 1.3 kcal mol-1. Furthermore, the POSG substitution leads to faster folding compared 
to that of any thioamide variant or control peptide examined here. Like for CaM and GB1, 
thioamide substitutions in collagen have effects that strongly depend on the position of 
incorporation. Further combinations of thioamide and pyrrolidine modifications may also 
garner additive gains in collagen stability, or even act to compensate for other modications 
previously observed to be destructive. 
 
Figure 5-5: Thermal stability of CMP thioamide variants. CD thermal melts of 
collagen plotted as fraction folded (Ff) values. 
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Analysis of thioamide substitutions in PPG and POG CMPs illustrates the three 
fundamental effects that thioamides are expected to have on proteins. In PPSG, the 
combination of weaker hydrogen bonding and steric clashes due to the larger van der 
Waals radius of sulfur and longer C=S bond length significantly destabilizes (ΔTM 
= -25.7°C) the protein (see Figure 5-4). In contrast, both PPSG and POSG collagen 
peptides are moderately stabilized compared to their oxoamide counterparts. At the Yaa 
position, the thioamide N–H can form a stabilizing interstrand hydrogen bond, while the 
thiocarbonyl projects into solvent. Thus, thioamide substitution at the Yaa position confers 
the energetic benefits of the stronger hydrogen bond donor without the penalties of the 
weaker acceptor or steric clashes. The disruption introduced by the PPGS thioamide is not 
as drastic as the PSPG replacement because it does not pack against the core of the triple 
helix, but it may provide general steric interference with neighboring strand contacts. The 
POSG and POGS peptides recapitulate the positional effects of the thioamide while 
retaining the stabilizing effects of Hyp. The additivity of the backbone and sidechain 
substitutions supports the idea that the conformations of the thioamide collagen variants 
are similar to the parent collagen model peptides (with the exception of PSPG, for which 
few conclusions can be drawn). In this regard, our data show that a thioamide substitution 
can act synergistically with a proline ring substitution for potential applications in 
thiopeptide based collagen materials. 
5.3 Conclusion 
Thioamides have the potential to be one of the most multifunctional probes in the 
large repertoire of unnatural amino acid substitutions available for protein labeling. They 
can be used as functional handles in IR, CD, or fluorescence spectroscopy, as 
photoswitches, or as perturbants in structure/function studies. With thioamide 
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substitutions across three protein systems, CaM, GB1, and CMPs, the data set amassed 
here represents the most comprehensive study to date bearing on the question of how 
thioamides affect protein thermostability. While virtually all previous reports of thioamides 
in secondary structure contexts have found the modification to be disruptive, we show 
that, within CaM, the replacement is tolerated in some positions within the C-terminal a-
helix as well as the preceding loop. While all thioamide substitutions in the β-sheet of GB1 
were destabilizing, at one position the impact was minimal. Our CMP results are consistent 
with findings by Raines, and although we do not yet have high resolution structures, the 
additivity of the effects of thioamidation and proline hydroxylation suggests that our CMPs 
adopt a fold consistent with structures like PDB entry 2CUO, shown in Figure 5-4. Overall, 
our analysis based on existing crystal and NMR structures allows us to rationalize many 
of our findings in terms of the physical properties of the thioamide bond and to consider 
how both perturbing and non-perturbing thioamide locations might be useful. Thioamide 
incorporation in the first turn of an α-helix is a strong helix breaker, and it is disruptive in 
sheets where it replaces a short hydrogen bond that is in the plane of the sheet. These 
findings can be explained by the longer C=S bond length and larger van der Waals radius 
of sulfur, and highlight the potential of thioamides as tools to modulate protein folding. 
Thioamides will be tolerated in helices where the substituted amide oxygen participates in 
longer H-bonds and in sheets where the carbonyl bond is at a more acute angle. We have 
also seen that thioamides are tolerated, or even stabilizing, when the disruptive effect of 
the thiocarbonyl is compensated by the stronger hydrogen bond donation of the thioamide 
N–H. Minimally perturbing substitutions are ideal for fluorescence studies using the 
thioamide as a quenching moiety. Increased thermal stability of collagen PPSG and POSG 
substitutions, as well as ValS136 and GluS139 in CaM, highlight the fact that thioamides can 
serve as stabilizing backbone replacements for interrogating hydrogen bonding networks. 
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The results reported here have set a foundation for rational thioprotein design to 
realize the above benefits to biophysics and protein engineering. A growing database of 
thioamide “mutants” could, in conjunction with appropriate computational models, allow 
one to predict the effects of thioamide substitution to achieve the desired destabilizing, 
neutral, or stabilizing effects on a protein of interest. Efforts are underway in our 
laboratories to obtain high resolution structural and dynamic information on thioamide 
substitution. In addition to the generation of thioamide proteins by NCL, Hecht's recent 
cotranslational incorporation of thioamide dipeptides using mutant ribosomes offers a 
potentially more facile semisynthetic route to thioproteins138. Deciphering the mechanism 
of incorporation of the natural thioglycine residue in the archael methyl-coenzyme M 
reductase could also permit the in vivo biosynthetic incorporation of backbone 
thioamides52. As thioamide proteins become more synthetically accessible, the results 
reported here should provide valuable insights into the design of appropriate thioproteins 
for diverse applications 
5.4 Materials and Methods 
General Information. Fmoc protected amino acids and peptide coupling reagents 
as well as Rink amide and 2-chlorotrityl resins were purchased from EMD Millipore 
(Billerica, MA, USA) with the exception of Fmoc Hyp(tBu)-OH, which was purchased from 
Advanced Chemtech (Louisville, KY, USA). Hydrazide hydrate solution was purchased 
from Oakwood Chemical (Estill, SC, USA). Piperidine was purchased from American 
Bioanalytical (Natick, MA, USA). VA-044 was purchased from Wako Pure Chemical 
Industries (Osaka, Japan). Triisopropylsilane (TIPS) was purchased from Santa Cruz 
Biotechnology, Inc (Dallas, TX, USA). GB124-56 A24C was purchased from Genscript 
(Piscataway, NJ, USA). Restriction enzymes and chitin purification resin were purchased 
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from New England Biolabs (Ipswich, MA, USA) and Pfu Turbo DNA Polymerase was 
purchased from Agilent Technologies (Santa Clara, CA, USA). DNA oligomers were 
purchased from Integrated DNA Technologies, Inc (Coralville, IA, USA). The pTXB1 
plasmid containing CaMS17C,1-116 was a gift from the Linse Laboratory of the Department 
of Biochemistry and Structural Biology at Lund University. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) was purchased from LabScientific, Inc (Highlands, NJ, 
USA). Protease inhibitor tablets were purchased from Roche Boehringer Mannheim 
(Indianapolis, IN, USA). Amicon Ultra centrifugal filter units were purchased from EMD 
Millipore (Billerica, MA, USA). Sodium 2-mercaptoethanelsulfonate (MES•Na) was 
purchased from TCI America (Portland, OR, USA). β-mercaptoethanol (βME) was 
purchased from  Bio-Rad Laboratories (Hercules, CA, USA). FPLC purification of proteins 
was performed on an AKTA system with HiTrap Q columns (GE Healthcare Bio-Sciences, 
Pittsburgh, PA, USA), while peptide HPLC was performed on a Varian Prostar system 
(currently Agilent Technologies, Santa Clara, CA, USA) for CaM and GB1 peptides and a 
Jasco HPLC instrument (Easton, MD, USA) for collagen. Thiopropyl sepharose 6b resin 
was also purchased from GE Healthcare (Princeton, NJ, USA).  Cuvettes for CD 
spectroscopy were purchased from Hellma Analytics USA (Plainview, NY, USA). All other 
reagents, solvents, and materials were purchased from either Fisher Scientific (Pittsburgh, 
PA, USA) or Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Matrix 
assisted laser desorption/ionization mass spectrometry (MALDI) was performed on a 
Bruker Ultraflex III mass spectrometer (Billerica, MA). High Resolution Mass Spectrometry 
(HRMS) for small molecules were obtained on a Waters LCT Premier XE LC/MS system 
(Milford, MA, USA). Nuclear magnetic resonance spectra were obtained on a Bruker DRX 
500 MHz instrument. Common abbreviations for all other chemicals are as follows: 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluoro-
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phosphate (HATU), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuoro-
phosphate (HBTU), O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexa-
fluorophosphate (HCTU), N-methylmorpholine (NMM), isobutyl chloroformate (ICBF), 
N,N-diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), 1,2-ethanedithiol (EDT), 
hydroxybenzotriazole (HOBt), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), tris(2-carboxyethyl)phosphine (TCEP), and guanidinium hydrochloride 
(Gdn•HCl). All work on Calmodulin was performed by Christopher Walters. All work on 
Collagen model peptides was performed by Yitao Zhang in the laboratory of Prof. David 
Chenoweth at the University of Pennsylvania. Solid phase peptide synthesis of full-length 
thio-GB1 was done by Zachary Reinert in the laboratory of Prof. W. Seth Horne at the 
University of Pittsburgh. Experimental details for those experiments is described 
elsewhere71.  
 
Figure 5-6: Synthesis of Thio-Isoleucine nitrobenztriazolide monomer. 
Fmoc-LeuS-Nbt was synthesized as previously described72,120. Fmoc-IleS-Nbt 
synthetic scheme is shown in Figure 5-6 and is described in detail here. 
(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl-
1-oxopentan-2-yl)carbamate (5-1). Fmoc-Ile-OH (3.53 g, 10.0 mmol) was dissolved in 
anhydrous THF (90 mL). N-methylmorpholine (2.20 mL, 20.0 mmol) was added and the 
reaction was cooled to -10 °C while the flask was purged with argon. Isobutyl 
chloroformate (1.30 mL, 10.0 mmol) was added dropwise while stirring. The reaction 
mixture was stirred for 15 min at -10 °C, then 4-nitro-o-phenylenediamine (1.53 g, 10.0 
122 
 
mmol) was added. The reaction was stirred under argon for 2 hours at -10 °C, then at 
room temperature overnight. After removing the solvent in vacuo, the residue was 
dissolved in DMF (50 mL). Upon addition of saturated aqueous KCl (250 mL) solution and 
Milli-Q water (250 mL), a yellow solid precipitated. The solid was filtered, washed with 
Milli-Q water and dried under vacuum. Compound 4 was isolated in 78.5% yield (3.84 g, 
7.85 mmol) and 79.4% purity, as determined by HPLC. HRMS (ESI) m/z calculated for 
C27H28N4O5 [M+H]+ is 489.2138, found 489.2130. 1H NMR (500 MHz, C2D6OS): δ 9.54 (s, 
1H), 8.29 (d, J = 2.7 Hz, 1H), 7.91 – 7.83 (m, 3H), 7.80 – 7.72 (m, 3H), 7.41 (t, J = 7.2 Hz, 
4H), 7.32 (t, J = 7.5 Hz, 2H), 6.79 (d, J = 9.1 Hz, 1H), 6.52 (s, 2H), 4.35 – 4.20 (m, 4H), 
4.09 (t, J = 8.2 Hz, 1H), 1.90 (ddt, J = 12.4, 8.5, 4.2 Hz, 1H), 1.56 (ddd, J = 13.7, 7.4, 3.3 
Hz, 1H), 1.30 – 1.17 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 0.88 (t, J = 7.4 Hz, 3H). 13C NMR 
(126 MHz, C2D6OS): δ 171.2, 156.4, 148.8, 143.7, 140.7, 135.5, 127.6, 127.0, 125.3, 
122.9, 121.2, 121.1, 120.1, 113.7, 65.8, 59.8, 46.7, 35.8, 24.7, 15.4, 10.7. 
(9H-fluoren-9-yl)methyl ((2S,3S)-1-((2-amino-5-nitrophenyl)amino)-3-methyl-
1-thioxopentan-2-yl)carbamate (5-2). Anhydrous Na2CO3 (0.239 g, 2.25 mmol) and 
P4S10 (1.00 g, 2.25 mmol) were suspended in anhydrous THF (30 mL) in an oven-dried 
round bottom flask and stirred under argon for 30 minutes until solution became clear. 
Compound 5-1 (1.10 g, 3.00 mmol) was added and the reaction stirred over night at room 
temperature under argon. The next day the solvent was removed in vacuo. The resulting 
residue was resuspended in ethyl acetate and filtered over a pad of Celite® (Sigma-
Aldrich, St. Louis, MO) to remove insoluble P4S10 adducts. The filtrate was washed twice 
with 5% NaHCO3 and once with brine. The aqueous layer was acidified with HCl and back 
extracted twice with ethyl acetate. The combined organic layers were dried over MgSO4, 
filtered and the solvent was removed in vacuo. The crude product was redissolved in 
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dichloromethane and purified over silica to afford pure product as a yellow foam in 50.8% 
yield (0.770 g, 1.52 mmol). Rf = 0.5 in ethyl acetate/hexanes (1:1). HRMS (ESI) m/z 
calculated for C27H28N4O4S [M+H]+ is 505.1910, found 505.1909. 1H NMR (500 MHz, 
CDCl3) δ 9.57 (s, 1H), 7.98 (s, 1H), 7.95 (d, J = 8.9 Hz, 1H), 7.77 – 7.70 (m, 2H), 7.49 (d, 
J = 7.5 Hz, 1H), 7.44 (d, J = 7.4 Hz, 1H), 7.42 – 7.33 (m, 2H), 7.27 (s, 2H), 7.30 – 7.20 (m, 
2H), 6.58 (d, J = 9.0 Hz, 1H), 5.70 (s, 1H), 4.27 (d, J = 7.7 Hz, 3H), 4.14 (t, J = 7.1 Hz, 
1H), 2.10 – 2.02 (m, 1H), 1.29 – 1.20 (m, 2H), 1.02 (d, J = 6.7 Hz, 3H), 0.97 (t, J = 7.3 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 206.2, 157.4, 148.5, 143.3, 141.3, 138.4, 128.1, 128.0, 
127.4, 127.3, 125.6, 125.0, 125.0, 124.9, 122.3, 120.3, 120.2, 115.3, 77.4, 67.6, 66.89, 
47.0, 39.1, 29.83, 15.9, 11.1. 
(9H-fluoren-9-yl)methyl ((2S,3S)-3-methyl-1-(6-nitro-1H-benzo[d][1,2,3]-
triazol- 1-yl)-1-thioxopentan-2-yl)carbamate (5-3, Fmoc-IleS-NBt). Compound 5-2 
(0.770 g, 1.52 mmol) was dissolved in 95% glacial acetic acid diluted with 5 % water (20 
mL). The solution was cooled to 0 °C and NaNO2 (156 mg, 2.26 mmol) was added slowly. 
Upon complete addition, the reaction mixture was stirred for 30 min at 0 °C, after which 
cold Milli-Q water (125 mL) was added. The precipitated orange solid was filtered, washed 
with cold Milli-Q water and dried in vacuo. The crude yield of the reaction was 57.7% 
(0.453 g, 0.88 mmol) and was used directly in solid phase peptide synthesis without further 
purification. Rf = 0.45 in dichloromethane. HRMS (ESI) m/z calculated for C27H25N5O4S 
[M+Na]+ is 538.1525, found 538.1508.  1H NMR (500 MHz, CDCl3) δ 9.70 (s, 1H), 8.46 (d, 
J = 8.7 Hz, 1H), 8.32 (d, J = 8.9 Hz, 1H), 7.76 (d, J = 7.6 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 
7.40 (t, J = 7.5 Hz, 2H), 7.31 (q, J = 8.1 Hz, 2H), 6.22 (dd, J = 9.9, 6.2 Hz, 1H), 5.70 (d, J 
= 9.9 Hz, 1H), 4.49 (dd, J = 10.9, 6.9 Hz, 1H), 4.41 (dd, J = 10.9, 6.8 Hz, 1H), 4.22 (t, J = 
6.9 Hz, 1H), 2.13 – 2.04 (m, 1H), 1.72 – 1.61 (m, 1H), 1.30 – 1.19 (m, 1H), 1.03 (d, J = 6.7 
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Hz, 3H), 0.91 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 209.5, 156.0, 149.5, 149.0, 
143.6, 143.6, 141.3, 131.7, 127.7, 127.0, 127.0, 125.0, 124.9, 122.2, 121.5, 119.9, 112.8, 
66.9, 65.7, 47.2, 41.1, 24.1, 16.2, 11.2. 
Purification of GB124-56 Cys24 (5-4). Crude peptide 5-4 was purchased from 
Genscript (Piscataway, NJ). Crude peptide (20 mg) was dissolved in CH3CN/H2O (1:1) 
containing 20 μL of 0.5 M TCEP bond breaker™ and purified by reverse phase HPLC 
(gradient 5A, Table 5.4) at a flow rate of 15 mL/min on a Grace Vydac C18 preparatory 
column. Individual fractions were characterized by MALDI- MS (see Table 5.5), and dried 
by lyophilization. Dried peptide was dissolved in CH3CN/H2O (1:1), quantified by UV/Vis 
(ε280 = 8,480 M-1 cm-1), aliquoted into 100 nmol portions and lyophilized for later use. 
Synthesis and Purification of GB11-23 -N2H3 (5-5). The N-terminal fragment of 
GB1 (5-5) was synthesized on a CEM Liberty 1 Automated Microwave Peptide 
Synthesizer (Matthews, NC) on a 100 μmol scale. The hydrazide resin was prepared 
according to Liu and coworkers119 and the first residue was coupled manually. 20% 
piperidine in DMF was used as deprotection reagent, 0.5 M HBTU in DMF was used as 
the activating reagent, and 2 M DIPEA in N-methyl-2-pyrrolidone (NMP) was used as the 
activator base. Five molar equivalents of each amino acid were used for each coupling 
step. Ala23 was coupled twice using Method 1 (listed below).  Leu12, Glu19, and Asp22 were 
coupled using a single coupling step as in Method 2. All other residues were coupled twice 
using Method 3. After synthesis was completed, a final deprotection was performed, 
consisting of an initial deprotection for 30 sec (35 W, 50 °C), followed by a 3 min 
deprotection (35 W, 50°C). 
Method 1: Two consecutive couplings for 10 min each (25 W, 50°C) were used.  
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Method 2: Initial deprotection for 30 sec (35 W, 50°C), followed by a 3 min 
deprotection (35 W, 50°C). A single coupling for 10 min (25 W, 50°C) was used.  
Method 3: Initial deprotection for 30 sec (35 W, 50°C), followed by a 3 min 
deprotection (35 W, 50°C). Two consecutive couplings for 10 min each (25 W, 50°C) were 
used. 
Peptide cleavage from resin was performed by treating the resin with a cleavage 
cocktail (18:1:1 Trifluoroacetic acid(TFA):Triisoproylsilane(TIPS):H2O) for 45 min. The 
solution was then collected by filtration, and dried by rotary evaporation. For purification, 
the crude residues were dissolved in CH3CN/H2O (1:1), diluted with H2O, and then purified 
by reverse phase HPLC (gradient 5B, Table 5.4) at a flowrate of 15 mL/min on a Grace 
Vydac C18 preparatory column. Individual fractions were characterized by MALDI-MS 
(Table 5.5), and dried by lyophilization. Dried peptide was dissolved in CH3CN/H2O (1:1), 
quantified by UV/Vis (ε274 = 1,400 M-1 cm-1), aliquoted into 100 nmol aliquots, and 
lyophilized for later use. 
Synthesis and Purification of GB11-23-N2H3 Thiopeptides (5-6 – 5-8). Residues 
8-23 were synthesized on a peptide synthesizer on a 150 μmol scale as described for 
GB11-23-N2H3 (5-5). Resin was split into 3 equal parts and remaining amino acids were 
coupled manually. For each coupling, 5 equiv of amino acid and 5 equiv of HBTU were 
dissolved in DMF (2 mL), pre-activated for 1 min in the presence of 10 equiv of DIPEA, 
and then stirred with the resin for 30 min at room temperature. For deprotections, 2% 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF (2 mL) was stirred with the resin for 2 min. 
The vessel was then drained, the resin was washed, and the process was repeated twice 
more. For thioamide couplings, 2 equiv of either Fmoc-IleS-NBt or Fmoc-LeuS-NBt were 
dissolved in dry DCM (1 mL), and stirred with the resin for 45 min in the presence of 2 
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equiv DIPEA. Upon completion of SPPS, resin was rinsed thoroughly with DCM and dried 
under vacuum. For cleavage, resin was treated with a cleavage cocktail (18:1:1 
TFA:TIPS:H2O) for 45 min. The solution was then collected by filtration, and dried by rotary 
evaporation. For purification, the crude residues were brought up in CH3CN/H2O (1:1), 
diluted with H2O to 5% CH3CN, and then purified by reverse phase HPLC using (gradient 
5B, Table 5.4) at a flowrate of 15 mL/min on a Grace Vydac C18 preparatory column. 
Individual fractions were characterized by MALDI-MS (Table 5.5), and dried by 
lyophilization. Dried peptide was dissolved in CH3CN/H2O (1:1), quantified by UV/Vis (ε274 
= 11,569 M-1 cm-1), aliquoted into 100 nmol portions and lyophilized for later use. 
Native Chemical Ligation of GB124-56 Cys24 with GB11-23-N2H3. Activation buffer 
(200 mM Na2HPO4, 6 M Gdn•HCl, pH 3.0) and ligation buffer (200 mM Na2HPO4, 6 M 
Gdn•HCl, pH 7.0) were degassed by purging with argon for 15 min. 100 nmol of the C- 
terminal fragment (5-4) was dissolved in 95 μL ligation buffer and 5 μL thiophenol was 
added. Then, 100 nmol of the N-terminal fragment (5-5, 5-6, 5-7, or 5-8) was dissolved in 
90 μL activation buffer and stirred at -15 °C for 10 minutes. Next, 10 μL of a 1 M solution 
of NaNO2 in activation buffer was added and the reaction was stirred for 15 minutes at -
15 °C. After 15 minutes, the C-terminal fragment was added to the N-terminal fragment, 
the pH was adjusted to 7.0, and the solution stirred at room temperature overnight. Upon 
completion, the reaction mixture was diluted to a volume of 3 mL with H2O, filtered through 
a 0.22 μm syringe filter and purified by HPLC (gradient 5C, Table 5.4) at a flowrate of 3.5 
mL/min on a Grace Vydac C18 semi-preparatory column. Individual fractions were 
characterized by MALDI-MS (Table 5.5), and pure fractions dried by lyophilization. Typical 
isolated yields for NCL reactions are 30 to 40 nmol (30-40% yield). 
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Desulfurization of Cys24. Desulfurization buffer (6 M Gdn•HCl, 0.2 M Na2HPO4, 
0.5 M TCEP, 0.2 M thioacetamide, pH 7.2) and water were degassed by purging with 
argon for 15 min. A 0.5 M solution of VA-044 was freshly prepared in degassed water. The 
GB1 NCL products were dissolved in 160 μL desulfurization buffer. Next, 20 μL of tBuSH 
and 20 μL of VA-044 solution were added and the microcentrifuge tube was put under Ar 
atmosphere, sealed with Parafilm and incubated in a 37 °C water bath for 10 hours. Once 
the reaction was complete, the tube was removed from the water bath and put on ice. The 
reaction was diluted with 450 μL H2O, then 150 μL CH3CN was added and the reaction 
mixture was purged with Ar for 10 minutes to remove excess tBuSH. The reaction was 
then diluted to 3 mL with H2O and purified by reverse phase HPLC (gradient 5D, Table 
5.4) at a flowrate of 3.5 mL/min on a Grace Vydac C18 semi-preparatory column. 
Individual fractions were characterized by MALDI-MS (Table 5.5), and dried by 
lyophilization.  
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Table 5.4: HPLC Gradients for Peptide Purification and Characterization. 
No. Time (min) %B No. Time (min) %B No. Time (min) %B 
5A 0:00 2 5B 0:00 5 5C 0:00 2 
5:00 2 5:00 5 15:00 2 
10:00 20 10:00 20 18:00 25 
30:00 30 25:00 30 48:00 35 
32:00 30 27:00 100 52:00 35 
33:00 100 30:00 100 53:00 100 
38:00 100 42:00 5 58:00 100 
39:00 2   60:00 2 
5D 0:00 2       
15:00 2     
18:00 15     
48:00 45     
52:00 45     
53:00 100     
58:00 100     
60:00 2     
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
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Table 5.5: MALDI-TOF MS Characterization of Peptides. 
Peptide 
[M+H]+ 
Calculated Found 
GB124-56 Cys24 (5-4) 3746.68 3746.74 
GB11-23-N2H3 (5-5) 2495.33 2495.40 
GB11-23 LeuS5-N2H3 (5-6) 2511.39 2511.37 
GB11-23 IleS6-N2H3 (5-7) 2511.39 2511.30 
GB11-23 LeuS7-N2H3 (5-8) 2511.39 2511.36 
GB1 Cys24 (5-9) 6212.78 6212.38 
GB1 LeuS5 Cys24 (5-10) 6228.84 6228.71 
GB1 IleS6 Cys24 (5-11) 6228.84 6228.23 
GB1 LeuS7 Cys24 (5-12) 6228.84 6228.90 
WT Oxo GB1 (5-13) 6180.72 6181.22 
GB1 LeuS5 (5-14) 6196.78 6197.19 
GB1 IleS6 (5-15) 6196.78 6197.27 
GB1 LeuS7 (5-16) 6196.78 6198.87 
 
Sample Preparation for CD. Dried peptides 5-13 – 5-16 were dissolved in 500 μL 
ligation Buffer (200 mM Na2HPO4, 6 M GnHCl, pH 7.0) and dialyzed against 2 L 20 mM 
Na2HPO4, pH 7.0. The dialysis buffer was exchanged for fresh buffer twice over a period 
of 24 hours. After dialysis, samples were concentrated to 300-400 uL, using Amicon Ultra 
centrifugal filter units (3 kDa MWCO).  
Concentration Determination of GB1. The absorbance for each GB1 sample 
was measured at 274 nm and Beer’s law was used to determine the concentration of each 
sample by using extinction coefficients of ε274 = 9,567 M-1 cm-1 and ε274 = 19,736 M-1 cm-1 
for the GB1 Oxo and GB1 thioamide proteins, respectively.  
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CD Wavelength Measurements. Each sample (300 μL) was added to a 1 mm 
path length Helma Analytics 110-QS CD cuvette and loaded into a Jasco J-1500 CD 
Spectrometer. CD wavelength scans were taken at 25 C by scanning at a 1 nm step 
between 350 nm and 190 nm with a bandwidth of 1 nm and an averaging time of 8 s per 
measurement. Blank spectra were obtained by measuring the CD signal of the relevant 
buffer in each cuvette with an averaging time of 2 s. The raw signal (θd, mdeg) from each 
sample was background subtracted against the blank buffer spectrum and converted to 
molar residue ellipticity (θMRE) using Equation 6, where c is the sample concentration, l is 
the path length and nR is the number of residues. 
 
Equation 6: Equation to calculate θMRE. 
CD Thermal Melts. Thermal denaturation was performed by monitoring θd at 220 
nm over a temperature range of 5 to 95 C. The temperature increase was set to 0.2 C 
per min with an equilibration time of 10 s. Measurements were made with an averaging 
time of 8 s per sample and a bandwidth of 1 nm. 
Two-State Fitting of GB1 Thermal Melts. The two-state model assumes that 
there is a single transition between the folded and unfolded states, with no intermediate 
state populated. For this model, the folded and unfolded linear baselines were fit by using 
the low temperature θf = mfT+bf and high temperature θu = muT+bu equations. The linear 
folded and unfolded baselines for GB1 Oxo were fit from 5 to 60 C and 90 to 95 C, 
respectively. The thioprotein folded and unfolded baselines were fit from 5 to 50 C and 
85 to 95 C, respectively. The entire data set was then fit to Equation 7, where ΔH and ΔS 
are adjustable parameters and R = 1.9872 cal mol-1 K-1. The fraction unfolded curve is 
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generated by minimizing the root mean square difference (RMSD) between 𝐹௖௔௟௖ and the 
experimental fraction unfolded against the parameters listed above over the entire 
temperature range. 
 
Equation 7: Equation used for two-state fit of CD data. 
The Fcalc fits of  θMRE data and fraction folded (1-Fcalc; Ff) plots for all constructs can 
be seen in Figure 5-7. The TM of each construct was calculated by 𝑇ெ =
௱ு
௱ௌ
, assuming the 
free energy ΔGU = 0 at the midpoint of the transition. The free energy at 25 C (ΔGU(25)) 
was determined by 𝛥𝐺 = 𝛥𝐻 − 𝑇𝛥𝑆 using the 𝛥𝐻 and 𝛥𝑆 calculated from the fits and T = 
298.15 K.  All data fitting was performed using the solver function in Microsoft Excel 
(Redmond, WA) and the plots were rendered in GraphPad Prism (LaJolla, CA). 
Changes in free energy of unfolding between GB1 Oxo and the thioprotein variants 
were calculated using Equation 7 as described by Becktel et al. and previously used in 
GB1 studies190,193. ΔTM is the difference in melting temperatures between GB1 Oxo and a 
particular thioprotein analogue. These calculations are made under the assumption that a 
single amino acid change only provides a small perturbation to the system and that the 
structural and functional characteristics of the system largely remain intact193. 
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Figure 5-7: Plots generated using the two-state fitting method for GB1 variants. Left: For 
each GB1 variant, a single set of raw data (θMRE) and fits from equations for θfit, θf, and θu. 
Right: The averaged fraction folded plots (1-Fcalc) from two replicated melts. 
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Sequences 
GB1 C-Terminus (GB124-56 A24C-OH, 5-4) 
CTAEKVFKQY ANDNGVDGEW TYDDATKTFT VTE-OH 
GB1 N-Terminus Hydrazide (GB11-23 -N2H3, 5-5) 
DTYKLILNGK TLKGETTTEA VDA-N2H3 
Thioamide (LS5) GB1 N-Terminus Hydrazide (GB11-23 LS5-N2H3, 5-6) 
DTYKLSILNGK TLKGETTTEA VDA-N2H3 
Thioamide (IS6) GB1 N-Terminus Hydrazide (GB11-23 IS6-N2H3, 5-7) 
DTYKLISLNGK TLKGETTTEA VDA-N2H3 
Thioamide (LS7) GB1 N-Terminus Hydrazide (GB11-23 LS7-N2H3, 5-8) 
DTYKLILSNGK TLKGETTTEA VDA-N2H3 
Full Length GB1 Cys24 (GB1 A24C-OH, 5-9) 
DTYKLILNGK TLKGETTTEA VDACTAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE-OH 
Full Length Thioamide GB1 Cys24 (GB1 LS5 A24C-OH, 5-10) 
DTYKLSILNGK TLKGETTTEA VDACTAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE-OH 
Full Length Thioamide GB1 Cys24 (GB1 IS6 A24C-OH, 5-11) 
DTYKLISLNGK TLKGETTTEA VDACTAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE-OH 
Full Length Thioamide GB1 Cys24 (GB1 LS7 A24C-OH, 5-12) 
DTYKLILSNGK TLKGETTTEA VDACTAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE-OH 
Full Length GB1 (GB11-56 LS5-OH, 5-13) 
DTYKLILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
TFTVTE-OH 
Full Length Thioamide GB1 (GB11-56 LS5-OH, 5-14) 
DTYKLSILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
TFTVTE-OH 
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Full Length Thioamide GB1 (GB11-56 IS6-OH, 4-12b) 
DTYKLISLNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
TFTVTE-OH 
Full Length Thioamide GB1 (GB11-56 LS7-OH, 4-12b) 
DTYKLILSNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK  
TFTVTE-OH 
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Chapter 6 : Improved Semi-Synthetic Strategy for Thioamide-
Incorporation into Proteins 
 
6.1 Introduction 
 
Previously we have observed that thioamides can perturb protein structure, 
specifically in β-sheet structures71. We were able to rationalize the observed changes in 
protein stability of thioamide-containing proteins based on available high-resolution 
structures of their cognate oxo-versions. However, the effects of dithioamide incorporation 
into proteins are less predictable and in some cases hard to rationalize based on available 
structural data78. High-resolution structures of thioamide-containing proteins would enable 
more detailed characterization and understanding of the effects of thioamide substitutions 
in proteins. Currently, most high-resolution structures of thioamides are small-molecule 
structures. While these structures provided valuable information on the geometry and 
some physicochemical properties of thioamides, they provide very limited information on 
their behavior in more complex settings of proteins. Thus far, the only protein structure 
that contains a backbone thioamide substitution is Methyl-Coenzyme M Reductase (MCR) 
from Methanosarcina barkeri52. 
We set out to scale up the production of thioamide-containing B1 domain of protein 
G (GB1). While we were able obtain sufficient quantities to perform protein stability 
measurements71, the generation of well diffracting crystals for high-resolution structures 
usually requires screening of optimal conditions and therefore requires significantly larger 
quantities of protein. We chose GB1 as model protein for this due to its low polymorphism 
of observed structures and relatively high thermal melting temperature of thioamide-
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containing derivatives71, indicating that they might be stable for extended periods of time 
during crystallization. We previously observed low isolated yields of C-terminal 
acylhydrazide modified peptides and therefore decided to switch to a semi-synthetic 
approach, where a shorter N-terminal fragment was to be synthesized, while the C-
terminal fragment would be expressed. After native chemical ligation (NCL) of the two 
fragments, we imagined the ligation site to be masked as an amino acid mimic to make 
the whole ligation ‘traceless’. 
6.2 Results and Discussion 
We envisioned the generation of the C-terminal fragment of GB1 with an N-
terminal cysteine through recombinant expression. The recombinant expression and 
purification of tag-less short protein fragments in high yield can be a challenging task. 
Various methods often employ fusion proteins and specific proteases to generate these 
fragments. Intein fusion proteins have been shown to be compatible with the generation 
of very short protein fragments of <40 amino acids211. We decided to use engineered 
inteins, which are inducible, self-excising protein domains, as purification handle. These 
have been widely recognized as useful tools in protein semi-synthesis and we have used 
them successfully in our lab212–214. Furthermore, we would rely on methionine 
aminopeptidase to expose N-terminal cysteine, as our lab has successfully utilized this 
technique in the past69,215. The ligation site we initially chose was the Gly9-Lys10 amide 
bond for various reasons: First, the designated ligation bond is in the loop region between 
the first two β-sheets, making the ligation site fairly accessible. Furthermore, the size of 
the N-terminal amino acid at the ligation site has been shown to have an influence on 
reaction rate. Glycine as the smallest amino acid has been found to be the fastest reacting 
one216. Additionally, cysteine can be masked to mimic the cognate lysine by alkylating 
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cysteine with 2-bromoethylamine post ligation144,217. We hereafter denote the resulting 
thialysine as CK.The full semisynthetic scheme is shown in Figure 6-1. 
 
Figure 6-1: Semi-synthetic scheme to obtain thioamide labeled GB1. C-terminal 
fragment will be recombinantly expressed while the N-terminal fragment will be 
synthesized on solid phase. After NCL the cysteine at the ligation site will be 
alkylated with 2-bromoethylamine to yield thialysine. 
Native chemical ligation between Gly9 and Lys10. We started with the synthesis 
of the N-terminal peptide GB11-9 L7S-N2H3. As before, we utilized Lei Liu’s acyl hydrazide 
method, which serve as latent thioesters71,119,120. We noticed during synthesis that the 
main product of our peptide synthesis still contained a trityl group after cleavage. This is 
unusual, since trityl protecting groups are considered more acid labile than other 
protecting groups. Only two amino acids were incorporated as trityl protected precursors 
into the peptide: Gln2 and Asn8. MS-MS fragmentation analysis revealed that the trityl 
group was still attached to Asn8 and not to Gln2. Switching to 2,4,6-Trimethoxybenzoyl 
(Tmob)-protected Asn as a different protecting group resolved this problem and our 
desired peptide was the main isolated product. 
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The recombinant expression of the C-terminal fragment proved to be somewhat 
more challenging. We started by cloning full length GB1 into a pTXB1 vector, where it 
would be expressed with a C-terminal Mycobacterium xenopi GyrA Intein (MxeGyrA) and 
His6-tag fusion. We used this construct as starting point to clone the NCL control construct 
(GB1 K10C) and the N-terminal deletion construct (GB110-56 K10C). Expression and 
purification of the full length GB1-MxeGyrA-His6 fusion using standard protein expression 
conditions worked well. However, we were unable to induce the self-splicing reaction, 
even with variations of pH, temperature, denaturant and 2-mercaptoethanol (BME) 
concentration (see Figure 6-2). 
 
Figure 6-2: SDS-PAGE (16% Tris-Glycine gel) showing attempted intein cleavage of 
GB1-MxeGyrA-His6 under varying conditions. BME concentrations used were 0.1 M, 
0.25 M, and 0.5 M. Data shown here is for the reaction at pH 9.0. Gel at pH 8.0 looked 
identical. MW: GB1-MxeGyrA-His6: 29.1 kDa; MxeGyrA-His6: 22.9 kDa; GB1: 6.2 kDa. 
Upon looking in the literature, we found that this observation is not unprecedented. 
The Iwaï lab has investigated the splicing efficiency of 20 different inteins with GB1 as one 
of their test substrates218. MxeGyrA was one of the least efficient inteins for GB1 with 0-
10% splicing efficiency, depending on the condition. However, the second best performing 
intein with GB1 was the DnaE intein from Nostoc punctiforme (NpuDnaE) with about 90% 
spicing efficiency in their experiments. This was an intein we utilized previously in our 
lab213 and were able to use to clone GB1-NpuDnaE-His6 into a pTXB1 vector. Expression 
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and purification of the full length GB1-NpuDnaE-His6 fusion using standard protein 
expression conditions worked well. After a preliminary test that cleavage was indeed 
occurring, we again varied BME concentration, temperature and pH to optimize cleavage 
efficiency. All cleavages were carried out for 24 hours and a representative gel is shown 
in Figure 6-3. Residual Intein-fusion protein was quantified based on band intensity. 
Temperature and BME concentration were the major contributors with pH having a minor 
effect. The best cleavage conditions concluded to be cleavage with 1 M BME at pH 8.5 
and 37°C, leaving 61.6% of the intein-fusion protein intact after 24 hours. 
 
Figure 6-3: SDS-PAGE (16% Tris-Glycine gel) showing intein cleavage of GB1-
NpuDnaE-His6 under varying conditions. BME concentrations used were 0.1 M, 0.2 
M, 0.5 M and 1.0 M. Data shown here is for the reaction at pH 7.5. Gels at pH 8.0, 8.5, 
and 9.0 looked similar. MW: GB1-NpuDnaE-His6: 23.1 kDa; MxeGyrA-His6: 16.9 kDa; 
GB1: 6.2 kDa. GB1 stains poorly and runs higher than expected at around 12 kDa. 
Using the optimized intein cleavage conditions (1 M BME, 60 hrs, 37°C, pH 8.5), 
we were able to express and purify full-length WT GB1 from an NpuDnaE fusion in high 
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yield. The same procedure was applicable to the expression and purification of the NCL 
control construct GB1 K10C. Unfortunately, the purification of the N-terminal deletion 
construct GB1 Δ1-9 K10C from NpuDnaE fusion was not successful as the intein did not 
cleave. Before testing intein fusions with NpuDnaE and MxeGyrA, we cloned two 
additional fusion proteins of GB1 Δ1-9 K10C. It was previously reported that a 56 amino acid 
disordered region of MxeGyrA can be replaced with a (GS)4-linker and would result in an 
intein we termed MxeGyrA(Δ) with altered cleavage capabilities211. Additionally, a T3C 
mutation in MxeGyrA can make the intein less susceptible to spontaneous cleavage. We 
therefore also cloned GB1 Δ1-9 K10C as a fusion with MxeGyrA(Δ) and MxeGyrA(Δ, T3C). 
Small scale expression and purification allowed testing to see which of these inteins are 
able to efficiently cleave (see Figure 6-4). Suprisingly, MxeGyrA and MxeGyrA(Δ) fusion 
constructs were deemed to be the most efficient. As to why a 9 amino acid deletion at the 
N-terminus causes a C-terminal intein-fusion protein to be cleaved while the full-length 
protein will not and vice versa is not intuitive and, without structural data, purely 
speculative. Further investigation of this phenomenon with attempts to crystalize various 
intein fusion constructs is currently underway. 
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Figure 6-4: SDS-PAGE (14% Tris-Tricine gel) of intein cleavage test for GB110-56 K10C-
Intein-His6 fusion constructs. All cleavages performed with 1 M BME at 37°C for 48 
hrs. Inteins: A: NpuDnaE; B: MxeGyrA; C: MxeGyrA(Δ); D: MxeGyrA(Δ, T3C) 
With all controls and NCL fragments in our hands, we were finally able to attempt 
our ligation. To our surprise we found that the major products was a GB11-9 L7S dimer. 
Activation of acyl hydrazide as well as the reaction were carried out as in previously for 
other GB1 ligations71,120 except for the use of 4-Mercaptophenylacetic acid (MPAA) 
instead of thiophenol. Figure 6-5 shows how the majority of the thioester peptide seemed 
to have reacted with itself. Although the N-terminus does not contain a cysteine, we 
hypothesize that the two fragments were able to align in a way where the N-terminal amine 
was in close enough proximity to undergo the nucleophilic attack. Interestingly the 
resulting dimer was only observed in its hydrolyzed form and not as thioester. Based on 
these results we decided to redesign our constructs and to move the ligation site. 
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Figure 6-5: NCL with ligation site between Gly9 and Lys10. Top: Scheme showing the 
expected vs. observed reaction product. Botton: MALDI-TOF MS of NCL reaction 
showing formation of GB1 dimer with only minimal product formation. 
Native chemical ligation between Leu12 and Lys13. We moved our ligation site 
over by three residues between residues Leu12 and Lys13. The ligation site is not ideal due 
to Leu as the C-terminal residue on the thioester fragment. Systematic studies on a model 
peptide have shown that ligation at Leu was amongst the longest with taking more than 
48 hours to go to completion216. However, we hoped to avoid the association we observed 
previously and therefore prevent dimer formation, since the new disconnection site would 
be in the second β-sheet strand instead of in the loop (see Figure 6-6). 
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Figure 6-6: Semi-synthetic scheme to generate thio-GB1. Key difference to the 
previous scheme is the different ligation site to prevent the previously observed 
dimer formation. 
We also switched our system to generate the C-terminal thioester in order to move 
away from Met aminopeptidase. The issue with Met aminopeptidase is that N-terminal 
cysteines can condensate with intracellular aldehydes and ketones, especially pyruvic 
acid, to form thiazolidines215. While this reaction is reversible through the treatment with 
methoxyamine at pH 4.0, this adds an extra step in the preparation of the protein215. 
Furthermore, it has been shown that Met aminopeptidase removes not only methionine, 
but also the penultimate amino acid, depending on the antepenultimate residue215, which 
in our case would result in an unreactive protein fragment.  
To achieve a higher sample homogeneity, we decided to switch to a protease-
based method to generate our C-terminal fusion protein. Various proteases have been 
utilized for this purpose in the past, including Factor Xa and Tobacco Etch Virus (TEV) 
protease. Factor Xa cleaves the C-terminal of an IEGR recognition sequence while TEV 
protease recognizes the sequence ENLYFQG and cuts between Q and G, although it has 
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been reported that G can be replaced by C and used to generate N-terminal cysteine 
fragments219,220. However, both proteases have known off-target effects upon prolonged 
incubation and we have previously experienced protein loss through aggregation with 
Factor Xa73. We decided to switch to a rather new protease system that does not just rely 
on a recognition sequence, but also on tertiary structure221. Ulp-1 is a naturally occurring 
enzyme in yeast that removes Small Ubiquitin-like Modifier (SUMO), a post-translational 
modification, from amino acid side chains. SUMO-fusions have been utilized to stabilize 
proteins for structural investigation and as purification tag222,223. Ulp-1 can be used to 
selectively cleave SUMO fusion proteins as it will recognize the tertiary fold of SUMO and 
cleave after the last residues of SUMO as long as there is not proline residue in the next 
two positions. 
We expressed and purified Ulp-1 as previously published without problems222. We 
cloned the gene for His6-SUMO-GB1 Δ1-12 K13C into a pET vector. Expression and 
purification went smoothly. Compared to the Met aminopeptidase-based method the 
SUMO/Ulp-1 pair gave protein in lower (but still good) yield (8.5 mg isolated protein / L 
expression), but in high homogeneity and in significantly shorter time, as it cut out several 
dialysis steps. The synthesis of GB11-12 LS7-N2H3 was carried out under identical conditions 
as the GB11-9 fragment. 
Using fragments with the new ligation site, we carried out our NCL reaction. As 
expected, the reaction took significantly longer and was deemed to be complete after 72 
hours, when no thioester peptide was detectable by MALDI-TOF MS (see Figure 6-7). 
During the reaction we observed significant drift in pH over time from 7.0 up to 7.6. While 
we readjusted the pH back to 6.9-7.0, the increased pH resulted in hydrolyzed peptide, 
lowering the overall yield. We initially attempted FPLC purification of the ligated protein, 
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but were not able to get sufficient separation between the ligated product and the unligated 
C-terminal fragment. HPLC purification on the other hand gave us good separation and 
allowed us to isolate our desired product in 21.2% yield (based on peptide as limited 
reagent). Further experiments for scale-up and aminoethylation are in progress. 
 
Figure 6-7: Progress of NCL reaction based on MALDI-TOF MS. Traces show 
reaction at the beginning (30 minutes; blue), at completion (72 hours, red), and post 
HPLC purification (green). * denotes MPAA disulfide adducts. 
   
6.3 Conclusion 
We have previously shown that incorporation of thioamides into β-sheet positions 
GB1 can have disruptive effect on the protein fold, but the extent of disruption is 
positionally dependent71. To provide further evidence for this hypothesis, high-resolution 
structures are necessary. We set out to synthesize thio-GB1 through semi-synthetic 
methods in order to be able to produce thioprotein in quantities sufficient for high-
resolution structures by NMR and crystallography. 
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While our first choice of ligation site was not suitable, we were successful in 
redesigning and optimizing our semisynthetic scheme. Using a protease-based method to 
generate our C-terminal ligation fragment with an N-terminal cysteine, we were able to 
obtain it in good yield and high purity. While our overall isolated yield for the ligation was 
only modest, we hope to increase it in the near future by monitoring the pH more carefully, 
increasing the concentration of reactants in the ligation, and by performing the reaction at 
37°C. Additionally, we still need to carry out aminoethylation reactions on both, the 
recombinantly expressed NCL control protein (GB1 K13C) as well as the NCL product. We 
anticipate that these reactions will proceed smoothly as it has with the previous construct 
GB1 K10CK. 
With this approach we anticipate that in the near future it will be possible to obtain 
mg quantities of thioamide labelled GB1 enabling high-resolution structures by NMR as 
well as X-ray crystallography.  
6.4 Materials and Methods 
General Information Fmoc protected amino acids, 2-chlorotrityl resin and peptide 
synthesis reagents were purchased from EMD Millipore (Billerica, MA, USA) or 
ChemImpex (Wood Dale, IL, USA). Nα-Fmoc-L-Thioleucine-nitrobenztriazolide (Fmoc-
LeuS-Nbt) was synthesized as previously described72. Hydrazine Hydrate solution was 
purchase from Oakwood Chemical (Estill, SC, USA). Isopropyl β-D-1-thiogalacto-
pyranoside (IPTG) was purchased from LabScientific, Inc. (Highlands, NJ, USA). 
cOmplete Mini, EDTA-free protease inhibitor tablets were purchased from Roche 
Diagnostics (Mannheim, Germany). High-Density Nickel Agarose Beads were purchased 
from GoldBio (St. Louis, MO, USA). Guanidine Hydrochloride was purchased from 
Invitrogen (Waltham, MA, USA). Amicon Ultra Spin Filters were purchased from EMD 
147 
 
Millipore. Slide-A-Lyzer G2 dialysis casettes were purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). All other reagents, solvents and materials were purchased 
from Fisher Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich (St. Louis, MO, USA) and 
used without further purification unless otherwise specified. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, 
USA). Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on 
a Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
mass spectrometer. UV-Vis absorption measurements were performed on a Hewlett-
Packard 8452A diode array spectrophotometer (currently Agilent Technologies; Santa 
Clara, CA, USA) or Thermo Fisher Scientific Genesys 150 UV/Vis Spectrophotometer 
(Waltham, MA, USA). Since OD600 measurements are instrument specific (measured 
scattering intensity depends on the distance between sample and detector), values 
obtained on the Genesys 150 were multiplied by a factor of 1.5 (empirically determined) 
to match values obtained on HP 8452A. Nuclear magnetic resonance (NMR) spectra were 
obtained on a Bruker DRX 500 MHz instrument (Billerica, MA, USA). Matrix assisted laser 
desorption/ionization with time-of-flight detector (MALDI-TOF) mass spectra were 
acquired on a Bruker Ultraflex III or Microflex LRF instrument. Fast protein liquid 
chromatography (FPLC) was performed on an Äkta Explorer system (GE Healthcare, 
Chicago, IL, USA). HiTrap Q HP (5mL) anion exchange columns and HiLoad Superdex 
75 pg 16/600 size exclusion chromatography column were purchased from GE 
Healthcare. Reverse-phase purification of crude peptides was performed on a Biotage 
Isolera System on Biotage SNAP Ultra C18 columns (Charlotte, NC, USA). Analytical 
HPLC was performed on an Agilent 1260 Infinity II series UHPLC system (Agilent, Santa 
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Clara, CA, USA). Preparative HPLC was performed on an Agilent 1260 Infinity II Prep 
HPLC system. HPLC columns were purchased from Phenomenex (Torrance, CA, USA). 
HPLC columns used were Analytical (150 x 4.6 mm), Semiprep (250 x 10 mm), and Prep 
size (250 x 21.2 mm) Luna® Omega 5 µm PS C18 100 Å columns from Phenomenex. 
Synthesis of Peptides used in Native Chemical Ligation. Peptides were 
synthesized using standard Fmoc solid phase peptide synthesis (SPPS) procedure on 2-
chlorotrityl chloride resin (100 - 200 mesh; 0.6 mmol substitution/g). Hydrazide resin for 
peptide synthesis was prepared according to Liu and coworkers119. For coupling, 5 equiv 
of amino acid and 5 equiv of HBTU or PyAOP were dissolved in DMF, pre-activated for 1 
min in the presence of 10 equiv of DIPEA, and then stirred with the resin for 30 min at 
room temperature. For deprotection, 2% (v/v) 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) 
in DMF was stirred with the resin three times for 2 min each. Thioleucine (denoted LeuS 
or LS) was introduced through activated nitrobenztriazole precursor and was synthesized 
as previously described71,72,120. 2 equiv of the precursor was dissolved in anhydrous 
CH2Cl2, and stirred with the resin for 45 min in the presence of 2 eq DIPEA. Upon 
completion of SPPS, resin was rinsed thoroughly with CH2Cl2 and dried under vacuum. 
For cleavage, resin was treated with 5 mL of a cleavage cocktail solution (35% 
trifluoroacetic acid, 5% ethane-1,2-dithiol, 5% thioanisole, 2.5% triisopropylsilane, 2.5% 
water, and 50% dichloromethane; all percentages as v/v) for 60 min. The peptide was 
precipitated by the addition of cold diethyl ether. Various peptides were synthesized and/or 
purified by or with help of Kristen E. Fiore. 
Synthesis and purification of GB11-9 LS7-N2H3 (6-1). Peptide was synthesized as 
described above on a 100 µmol scale. The crude peptide was dissolved in 1 mL dimethyl 
sulfoxide (DMSO) and purified by reverse phase chromatography on a Biotage SNAP 
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Ultra C18 (30g) cartridge using Gradient 6A at a flowrate of 25 mL/min. Pure fractions 
were combined and dried by lyophilization. Mixed fractions containing the desired product 
as well as other peptide masses were combined, dried by lyophilization and re-purified by 
reverse phase HPLC on a Phenomenex Luna Omega Prep column using Gradient 6B at 
a flowrate of 25 mL/min. Pure fractions were combined and dried by lyophilization. 
 
Figure 6-8: MALDI-TOF MS of purified GB11-9 LS7-N2H3 (6-1). [M+Na]+: expected: 
1,131.58; observed: 1,131.86. 
Synthesis and purification of GB11-12 LS7-N2H3 (6-2). Peptide was synthesized 
as described above on a 100 µmol scale. The crude peptide was dissolved in 1 mL 
dimethyl sulfoxide (DMSO) and purified by reverse phase chromatography on a Biotage 
SNAP Ultra C18 (30g) cartridge using Gradient 6C at a flowrate of 25 mL/min. Pure 
fractions were combined and dried by lyophilization. Mixed fractions containing the desired 
product as well as other peptide masses were combined, dried by lyophilization and re-
purified by reverse phase HPLC on a Phenomenex Luna Omega Prep column using 
Gradient 6D at a flowrate of 25 mL/min. Pure fractions were combined and dried by 
lyophilization.  
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We observed an inseparable mass adduct of +104 in our purified peptide. We 
analyzed this peak with m/z of 1,556 by MALDI-TOF/TOF MS. For our analysis we 
assumed that this is a modification of our desired peptide. We were able to assign 8 out 
of 12 b-ions, missing only b1 (too small), b7 (usually not observed for thioamides), b9 and 
b12 (see Figure 6-9). However, we were not able to assign any of the expected y-ions to 
any of the observed peaks. This indicated that the modification appeared on the most C-
terminal residue. Given that the C-terminal residues is Leu, we concluded that this mass 
adduct is modification of the C-terminal acyl-hydrazide. We deemed fractions containing 
this mass adduct as “pure”, since the modification will either be reversible, so that the 
peptide could be converted to a thioester in later steps, or irreversible, in which case it 
would be unreactive during later NCL reactions and can be purified away in later steps. 
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Figure 6-9: Top: MALDI-TOF MS of purified GB11-12 LS7-N2H3 (6-2). [M+H]+: expected: 
1,451.82; observed: 1,452.21. *denotes inseparable product with +104 mass differ-
ence. Bottom: MS/MS analysis of peak at m/z = 1,556 shows most expected b-ions 
of 6-2 up to b11 but none of the expected y-ions, indicating modification of the C-
terminal acyl-hydrazide. 
General information about cloning. All PCR reactions were carried out on a 
T100 thermocycler from Bio-Rad (Hercules, CA, USA). Primers and double stranded DNA 
fragments (gBlocks) were purchased from Integrated DNA Technologies (Coralville, IA, 
USA). dNTPs, SYBR Safe DNA gel stain and Agarose were purchased from Invitrogen 
(Waltham, MA, USA). Phusion High-Fidelity DNA polymerase, Q5 High-Fidelity DNA 
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polymerase, Q5 High-Fidelity DNA polymerase Master Mix, HiFi DNA Assembly Master 
Mix, Restriction Enzymes, competent High Efficiency E. coli cells (NEB 5-alpha and NEB 
10-beta), T4 DNA Polynucleotide Kinase, T4 DNA Ligase and Monarch Gel Extraction Kit 
were purchased from New England Biolabs (Ipswich, MA, USA). Gel Green DNA gel stain 
was purchased from Biotium (Freemont, CA, USA). DNA Clean & Concentrator Kit and 
Plasmid Miniprep Kit were purchased from Zymo Research (Irvine, CA, USA). DNA 
concentrations were determined with a TECAN Nanoquant plate on an Infinite M1000Pro 
plate reader (Tecan, Männedorf, Switzerland). DNA sequencing (Sanger sequencing) was 
performed at the University of Pennsylvania DNA Sequencing Facility (Philadelphia, PA, 
USA). Agarose gels were visualized on a Typhoon Imager (GE Healthcare, Marlborough, 
MA, USA) or a SmartBlue transilluminator (Southern Labware, Cumming, GA 30028). 
PCR of constructs containing K13C mutation was performed by Kristen E. Fiore. pET His6-
SUMO-TEV (2S-T) plasmid was a gift from Scott Gradia (Addgene plasmid # 29711; 
http://n2t.net/addgene:29711; RRID: Addgene_29711). pFGET19_Ulp1 was a gift from 
Hideo Iwai (Addgene plasmid #64697; http://n2t.net/addgene:64697; RRID: 
Addgene_64697). 
General procedure for PCR. Primers were dissolved in Milli-Q grade water to be 
at a concentration of 50 µM. The amount of plasmid used ranged from 0.1 – 1 ng total 
DNA for amplifications using Q5 polymerase and 0.5-10 ng for amplifications using 
Phusion polymerase. Primers, plasmid and buffer components were mixed according to 
manufacturer recommendations. PCR was carried out for 35 cycles at annealing 
temperatures calculated with the New England Biolabs Tm calculator tool 
(https://tmcalculator.neb.com). Alternatively, a ‘Touchdown protocol’ was used, where 
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annealing started with either 70° or 72°C in the first cycle and was reduced in each of the 
19 subsequent cycles by 0.5°C each, followed by 15 amplifications at 55°C. 
Following amplification, the PCR product was isolated using a DNA Concentrator 
& Cleanup Kit. PCR product was quantified to verify successful PCR amplification. PCR 
product was circularized by mixing 2 µL PCR product with 5 µL Milli-Q grade water, 1 µL 
10x T4 DNA Ligase Buffer, 1 µL T4 Polynucleotide Kinase, 0.5 µL T4 DNA Ligase and 0.5 
µL DpnI. This mixture was incubated at 37°C for 45 minutes, cooled on ice and 50 µL of 
competent NEB 5-alpha cells were added. Cells were transformed and plated on an LB-
Agar plate containing appropriate antibiotic. Individual colonies were picked, grown up in 
5 mL LB-medium and their DNA was extracted using a Plasmid Miniprep Kit according to 
manufacturer’s protocol. Quantified DNA was submitted for sanger sequence analysis to 
verify correct sequence. Sequencing primer was provided by Sequencing Center and 
aligns with T7 promoter unless otherwise noted. 
General procedure for Gibson Assembly. Primers were dissolved in Milli-Q 
grade water to be at a concentration of 50 µM. The amount of plasmid used ranged from 
0.1 – 1 ng total DNA for amplifications using Q5 polymerase and 0.5-10 ng for 
amplifications using Phusion polymerase. Vector and insert were amplified simultaneously 
using a ‘Touchdown protocol’, where annealing started with 70° in the first cycle and was 
reduced in each of the 19 subsequent cycles by 0.5°C each, followed by 15 amplifications 
at 55°C. PCR product was purified using a 1% Agarose gel containing SYBR Safe or 
GelGreen Dye. Gel was visualized using a Blue light transilluminator and bands of the 
expected size were excised. DNA was extracted using a DNA gel extraction kit according 
to the manufacturer’s protocol and isolated DNA was quantified. DNA assembly was 
performed with 100 ng of vector DNA and 2 equiv of insert DNA (5 equiv for insert <300 
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bp) using a HiFi DNA Assembly Mix according to manufacturer’s protocol. 2 µL of the 
ligated product were transformed in 50 µL competent NEB10β cells according to 
manufacturer’s instructions and plated on an LB-Agar plate containing appropriate 
antibiotic. Individual colonies were picked, grown up in 5 mL LB-medium and their DNA 
was extracted using a Plasmid Miniprep Kit according to manufacturer’s protocol. 
Quantified DNA was submitted for sanger sequence analysis to verify correct sequence. 
Sequencing primer was provided by Sequencing Center and aligns with T7 promoter 
unless otherwise noted. 
Cloning of pTXB1 GB1-MxeGyrA-His6. Plasmid was constructed using Gibson 
Assembly. The Vector donor plasmid was pTXB1 αS-MxeGyrA-His6 and construction of 
this plasmid is described elsewhere224. The insert was purchased as gBlock from IDT. 
gBlock (5’ to 3’ strand only): 
TTAACTTTAA GAAGGAGATA TACATATGCA GTATAAGTTA ATCCTTAATG 
GGAAGACTCT GAAGGGGGAA ACAACAACTG AAGCGGTAGA CGCCGCCACG 
GCAGAAAAGG TCTTTAAGCA GTATGCCAAT GATAATGGGG TTGATGGTGA 
GTGGACTTAC GACGATGCGA CAAAGACGTT CACCGTTACC GAGTGCATCA 
CGGGAGATGC ACTAGTTG 
Forward primer for vector: 
5’ – TGCATCACGG GAGATGCA – 3’ 
Reverse complement primer for vector: 
5’ – ATGTATATCT CCTTCTTAAA GTTAAAC – 3’ 
Cloning of pTXB1 GB1(K10C)-MxeGyrA-His6. Plasmid was generated through 
site-directed mutagenesis PCR from plasmid pTXB1 GB1-MxeGyrA-His6. 
Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CCCATTAAGG ATTAACTTAT ACTGC – 3’ 
Cloning of pTXB1 GB1(Δ2-9 K10C)-MxeGyrA-His6. Plasmid was generated 
through deletion PCR from plasmid pTXB1 GB1(K10C)-MxeGyrA-His6. 
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Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC – 3’ 
Cloning of pTXB1 GB1-PacI-MxeGyrA-His6. Plasmid was generated through 
insertion PCR from plasmid pTXB1 GB1-MxeGyrA-His6. The PacI restriction enzyme site 
was introduced between the DNA sequence of GB1 and the MxeGyrA Intein. 
Forward primer: 
5’ – TTAATGCATC ACGGGAGATG CA – 3’ 
Reverse complement primer: 
5’ – TTAACTCGGT AACGGTGAAC GT – 3’ 
Cloning of pTXB1 GB1-PacI-NpuDnaE-His6. Plasmid was generated through 
restriction enzyme cloning. The vector donor plasmid was pTXB1-GB1-PacI-MxeGyrA-
His6 and the insert donor plasmid was pTXB1-Ub-PacI-NpuDnaE-His6 (construction of this 
plasmid is described elsewhere )213. Both plasmids were digested using PacI and NdeI in 
CutSmart buffer according to manufacturer recommendations. Vector and insert were 
purified using a 1% Agarose gel. After gel extraction DNA fragments were combined in a 
1:1 ratio and ligated using T4 DNA Ligase. The sequence was confirmed by DNA 
sequencing analysis. 
Cloning of pTXB1 GB1-NpuDnaE-His6. Plasmid was generated by deleting the 
PacI restriction enzyme site from plasmid pTXB1 GB1-PacI-NpuDnaE-His6 by the means 
of deletion PCR.  
Forward primer: 
5’ – TGCCTGAGCT ATGAAACGG – 3’ 
Reverse complement primer: 
5’ – CTCGGTAACG GTGAACGT – 3’ 
Cloning of pTXB1 GB1(K10C)-NpuDnaE-His6. Plasmid was generated through 
site-directed mutagenesis PCR from plasmid pTXB1 GB1-NpuDnaE-His6. 
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Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CCCATTAAGG ATTAACTTAT ACTGC – 3’ 
Cloning of pTXB1 GB1(Δ2-9 K10C)-NpuDnaE-His6. Plasmid was generated 
through site-directed mutagenesis and simultaneous deletion PCR from plasmid pTXB1 
GB1-NpuDnaE-His6. 
Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC – 3’ 
Cloning of pTXB1 GB1-MxeGyrA(Δ)-His6. It was previously reported that 
MxeGyrA can be truncated to replace residues 107-160 with a (GS)4 linker211. Plasmid 
was generated through simultaneous deletion and insertion PCR from plasmid pTXB1 
GB1-MxeGyrA-His6. 
Forward primer: 
5’ – GGTTCAGGCT CGTTCTACTA CGCGAAAGTC – 3’ 
Reverse complement primer: 
5’ – ACTGCCGCTA CCTTGAATCA CCGCGTAATC – 3’ 
Cloning of pTXB1 GB1-MxeGyrA(Δ, T3C)-His6. It was previously reported that a 
T3C mutation in MxeGyrA can suppress premature hydrolysis of the thioether intermediate 
by tying up the cysteine responsible for thioester formation in a disulfide bond211. Plasmid 
was generated through site-directed mutagenesis PCR from plasmid pTXB1 GB1-
MxeGyrA(Δ)-His6. 
Forward primer: 
5’ – TGTGGAGATG CACTAGTTGC – 3’ 
Reverse complement primer: 
5’ – GATGCACTCG GTAACGGT – 3’ 
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Cloning of pTXB1 GB1(Δ2-9 K10C)-MxeGyrA(Δ)-His6. Plasmid was generated 
through site-directed mutagenesis and simultaneous deletion PCR from plasmid pTXB1 
GB1-MxeGyrA(Δ)-His6. 
Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC – 3’ 
Cloning of pTXB1 GB1(Δ2-9 K10C)-MxeGyrA(Δ, T3C)-His6. Plasmid was 
generated through site-directed mutagenesis and simultaneous deletion PCR from 
plasmid pTXB1 GB1-MxeGyrA(Δ, T3C)-His6. 
Forward primer: 
5’ – TGTACTCTGA AGGGGGAAA – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC – 3’ 
Cloning of pTXB1 GB1(K13C)-MxeGyrA(Δ)-His6. Plasmid was generated 
through site-directed mutagenesis PCR from plasmid pTXB1 GB1-MxeGyrA(Δ)-His6. 
Forward primer: 
5’ – TGCGGGGAAC ACACAACTG – 3’ 
Reverse complement primer: 
5’ – CAGAGTCTTC CCATTAAGGA TTAACTTATA – 3’ 
Cloning of pTXB1 GB1(K13C)-NpuDnaE-His6. Plasmid was generated through 
site-directed mutagenesis PCR from plasmid pTXB1 GB1-NpuDnaE-His6. 
Forward primer: 
5’ – TGCGGGGAAC ACACAACTG – 3’ 
Reverse complement primer: 
5’ – CAGAGTCTTC CCATTAAGGA TTAACTTATA – 3’ 
Cloning of pTXB1 GB1(Δ2-12 K13C)-MxeGyrA(Δ)-His6. Plasmid was generated 
through site-directed mutagenesis and simultaneous deletion PCR from plasmid pTXB1 
GB1-MxeGyrA(Δ)-His6. 
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Forward primer: 
5’ – TGCGGGGAAC ACACAACTG – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC AAAATTATTT CT – 3’ 
Cloning of pTXB1 GB1(Δ2-12 K13C)-NpuDnaE-His6. Plasmid was generated 
through site-directed mutagenesis and simultaneous deletion PCR from plasmid pTXB1 
GB1-NpuDnaE-His6. 
Forward primer: 
5’ – TGCGGGGAAC ACACAACTG – 3’ 
Reverse complement primer: 
5’ – CATATGTATA TCTCCTTCTT AAAGTTAAAC AAAATTATTT CT – 3’ 
Cloning of pET His6-SUMO-TEV -EcoRI. pET His6-SUMO-TEV (2S-T) plasmid 
was a gift from Scott Gradia (Addgene plasmid # 29711 ; http://n2t.net/addgene:29711 ; 
RRID:Addgene_29711). One of the EcoRI restriction enzyme sites in an empty region of 
the plasmid about 400 bp 5’ from the Amp-R promoter was deleted by deletion PCR to 
enable EcoRI specific restriction enzyme cloning in the future. 
Forward primer: 
5’ – TTCTTGAAGA CGAAAGGGC – 3’ 
Reverse complement primer: 
5’ – TCATGTTTGA CAGCTTATCA T – 3’ 
Cloning of pET His6-SUMO-GB113-56 K13C. Plasmid was constructed using 
Gibson Assembly. The Vector donor plasmid was pET His6-SUMO-TEV -EcoR1. The 
insert donor plasmid was GB1(Δ2-12 K13C)-MxeGyrA(Δ)-His6. Primers were designed to 
introduce 10 nt overlaps, i.e. the 5’ and 3’ and of insert contained 10 nt of the vector and 
vice versa. This created the necessary 20 nt overlap for Gibson assembly. 
Forward primer for vector: 
5’ – CGTTACCGAG TAACGGATCC GCGATCG – 3’ 
Reverse complement primer for vector: 
5’ – TTTCCCCGCA CCCAGCAATC TGTTCTCT – 3’ 
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Forward primer for insert: 
5’ – GATTGGTGGG TGCGGGGAAA CAACA – 3’ 
Reverse complement primer for insert: 
5’ – GGATCCGTTA CTCGGTAACG GTGAACG – 3’ 
Amino acid sequences of various fragments used: 
GB1 
MQYKLILNGK TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE 
GB1 K10C 
MQYKLILNGC TLKGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE 
GB110-56 K10C 
CTLKGETTTE AVDAATAEKV FKQYANDNGV DGEWTYDDAT KTFTVTE 
GB1 K13C 
MQYKLILNGK TLCGETTTEA VDAATAEKVF KQYANDNGVD GEWTYDDATK 
TFTVTE 
GB113-56 K13C) 
CGETTTEAVD AATAEKVFKQ YANDNGVDGE WTYDDATKTF TVTE 
MxeGyrA-His6 (Note: Segment in red is replaced by (GS)4 linker in MxeGyrA(Δ)-His6) 
CITGDALVAL PEGESVRIAD IVPGARPNSD NAIDLKVLDR HGNPVLADRL 
FHSGEHPVYT VRTVEGLRVT GTANHPLLCL VDVAGVPTLL WKLIDEIKPG 
DYAVIQRSAF SVDCAGFARG KPEFAPTTYT VGVPGLVRFL EAHHRDPDAQ 
AIADELTDGR FYYAKVASVT DAGVQPVYSL RVDTADHAFI TNGFVSHATG 
LTGLKLHHHH HH 
NpuDnaE 
CLSYETEILT VEYGLLPIGK IVEKRIECTV YSVDNNGNIY TQPVAQWHDR 
GEQEVFEYCL EDGSLIRATK DHKFMTVDGQ MLPIDEIFER ELDLMRVDNL 
PNIKIATRKY LGKQNVYDIG VERDHNFALK NGFIASAAFN HHHHHH 
MxeGyrA(Δ)-His6 
CITGDALVAL PEGESVRIAD IVPGARPNSD NAIDLKVLDR HGNPVLADRL 
FHSGEHPVYT VRTVEGLRVT GTANHPLLCL VDVAGVPTLL WKLIDEIKPG 
DYAVIQGSGS GSGSFYYAKV ASVTDAGVQP VYSLRVDTAD HAFITNGFVS 
HATGLTGLKL HHHHHH 
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MxeGyrA(Δ, T3C)-His6 
CICGDALVAL PEGESVRIAD IVPGARPNSD NAIDLKVLDR HGNPVLADRL 
FHSGEHPVYT VRTVEGLRVT GTANHPLLCL VDVAGVPTLL WKLIDEIKPG 
DYAVIQGSGS GSGSFYYAKV ASVTDAGVQP VYSLRVDTAD HAFITNGFVS 
HATGLTGLKL HHHHHH 
His6-SUMO 
MKSSHHHHHH GSSMASMSDS EVNQEAKPEV KPEVKPETHI NLKVSDGSSE 
IFFKIKKTTP LRRLMEAFAK RQGKEMDSLR FLYDGIRIQA DQTPEDLDME 
DNDIIEAHRE QIGG 
His-Ulp1 
MRGSHHHHHH GLVPRGSLVP ELNEKDDDQV QKALASRENT QLMNRDNIEI 
TVRDFKTLAP RRWLNDTIIE FFMKYIEKST PNTVAFNSFF YTNLSERGYQ 
GVRRWMKRKK TQIDKLDKIF TPINLNQSHW ALGIIDLKKK TIGYVDSLSN 
GPNAMSFAIL TDLQKYVMEE SKHTIGEDFD LIHLDCPQQP NGYDCGIYVC 
MNTLYGSADA PLDFDYKDAI RMRRFIAHLI LTDALK 
Generation of E. coli Glycerol stocks for recombinant protein expression. 
Desired plasmid was transformed into BL21(DE3) E. coli cells by heat-shock and grown 
on an LB-Agar plate containing kanamycin (50µg/mL) for pFGET19 plasmid or ampicillin 
(100µg/mL) for all other plasmids. Plates were incubated at 37°C for at least 16 hours until 
colonies formed. An individual colony was picked and grown in 3 mL of sterile LB medium 
containing the appropriate antibiotic overnight at 37°C with 250 RPM shaking until 
saturation. 500 µL of this saturated culture were mixed with 500 µL 50% (v/v) sterile 
glycerol solution and frozen at -80°C. 
General Procedure for recombinant expression and purification of proteins 
from Intein fusion proteins. The protocol is based on a previously published 
procedure213. For each liter of expression, four 5 mL primary cultures of sterile LB-media 
containing the ampicillin (100 µg/mL) were inoculated by scraping the surface of the frozen 
glycerol stock with a sterile pipette tip. Primary cultures were grown overnight at 37°C with 
250 RPM shaking until saturation. Each liter of sterile LB-media containing ampicillin (100 
µg/mL) was inoculated by addition of three primary cultures and grown at 37°C with 250 
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RPM shaking. Upon reaching an OD600 of 0.6-0.8, culture was switched to an incubator 
operating at 18°C with 250 RPM shaking. After allowing the media temperature to adjust 
for 15 minutes, IPTG was added to a final concentration of 1 mM to induce protein 
expression. Protein expression was continued at 18°C with 250 RPM shaking for 20 hours. 
Cells were harvested by centrifugation at 4,000 RPM in a GS3 rotor and Sorvall RC-5 
centrifuge for 20 min at 4°C. The supernatant was discarded and the cell pellet was 
suspended in 30 mL lysis buffer (40 mM Tris, 1 mM PMSF, pH 8.3) containing a broad-
spectrum protease inhibitor tablet. Resuspended cells were then lysed on ice by 
sonication (35 amps power, 1 second pulse, 2 second rest, 5 minutes total sonication time) 
and then pelleted at 14,000 RPM in an SS-34 rotor (Sorvall RC-5 centrifuge) for 30 min at 
4°C. In the meantime, 4 mL (settled volume) of Nickel Agarose beads were washed with 
20 mL equilibration buffer (50 mM HEPES, pH 7.5). The crude cell lysate was incubated 
with the washed nickel resin for 1 h on ice with shaking. The slurry was then added to a 
fritted column and the liquid was allowed to flow through. The resin was then washed with 
20 mL of equilibration buffer and 25 mL of wash buffer (50 mM HEPES, 5 mM imidazole, 
pH 7.5). Intein fusion protein was then eluted from the resin in 10 mL of elution buffer (50 
mM Tris, 300 mM imidazole, pH 8.5). Intein cleavage was induced by addition 758 µL of 
β-Mercaptoethanol (1 M final concentration). Cleavage was carried out at room 
temperature, 4°C, or 37°C for 60-75 hours before it was dialyzed into 20 mM Tris, pH 8.0 
using Slide-A-Lyzer 2,000 MWCO cassettes. If protein has precipitated during cleavage, 
8 M Urea was added immediately before dialysis until protein was dissolved again. 
Additionally, 20 µL of TCEP Bond-Breaker solution was added to cysteine containing 
proteins. After 2 rounds of dialysis at 4°C against at least 100 times the sample volume, 
sample was removed from dialysis cassette. 4 mL (settled volume) of Nickel Agarose 
beads were washed with 20 mL equilibration buffer (50 mM HEPES, pH 7.5) and dialyzed 
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sample was incubated with the washed nickel resin for 1 h on ice with shaking. The slurry 
was then added to a fritted column and the liquid was allowed to flow through and 
collected. The desired cleaved protein was contained in the flow-through fraction, while 
uncleaved fusion protein and cleaved intein product were bound to the resin. The crude 
product was dialyzed twice against 10 mM NH4HCO3 before quantification and 
lyophilization. Various protein expressions and/or purifications were carried out by or with 
help of Kristen E. Fiore. 
2-Bromoethylamine labeling of Cysteine containing proteins. Proteins were 
dissolved in alkylation buffer (8 M Urea, 0.55 M Tris, pH 8.5). 5 equiv. of Tris(2-
carboxyethyl)phosphine (TCEP) were added and solution was incubated at room 
temperature for 15 minutes. 20 equiv of 2-Bromoethylamine were dissolved in a minimal 
amount of 0.55 M Tris, pH 8.5 and added. Reactions were incubated in a waterbath at 
37°C for 3-4 hours until reaction was deemed complete by MALDI-TOF MS. Crude 
reaction was diluted by 5 fold and dialyzed twice against 20 mM Tris, pH 8.0 at 4°C before 
FPLC purification. 
Recombinant expression of GB1 (6-3). Protein was expressed as described 
above as GB1-NpuDnaE-His6 fusion protein. Intein was cleaved at 37°C for 60 hours. After 
2nd nickel column, protein was dialyzed against 20 mM Tris, pH 8.0 and purified by FPLC 
using gradient 6E. Quantification post FPLC by UV-Vis (ε280 = 9,970 M-1 cm-1) determined 
the yield as 14.5 mg/L expression. Expression and purification are shown in Figure 6-10. 
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Figure 6-10: Characterization of GB1 expression. Top: SDS-PAGE (14% Tris-Tricine 
gel) of GB1 (WT) expression/purification. MW: GB1-NpuDnaE-His6: 23.1 kDa; 
NpuDnaE-His6: 19.6 kDa; GB1: 6.2 kDa. GB1 runs at a higher than expected 
molecular weight at about 11 kDa. Bottom: MALDI-TOF analysis of GB1. [M+H]+: 
expected: 6,223.85 observed: 6,222.37. 
Recombinant expression of GB1 K10CK (6-5). Protein was expressed as 
described above as GB1 K10C-NpuDnaE-His6 fusion protein. Intein was cleaved at 37°C 
for 60 hours. After dialysis, protein 6-4 was quantified by UV-Vis (ε280 = 9,970 M-1 cm-1; 
yield = 14.2 mg/L expression) before lyophilization. Lyophilized protein from 2 L 
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expression was alkylated as described above and purified on FPLC using gradient 6E. 
Quantification post FPLC by UV-Vis (ε280 = 9,970 M-1 cm-1) determined yield to be 6.7 mg 
/ 48% (some protein was spilled post dialysis). Expression and purification are shown in 
Figure 6-11. 
 
Figure 6-11: Characterization of GB1 K10CK (6-5) expression. Top: SDS-PAGE (14% 
Tris-Tricine gel) of expression/purification. MW: GB1 K10C-NpuDnaE-His6: 23.1 kDa; 
NpuDnaE-His6: 19.6 kDa; GB1: 6.2 kDa. GB1 K10C runs at a higher than expected 
molecular weight at about 11 kDa. Bottom: MALDI-TOF analysis of protein before 
(blue) and after (green) labelling. GB1 K10C (6-4): [M+H]+: expected: 6,198.81 
observed: 6,197.30. GB1 K10CK (6-5): [M+H]+: expected: 6,241.88 observed: 6,242.53. 
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Recombinant expression of GB110-56 K10C (6-6). Protein was expressed as 
described above as GB110-56 K10C-MxeGyrA-His6 fusion protein. Intein was cleaved at 4°C 
for 72 hours. After dialysis, protein was quantified by UV-Vis (ε280 = 9,970 M-1 cm-1; yield 
= 20.9 mg/L expression) before lyophilization. N-terminal cysteine has been observed to 
form +70 mass adducts from pyruvate addition. This was also the main observed species 
in MALDI-TOF MS. Reversal of this thiazolidine (Thz) modification is achieved by 
treatment thiazolidine deprotection buffer (6 M Gdn*HCl, 0.2 M sodium phosphate, 0.2 M 
Methoxyamine, pH 4.0) overnight215. After Thz deprotection, protein was dialyzed twice 
against 10 mM NH4HCO3 and lyophilized. Expression and purification are shown in Figure 
6-12 
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Figure 6-12: Characterization of GB110-56 K10C (6-6) expression. Top: SDS-PAGE 
(14% Tris-Tricine gel) of expression/purification. MW: GB110-56 K10C-MxeGyrA(Δ)-
His6: 22.8 kDa; MxeGyrA(Δ)-His6: 17.7 kDa; GB110-56 K10C: 5.1 kDa. GB110-56 K10C runs 
at a higher than expected molecular weight at about 11 kDa and stains poorly. 
Bottom: MALDI-TOF analysis. GB110-56 K10C (Pyruvate adduct): [M+H]+: expected: 
5,207.50 observed: 5,208.79 
Recombinant expression of GB1 K13C (6-8). Protein was expressed as 
described above as GB1 K13C-NpuDnaE-His6 fusion protein. Intein was cleaved at room 
temperature for 74 hours. After 2nd nickel column, protein was dialyzed against 20 mM 
Tris, pH 8.0 and purified by FPLC using gradient 6F. Quantification post FPLC by UV-Vis 
(ε280 = 9,970 M-1 cm-1) determined the yield as 12.7 mg/L expression. Expression and 
purification are shown in Figure 6-13. 
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Figure 6-13: Characterization of GB1 K13C (6-8) expression. Top: SDS-PAGE (14% 
Tris-Tricine gel) of expression/purification. MW: GB1 K13C-NpuDnaE-His6: 23.1 kDa; 
NpuDnaE-His6: 19.6 kDa; GB1: 6.2 kDa. GB1 K13C runs at a higher than expected 
molecular weight at about 11 kDa. Bottom: MALDI-TOF analysis. GB1 K13C [M+H]+: 
expected: 6,198.81 observed: 6,198.26.  
Recombinant expression of Ulp-1. The protocol is based on a previously 
published procedure222. For each liter of expression, four 5 mL primary cultures of sterile 
LB-media containing the kanamycin (50 µg/mL) were inoculated by scraping the surface 
of the frozen glycerol stock with a sterile pipette tip. Primary cultures were grown overnight 
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at 37°C with 250 RPM shaking until saturation. Each liter of sterile LB-media containing 
ampicillin (50 µg/mL) was inoculated by addition of three primary cultures and grown at 
37°C with 250 RPM shaking. Upon reaching an OD600 of 0.6-0.8, IPTG was added to a 
final concentration of 1 mM to induce protein expression. Protein expression was 
continued at 37°C with 250 RPM shaking for 5 hours. Cells were harvested by 
centrifugation at 4,000 RPM in a GS3 rotor and Sorvall RC-5 centrifuge for 20 min at 4°C. 
The supernatant was discarded and the cell pellet was suspended in 40 mL lysis buffer 
(40 mM Tris, 500 mM NaCl, 1 mM PMSF, pH 8.3) containing a broad-spectrum protease 
inhibitor tablet. Resuspended cells were then lysed on ice by sonication (35 amps power, 
1 second pulse, 2 second rest, 5 minute total sonication time) and then pelleted at 14,000 
RPM in an SS-34 rotor (Sorvall RC-5 centrifuge) for 30 min at 4°C. In the meantime, 5 mL 
(settled volume) of Nickel Agarose beads were washed with 20 mL equilibration buffer (50 
mM HEPES, 20 mM imidazole, pH 7.5). The crude cell lysate was incubated with the 
washed nickel resin for 1 h on ice with shaking. The slurry was then added to a fritted 
column and the liquid was allowed to flow through. The resin was then washed with 30 
mL of equilibration buffer and was then eluted from the resin in 12 mL of elution buffer (50 
mM HEPES, 300 mM imidazole, pH 7.5). The crude protein was FPLC purified by size-
exclusion chromatography using gradient 6G on a HiLoad Superdex 75pg 16/600 column. 
Fractions were analyzed by SDS-PAGE and pure fractions from peak were combined and 
spin concentrated using an Amicon Ultra-4 10k MWCO Spin Filter until the volume was 
about 1 mL. 1 mL of protein solution was mixed with 20 uL of 1 M Dithiothreitol (DTT; 10 
mM final concentration) and 980 µL 50% (v/v) glycerol, aliquoted and frozen at -80°C until 
further use. 
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Figure 6-14: SDS-PAGE (14% Tris-Tricine gel) following expression and purification 
of Ulp-1 (6-9). The post FPLC band was run on a separate gel with identical 
composition and run conditions. The molecular weight of Ulp-1 is 27.4 kDa. 
Recombinant expression and purification of GB113-56 K13C (6-10) from SUMO 
fusion protein. The protocol is based on the expression and purification protocol of a 
previously published procedure222. For each liter of expression, four 5 mL primary cultures 
of sterile LB-media containing the ampicillin (100 µg/mL) were inoculated by scraping the 
surface of the frozen glycerol stock with a sterile pipette tip. Primary cultures were grown 
overnight at 37°C with 250 RPM shaking until saturation. Each liter of sterile LB-media 
containing ampicillin (100 µg/mL) was inoculated by addition of three primary cultures and 
grown at 37°C with 250 RPM shaking. Upon reaching an OD600 of 0.6-0.8, culture was 
switched to an incubator operating at 18°C with 250 RPM shaking. After allowing the 
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media temperature to adjust for 15 minutes, IPTG was added to a final concentration of 1 
mM to induce protein expression. Protein expression was continued 18°C with 250 RPM 
shaking for 20 hours. Cells were harvested by centrifugation at 4,000 RPM in a GS3 rotor 
and Sorvall RC-5 centrifuge for 20 min at 4°C. The supernatant was discarded and the 
cell pellet was suspended in 30 mL lysis buffer (40 mM Tris, 1 mM PMSF, pH 8.3) 
containing a broad-spectrum protease inhibitor tablet. Resuspended cells were then lysed 
on ice by sonication (35 amps power, 1 second pulse, 2 second rest, 5 minute total 
sonication time) and then pelleted at 14,000 RPM in an SS-34 rotor (Sorvall RC-5 
centrifuge) for 30 min at 4°C. In the meantime, 4 mL (settled volume) of Nickel Agarose 
beads were washed with 20 mL equilibration buffer (50 mM HEPES, pH 7.5). The crude 
cell lysate was incubated with the washed nickel resin for 1 h on ice with shaking. The 
slurry was then added to a fritted column and the liquid was allowed to flow through. The 
resin was then washed with 20 mL of equilibration buffer and 25 mL of wash buffer (50 
mM HEPES, 5 mM imidazole, pH 7.5). Intein fusion protein was then eluted from the resin 
in 10 mL of elution buffer (50 mM HEPES, 300 mM imidazole, pH 7.5). 50 µL of thawed 
Ulp-1 and DTT (1 mM final concentration) were added and incubated on a rotisserie at 
room temperature overnight. The next day, protein was dialyzed twice against 10 mM 
NH4HCO3 using a Slide-A-Lyzer 2,000 MWCO cassette. 4 mL (settled volume) of Nickel 
Agarose beads were washed with 20 mL equilibration buffer (50 mM HEPES, pH 7.5) and 
dialyzed sample was incubated with the washed nickel resin for 1 h on ice with shaking. 
The slurry was then added to a fritted column and the liquid was allowed to flow through 
and collected. The desired cleaved protein was contained in the flow-through fraction, 
while uncleaved fusion protein and cleaved SUMO product were bound to the resin. The 
resulting protein was >95% pure based on SDS-PAGE and MALDI and therefore 
lyophilized post quantification via UV-Vis (ε280 = 8,480 M-1 cm-1). The isolated yield was 
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determined to be 8.5 mg/L expression. Figure 6-15 shows the cleavage of the SUMO 
fusion protein by Ulp-1. GB113-56 K13C runs at a higher molecular weight than expected 
and stains poorly with Coomassie stain. It is visible as faint band at around 11 kDa. 
 
 
Native Chemical Ligation of GB110-56 K10C with GB11-10-N2H3. C-terminal 
fragment (6-6, 27.5 mg, 5.36 mmoles) was dissolved in 1 mL ligation buffer (200 mM 
Na2HPO4, 6 M Gdn•HCl, pH 7.5) and 2.5 equiv TCEP bond-breaker solution was added. 
N-terminal fragment (6-1, 1.94 mg, 1.75 umol) was dissolved in 500 μL activation buffer 
Figure 6-15: Characterization of GB113-56 K13C (6-10) expression. Left: SDS-PAGE 
(14% Tris-Tricine gel) following purification of 6-10 from a SUMO fusion protein. 
MW: His6-SUMO-GB113-56 K13C: 17.8 kDa; His6-SUMO: 13.0 kDa; GB113-56 K13C: 4.8
kDa. GB113-56 K13C runs at a higher than expected molecular weight at about 11 kDa. 
Right: MALDI-TOF analysis. GB113-56 K13C [M+H]+: expected: 4,795.07 observed: 
4,793.57. * denotes MPAA adduct. 
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(200 mM Na2HPO4, 6 M Gdn•HCl, pH 3.0) and stirred at -15 °C for 10 minutes. Next, 80.4 
μL of a 1 M solution of NaNO2 in water (15 equiv.) was added and the reaction was stirred 
for 15 minutes at -15 °C. After 15 minutes, the reaction was allowed to warm to room 
temperature and 150 equiv. MPAA in 1.2 mL ligation buffer were added. The N-terminal 
fragment was stirred for 1 hour to allow formation of the thioester before the C-terminal 
fragment was added to the N-terminal fragment. The pH was adjusted to 7.5, and the 
solution stirred at room temperature for 19 hours.  
Native Chemical Ligation of GB113-56 K13C with GB11-12-N2H3. C-terminal 
fragment (6-10, 8.5 mg, 1.77 mmoles) was dissolved in 2 mL ligation buffer (200 mM 
Na2HPO4, 0.1 M MPAA, 6 M Gdn•HCl, pH 7.0). N-terminal fragment (6-2, 2.1 mg, 1.44 
umol) was dissolved in 480 μL activation buffer (200 mM Na2HPO4, 6 M Gdn•HCl, pH 3.0) 
and stirred at -15 °C for 10 minutes. Next, 20 μL of a 1 M solution of NaNO2 in water was 
added and the reaction was stirred for 15 minutes at -15 °C. After 15 minutes, the C-
terminal fragment was added to the N-terminal fragment, the pH was adjusted to 7.0, and 
the solution stirred at room temperature for 72 hours. Occasionally, the reaction progress 
was checked by MALDI-TOF MS and the pH was adjusted to pH 7.0. Upon completion, 
the reaction mixture was diluted to a volume of 12 mL with H2O and dialyzed twice against 
20 mM Tris, pH 8.0. The product was then attempted to be purified by FPLC on a HiTrap 
Q HP column using gradient 6F. However, product 6-11 and unreacted C-terminal 
fragment 6-10 coeluted. All fractions containing product were combined and lyophilized. 
Crude product was dissolved in 0.1% TFA in water and purified on HPLC using gradient 
6H. We initially used a Luna Omega C18 semiprep column at a flowrate of 4 mL/min. After 
observing good separation, we switched to a Luna Omega C18 prep column operating at 
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a flowrate of 25 mL/min, resulting in a slight shift of retention times as indicated in Table 
6.1. 
 
Table 6.1: Peptide/Protein Purification Methods and Retention Times. 
Peptide/Compound Gradient 
Retention Time/ 
Elution Volume 
Column 
GB11-9 LS7-N2H3 (6-1) 
6A 
6B 
11.5 min 
21.1 min 
SNAP Ultra C18 30g 
Luna Omega Prep 
GB11-12 LS7-N2H3 (6-2) 
6C 
6D 
19.0 min 
17.6 min 
SNAP Ultra C18 30g 
Luna Omega Prep 
GB1 (WT) (6-3) 6E 50 mL HiTrap Q HP 5 mL 
GB1 K10C (6-4) 6E 71 mL HiTrap Q HP 5 mL 
GB1 K10CK (6-5) 6E 53 mL HiTrap Q HP 5 mL 
GB1 K13C (6-8) 6F 56 mL HiTrap Q HP 5 mL 
Ulp-1 (6-9) 6G 70 mL HiLoad Superdex 75 pg 16/600 
GB113-56 K13C (6-10) 6H 
38.4 min 
37.5 min 
Luna Omega Semiprep 
Luna Omega Prep 
GB1 LS7 K13C (6-11) 6H 
41.9 min 
41.5 min 
Luna Omega Semiprep 
Luna Omega Prep 
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Table 6.2: FPLC and HPLC gradients used for Peptide/Protein Purification and 
Characterization.  
No. Time (min) 
or CV 
%B No. Time (min) 
or CV 
%B No. Time (min) 
or CV 
%B 
6A^ 0 CV 15 6B^ 0:00 5 6C^ 0 CV 15 
2 CV 15 2:00 5 3 CV 15 
12 CV 35 4:00 15 23 CV 45 
12 CV 100 34:00 30 23 CV 100 
14 CV 100 36:00 30 26 CV 100 
14 CV 50 37:00 100 26 CV 50 
17 CV 50 40:00 100 28 CV 50 
6D^ 0:00 5 6E# 0.0 CV 0 6F# 0.0 CV 0 
5:00 5 2.0 CV 0 2.0 CV 0 
8:00 20 14.0 CV 20 22.0 CV 30 
18:00 25 15.6 CV 20 23.6 CV 30 
20:00 25 25.6 CV 100 23.6 CV 100 
21:00 100 20.6 CV 100 28.6 CV 100 
26:00 100 20.6 CV 0 28.6 CV 0 
6G# 0.0 CV 15 6H^ 0:00 2    
1.2 CV 15 10:00 2   
  15:00 20   
  45:00 35   
  47:00 35   
  48:00 100   
  53:00 100   
  55:00 2   
^HPLC: Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
#FPLC: Solvent A: 20 mM Tris, pH 8.0; Solvent B: 20 mM Tris, 1 M NaCl, pH 8.0 
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Table 6.3: MALDI-TOF MS Characterization of Peptides and Proteins. 
Peptide 
[M+H]+ 
Calculated Found 
GB11-9 LS7-N2H3 (6-1) 1,131.58 ([M+Na]+) 1,131.86 ([M+Na]+) 
GB11-12 LS7-N2H3 (6-2) 1,451.82 1,452.21 
GB1 (WT) (6-3) 6,223.85 6,222.37 
GB1 K10C (6-4) 6,198.81 6,197.30 
GB1 K10CK (6-5) 6,241.88 6,242.53 
GB110-56 K10C (6-6) 5,207.50  (pyruvate adduct) 
5,208.79 
(pyruvate adduct) 
(GB11-9 LS7)2-OH (6-7) 2,712,12 2,172.30 
GB1 K13C (6-8) 6,198.81 6,198.26 
GB113-56 K13C (6-10) 4,795.07 4,793.57 
GB1 LS7 K13C (6-11) 6,214.81 6,214.23 
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Chapter 7 : Synthesis, Characterization and Attempted Genetic 
Incorporation of Nε-alkyl lysine and Nε-Thioaalkyl lysine 
derivatives 
 
7.1 Introduction 
While our lab has built significant expertise in incorporating thioamides into full-
length proteins using semi-synthetic methods, it is still cumbersome and not high-yielding. 
Genetic incorporation of thioamides would be the ‘holy grail’, as it would increase yields, 
facilitate purification and enable less specialized labs to express thioamide labelled 
proteins. Unfortunately, it is still a long way to go to reach this goal. Thus far, there are 
only two examples of ribosomal incorporation of thioamides into full-length proteins, both 
utilizing in vitro protein translation with in vitro aminoacylated tRNAs. The first example is 
from the Hecht lab138. In this study, they introduced random mutations in two different 
regions of the 23S rRNA to generate modified ribosomes that would allow incorporation 
of various dipeptides and dipeptide analogues, including PheS-Gly dipeptide. After 
aminoacylating tRNA in vitro with the PheS-Gly, they used this tRNA for in vitro protein 
expression with a cell extract from E. coli containing the modified ribosomes. While they 
were able to provide some evidence for successful thioamide incorporation, based on 
fluorescence quenching, it is not known if the desired dipeptide was incorporated 
quantitatively. Furthermore, the isolated yield was less than 100 ng, making it difficult to 
obtain protein quantities needed for biochemical assays. 
The other example of ribosomal thioamide incorporation is similar in nature and 
comes from the Söll lab225. Similar to the study by the Hecht lab, this study uses in vitro 
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aminoacylated tRNA in cell-free in vitro translation experiments. Unlike Hecht’s 
aminoacylation approach, which relied on synthesis of the aminoacylated dinucleotide and 
ligating it to truncated tRNA with T4 RNA Ligase, the Söll lab utilizes Flexizyme. Flexizyme 
is a catalytic RNA developed by the Suga lab that is capable of aminoacylating tRNA226. 
It recognizes an activated leaving group, in this case 3,5-dinitrobenzyl esters, and 
aminoacylates tRNA, virtually independent from the rest of the dinitrobenzyl ester (DBE) 
molecule. The Söll lab synthesized 3,5-dinitrobenzyl esters of Nε-acetyl-lysine (Lys(Ac)-
DBE), Nε-thioacetyl-lysine (Lys(AcS)-DBE), and Nε-selenoacetyl-lysine (Lys(AcSe)-DBE) 
and were able to aminoacylate tRNA in a flexizyme reaction using their substrates. While 
they were unable to incorporate Lys(AcSe) into any of their tested constructs, they 
successfully incorporated up to two unnatural amino acids into full-length Histone 3, as 
supported by MS/MS characterization of tryptic digests. However, similar to the other 
study their yield was very low only yielding low µg amounts of expressed protein. Together 
these two studies show that once thioamides are attached to tRNA, they can be 
successfully incorporated into proteins and don’t seem to interfere with any of the 
associated processes. However, while being very valuable proof-of-concept studies, none 
of these approaches yield protein amounts that would allow further biochemical assays. 
The low yields are inherent to techniques that rely on in vitro aminoacylated tRNA, as 
these tRNAs have only a single turnover while also slowly undergoing hydrolysis of the 
aminoacylated tRNA under protein expression conditions.  
We were interested in testing a different approach to unnatural amino acid (UAA) 
incorporation that relies on an tRNA synthetase (RS). This method, pioneered by the 
Schultz Lab, requires the synthetase/tRNA pair to be orthogonal in the expression system 
used, meaning that the orthogonal synthetase doesn’t aminoacylate any cognate tRNA 
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and that the orthogonal tRNA doesn’t get aminoacylated by any of the cognate 
synthetases227,228. Once this orthogonality is ensured, the synthetase can be mutated to 
accommodate unnatural amino acids, effectively expanding the genetic code by adding 
an additional amino acid/tRNA pair (see Figure 7-1). Hundreds of unnatural amino acids 
have been incorporated into various proteins using this approach229. Usually the amber 
stop codon UAG is used as recognition site for the tRNA, since the amber codon is the 
rarest of the three stop codons. This implies a competition between release factor, 
specifically release factor I for amber codons, and the orthogonal, aminoacylated tRNA. 
The two main products are usually the truncated protein and full-length desired protein 
containing the unnatural amino acid. Our lab has utilized this approach previously to 
incorporate various unnatural amino acids224,230–232. 
 
Figure 7-1: Codon reassignment strategy for the site-specific incorporation of 
unnatural amino acids: An orthogonal synthetase/tRNA pair are responsible for 
site-specific of the unnatural amino acid. Figure adapted from Lei Wang233. 
 We were interested in using this approach to incorporate Nε-thioacetyl-
lysine (Lys(AcS)) and Nε-thioheptyl-lysine (Lys(HeptS)). Lys(AcS) was of interest since 
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various versions of synthetases able to incorporate Lys(Ac) have been reported. 
Lys(HeptS) incorporation was suggested by our collaborator, Prof. Wenshe Liu, as they 
have evolved a synthetase that aminoacylates tRNA with Nε-octyl-lysine (Lys(Oct)). 
However, they noted that there is a variety of Nε-alkyl-lysine derivatives it can utilize and 
as part of their substrate scope, they were curious if their synthetase would be able to 
incorporate Lys(HeptS). The synthetases for both are based on pyrrollysine synthetase 
(PylRS) from Methanosarcina barkeri or Methanosarcina mazei. The PylRS/tRNAPyl pair 
is often used since it is orthogonal in E. coli as well as in mammalian cell lines234. The 
synthetase is unique in that recognition of its cognate tRNA does not occur through 
recognition of the anticodon234,235. Therefore the Pyl system can be modified to recognize 
various codons, although the UAG amber stop codon is most commonly used since it is 
its cognate recognition codon235. 
7.2 Results and Discussion 
We chose super-folder green fluorescent protein (sfGFP) as our test system. It is 
a well-established test system for unnatural amino acid incorporation. The advantage of 
sfGFP as test system that the protein is expressed at high levels, very stable, and yield 
can be determined based on absorption or fluorescence. In the sfGFP system the amber 
stop codon, here denoted as Z in 1-letter code, is usually placed in one of the sheets of 
the β-barrel structure. Truncation at the amber codon site results in a shortened sfGFP 
fragment that has the amino acids needed for chromophore maturation, but is unable to 
fold properly and is therefore non-fluorescent. 
Initial attempts were carried out at the Unnatural Amino Acid workshop at the 
Oregon State University in Corvallis, OR. We attempted to incorporate Lys(Ac) and 
Lys(AcS) into GFP using the AcK3 synthetase developed by Chin and coworkers236. While 
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Lys(Ac) is commercially available, we had to synthesize Lys(AcS) ourselves. We based 
our synthesis on a published procedure for a protected Lys(AcS) derivative and were able 
to obtain our desired compound over 2 steps in high purity and high yield132. We expressed 
in our protein in autoinducing media. WT full-length sfGFP was used as positive control 
and an expression not containing any unnatural amino acid was used as negative control. 
As evident from Figure 7-2, the synthetase is not very efficient at incorporating Lys(Ac). 
Unfortunately the tiny amount of full-length protein with Lys(AcS) is comparable to the 
amount of full-length protein in the absence of UAA, indicating that it might just be non-
specific incorporation. However, the amount of protein obtained from the oxo-control 
Lys(Ac) were discouraging. 
 
Figure 7-2: Attempted incorporation of Lys(Ac) and Lys(AcS) into sfGFP. Left: SDS-
PAGE analysis of cells shows the main product to be truncated protein. Right: 
Fluorescence measurement supports that only a small fraction of Lys(Ac) got 
incorporated to generate fluorescent full-length GFP.  
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Recently we started a collaboration with the lab of Prof. Wenshe Liu (Texas A&M, 
College Station, TX, USA). His lab has evolved a new synthetase that is capable of 
incorporating a variety of Nε-alkyl lysine derivatives. Upon receiving their plasmid, we 
decided to utilize the same plasmid backbone to test a newly described Nε-acetyl lysine 
synthetase237 and introduced the new synthetase into the plasmid using Gibson Assembly. 
The new synthetase was evolved using the phage-assisted continuous evolution (PACE) 
system for rapid directed evolution developed by Liu and coworkers238. With their 
optimized synthetase they were able to obtain 20-25% of WT GFP expression (based on 
fluorescence), compared to about 2% with the previously used synthetase.  
To generate a GFP test system, we used plasmids with sfGFP and sfGFP(Y151Z) 
from our collaborator Prof. Abhishek Chatterjee (Boston College, Chestnut Hill, MA, USA). 
However, these plasmids contained a T5 promoter site that is recognized by endogenous 
E. coli RNA polymerases. We were interested in a T7 system, where our gene of interest 
would only be recognized by T7 RNA polymerase present in E. coli BL21 (DE3). We used 
Gibson assembly to create a pET based T7-compatible vector where sfGFP is under 
control of the lac operon. 
Since none of the amino acids we planned to incorporate are commercially 
available, we synthesized Lys(HeptS)-OH (7-6) and its oxo analogue Lys(Hept)-OH (7-4) 
ourselves. While the synthesis was rather low yielding, we obtained sufficient material for 
initial test expressions and did not bother optimizing synthetic conditions. 
We set up 25 mL expressions to test incorporation of unnatural amino acids into 
sfGFP. Proteins were expressed for 24 hours in 25 mL autoinducing medium containing 
20 mM nicotinamide to suppress, endogenously expressed CobB, a NAD-dependent 
lysine deacylase236. After 24 hours, OD600 and fluorescence of the crude suspension was 
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measured before harvesting and purifying cells. As shown in Figure 7-3, cells produced 
significantly lower amount of protein (estimated by fluorescence), especially if one were 
to take the number of cells (estimated by optical density) into account: Only 9.0 % of WT 
fluorescence were observed with Lys(Ac) incorporation and 18.6% with Lys(Hept). 
Measured fluorescence for thio-amino acid incorporation is roughly 1/3 of the 
corresponding oxo version (4.0% and 6.2%) and only slightly above the negative control 
without UAA (3.6% and 4.0%), which accounts for non-specific readthrough. We were 
wondering if the decrease in observed fluorescence is due to lower amount of full-length 
protein or if incorporated thioamides could potentially partially quench fluorescence. 
 
Figure 7-3: OD600 (top) and fluorescence (bottom) measurements (in triplicate) of 
cells grown for 24 hours in autoinducing medium. Non-WT expressions contained 
10 mM Lys(Ac)/Lys(AcS) or 1 mM Lys(Hept)/Lys(HeptS). 
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To further analyze the amount of amino acid incorporated into proteins, we 
harvested the cells and isolated the protein using nickel affinity columns. Since the His tag 
is on the C-terminal end of the protein, only full-length protein will be purified, while 
truncated protein will be washed away. Purified proteins were desalted and further 
analyzed by Trypsin digests. SDS-PAGE and results of tryptic digest results are shown in  
Figure 7-4 for incorporation experiments using acetyllysine synthetase mmchAcK3RS, 
and Figure 7-5 for incorporation experiments using octyllysine synthetase mmOctKRS. In 
neither case, we did not observe incorporation of the desired thio-amino acid; in all cases 
the purified protein seems to solely contain the oxo-analogue. The mechanism of this is 
not clear. A likely alternative, is that some of the thio-amino acid undergoes S-to-O 
exchange in the growth medium or in the cell and that the synthetase is only able to 
incorporate oxo-amino acid. This hypothesis is supported by the observed reduced protein 
yield, as the concentration of oxo-amino acid in this case is significantly lower. 
Furthermore, Söll et al.225 have shown that when tRNA is aminoacylated with Lys(AcS), 
the amino acid will get incorporated into the protein and it is possible to isolate the 
thioamide containing protein. This, in our opinion, excludes the possibility of enzymatic 
processing after thioamide incorporation. However, further systematic investigation would 
be necessary to elucidate the mechanism. 
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Figure 7-4: Result of attempted UAA incorporation using mmchAcK3 synthetase. 
Top: SDS-PAGE of crude cells extract and purified protein for WT (sfGFP) and TAG 
(sfGFP Y151Z) constructs. Expression were performed in the presence of 10 mM 
UAA. Purified WT protein was diluted (1:5) before loading to not overload gel. MW: 
sfGFP: 27.7 kDa, sfGFP1-150: 16.9 kDa. Bottom: MALDI-TOF MS of tryptic digest 
shows that in both cases fragment 141-156 didn’t contain thioamino acid. Expected 
masses: sfGFP141-156 Y151K(Ac): 1,934.96; : sfGFP141-156 Y151K(AcS): 1,950.94. 
observed: 1,935.13 for Lys(Ac) incorporation; 1,935.14 for Lys(AcS) incorporation. 
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Figure 7-5: Result of attempted UAA incorporation using mmOctK synthetase. Top: 
SDS-PAGE of crude cells extract and purified protein for WT (sfGFP) and TAG 
(sfGFP Y151Z) constructs. Expression were performed in the presence of 1 mM UAA. 
Purified WT protein was diluted (1:5) before loading to not overload gel. MW: sfGFP: 
27.7 kDa, sfGFP1-150: 16.9 kDa. Bottom: MALDI-TOF MS of tryptic digest shows that 
in both cases fragment 141-156 didn’t contain thioamino acid. Expected masses: 
sfGFP141-156 Y151K(Hept): 2,005.04; : sfGFP141-156 Y151K(HeptS): 2,021.02. observed: 
2,005.19 for Lys(Hept) incorporation; 2,005.25 for Lys(HeptS) incorporation. 
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7.3 Conclusion 
We attempted genetic incorporation of side-chain thioamide Lys(AcS) and 
Lys(HeptS) using newly evolved aminoacyl-tRNA synthetases and amber suppression. 
The thio-amino acids and their cognate oxo-control were synthesized, since only Lys(Ac) 
was commercially available. While the synthesis of Lys(AcS) was straightforward, the 
synthesis of Lys(HeptS) was low-yielding and might need optimization in the future. 
However, we were able to obtain the amounts needed for small scale test expressions. 
Test expression showed good growth and high cell densities after 24 hours of 
expression in autoinducing media, indicating that amino acids did not have an obvious 
negative impact on cell viability. Fluorescence measurements as well as SDS-PAGE 
analysis of crude cell extracts and purified proteins indicate low amounts of protein. 
Incorporation of thio-amino acids further reduced protein yields by about 2/3. 
 Tryptic digest of purified peptides followed by MALDI-TOF MS analysis indicates 
that none of the thio-amino acids were incorporated and only their cognate oxo version 
was incorporated. While we are uncertain of the source of this amino acid, we hypothesize 
that the thio-amino acid undergoes S-to-O exchange and that only the oxo version can 
get recognized by the synthetase. 
The field of genetic code expansion is rapidly evolving with new and improved 
synthetases being described frequently. We hope that in the future a synthetase capable 
of incorporating Nε-thioalkyl lysine derivatives will become available. 
7.4 Materials and Methods 
General Information Lysine derivatives and PyAOP were purchased from 
ChemImpex (Wood Dale, IL, USA). cOmplete Mini, EDTA-free protease inhibitor tablets 
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were purchased from Roche Diagnostics (Mannheim, Germany). High-Density Nickel 
Agarose Beads were purchased from GoldBio (St. Louis, MO, USA). Amicon Ultra Spin 
Filters were purchased from EMD Millipore. Sephadex G-25 PD-10 desalting columns 
were purchased from GE Healthcare (Chicago, IL, USA). All other reagents, solvents and 
materials were purchased from Fisher Scientific (Pittsburgh, PA, USA) or Sigma-Aldrich 
(St. Louis, MO, USA) and used without further purification unless otherwise specified. 
High resolution electrospray ionization mass spectra (ESI-HRMS) were collected 
with a Waters LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, 
USA). Low resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on 
a Waters Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) 
mass spectrometer. UV-Vis absorption measurements were performed on a Hewlett-
Packard 8452A diode array spectrophotometer (currently Agilent Technologies; Santa 
Clara, CA, USA) or Thermo Fisher Scientific Genesys 150 UV/Vis Spectrophotometer 
(Waltham, MA, USA). Since OD600 measurements are instrument specific (measured 
scattering intensity depends on the distance between sample and detector), values 
obtained on the Genesys 150 were multiplied by a factor of 1.5 (empirically determined) 
to match values obtained on HP 8452A. Fluorescence data was acquired on a Photon 
Technologies International (PTI) QuantaMaster40 fluorometer (currently Horiba Scientific, 
Edison, NJ, USA). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DRX 500 MHz instrument (Billerica, MA, USA). Matrix assisted laser desorption/ionization 
with time-of-flight detector (MALDI-TOF) mass spectra were acquired on a Bruker Ultraflex 
III or Microflex LRF instrument. Reverse-phase purification of small molecules was 
performed on a Biotage Isolera System on Biotage SNAP Ultra C18 columns (Charlotte, 
NC, USA).  
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Figure 7-6: Synthetic scheme for the synthesis of Lys(AcS)-OH (7-2). 
Synthesis of Boc-Lys(AcS)-OH (7-1). Boc-Lys-OH (492 mg, 2.0 mmoles) was 
suspended in 4.4 mL EtOH and 4.0 mL of a 10% (w/v) Na2CO3 solution were added. Ethyl 
dithioacetate (252 µL, 2.2 mmoles) were added and stirred overnight. Next day the solvent 
was removed in vacuo. The crude reaction mixture was dissolved in 10 mL H2O and 3 M 
HCl was added dropwise while stirring until solution was milky white and pH was ~2. The 
product was extracted 3 times with CH2Cl2 before being dried over MgSO4. After filtration 
the solvent was removed in vacuo to yield the product as orange foam (567 mg, 1.86 
mmoles, 93.3%). 1H NMR (500 MHz, Chloroform-d) δ 10.88 (s, 1H), 8.37 (s, 1H), 5.35 (d, 
J = 7.7 Hz, 1H), 4.07 (d, J = 75.4 Hz, 1H), 3.52 (s, 2H), 2.50 – 2.34 (m, 3H), 1.77 (s, 1H), 
1.69 – 1.49 (m, 3H), 1.42 – 1.23 (m, 11H). 13C NMR (126 MHz, CDCl3) δ 200.42, 176.09, 
155.94, 81.99, 80.35, 77.42, 77.16, 76.91, 54.37, 52.99, 45.88, 33.50, 31.90, 28.16, 26.94, 
22.68. 
Synthesis of Lys(AcS)-OH (7-2). Boc-Lys(AcS)-OH (7-1, 567 mg, 1.86 mmoles) 
were dissolved in 3 mL CH2Cl2. 3 mL Trifluoroacetic acid were added and the reaction 
was stirred at room temperature for 45 minutes, after which the solvent was removed in 
vacuo. The crude product was dissolved in 2 mL MeCN and precipitated with 90 mL of 
cold ether. The precipitate was pelleted by centrifugation at 4,000 RPM for 15 minutes 
and the supernatant was discarded. The pellet was allowed to air dry for 15 minutes before 
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being redissolved in 3 mL MeCN/H2O (1:1) and dried by lyophilization. The product was 
obtained in high purity as white powder (542 mg, 1.70 mmoles, 91.6%). 1H NMR (500 
MHz, Deuterium Oxide) δ 3.77 (t, J = 6.1 Hz, 1H), 3.64 (t, J = 7.1 Hz, 2H), 2.52 (s, 3H), 
2.02 – 1.84 (m, 2H), 1.80 – 1.67 (m, 2H), 1.55 – 1.37 (m, 2H). ESI+-HRMS calculated for 
C8H16N2O2SNa+: 259.2022; found: [M+Na]+: 259.2004. 
 
Figure 7-7: Synthetic scheme for the synthesis of Lys(Hept)-OH (7-4) and 
Lys(HeptS)-OH (7-6). 
Synthesis of Boc-Lys(Hept)-OH (7-3). Heptanoic acid (312 μL, 2.2 mmoles) and 
DIPEA (348 μL, 2.0 mmoles) dissolved in 10 mL CH2Cl2. PyAOP (1.04 g, 2.0 mmoles) 
added and solution turned yellow. Reaction stirred for 1 hour before Boc-Lys-OH (492 mg, 
2.0 mmoles) was added. 2 mL of MeOH added to aid solubility and solution was sonicated 
until clear. Reaction was stirred at room temperature overnight. Next day the solvent was 
removed in vacuo before being redissolved in MeOH and purified by reverse phase 
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chromatography on Biotage system using a SNAP Ultra C18 (60g) column and gradient 
7A at a flowrate of 60 mL/min. Fractions containing pure product were combined and 
lyophilized. Product yielded as clear oil (653 mg /1.82 mmoles / 91.2%). ESI+-HRMS 
calculated for C18H35N2O5+: 359.2546; found: [M+H]+: 359.2552. 
Synthesis of Lys(Hept)-OH (7-4). Boc-Lys(Hept)-OH (7-3; 326 mg, 0.91 mmoles) 
was dissolved in 2 mL CH2Cl2. 2 mL of TFA added and stirred for 1 hour. Solvent removed 
in vacuo and redissolved in minimal amount of MeOH for reverse phase purification on 
Biotage system using a SNAP Ultra C18 (12g) column and gradient 7B at a flowrate of 12 
mL/min. Pure fractions were combined and lyophilized to yield a clear oil. Product 
redissolved in MeCN/H2O (1:1) and lyophilized overnight again to give a white powder 
(212 mg / 0.57 mmoles / 62.6%). For NMR, 50 mg of the sample were suspended in 600 
μL D2O and 15 μL NaOD (40% (w/v) in D2O) were added for solubility. 1H NMR (500 MHz, 
Deuterium Oxide) δ 3.22 (t, J = 6.4 Hz, 1H), 3.18 (t, J = 6.8 Hz, 2H), 2.23 (t, J = 7.2 Hz, 
2H), 1.69 – 1.47 (m, 6H), 1.39 – 1.31 (m, 2H), 1.29 (s, 6H), 0.86 (t, J = 6.6 Hz, 3H). 13C 
NMR (126 MHz, D2O) δ 183.55, 177.03, 55.91, 39.13, 35.84, 34.33, 30.69, 28.33, 27.84, 
25.39, 22.48, 21.87, 13.35. ESI+-HRMS calculated for C13H27N2O3+: 259.2022; found: 
[M+H]+: 259.2004. 
Synthesis of Boc-Lys(HeptS)-OH (7-5). P4S10 (609 mg, 1.37 mmoles) and 
Na2CO3 (106 mg, 1.37 mmoles) were suspended in THF and stirred under Ar for 1 hour 
until solution became clear and yellow. Since starting material was a thick oil, thionation 
solution was added to vial containing Boc-Lys(Hept)-OH (7-3; 326 mg, 0.91 mmoles). After 
solubilizing everything by sonication, the reaction was stirred overnight under Ar. Next 
day, the solvent was removed in vacuo, redissolved in minimal DMSO and purified by 
reverse phase on Biotage system using a SNAP Ultra C18 (30g) column and gradient 7C 
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at a flowrate of 12 mL/min.. Fractions containing pure product were combined and 
lyophilized. Product yielded as reddish, gum-like solid (51.7 mg, 138 μmoles, 15.2%). 
ESI+-HRMS calculated for C18H35N2O4S+: 375.2318; found: [M+H]+: 375.2552. 
Synthesis of Lys(HeptS)-OH (7-6). Boc-Lys(HeptS)-OH (7-5; 51.7 mg, 138 
µmoles) was dissolved in 2 mL CH2Cl2. 2 mL TFA added and stirred for 1 hour and solvent 
removed in vacuo. Crude product redissolved in a minimal amount of DMSO and purified 
on Biotage system using a SNAP Ultra C18 (12g) column and gradient 7B at a flowrate of 
12 mL/min. Fractions containing product combined and lyophilized. Product yielded as 
fluffy white powder (18.0 mg / 46.4 μmoles / 33.6%). For NMR, 10 mg of the sample were 
suspended in 600 μL D2O and 15 μL NaOD (40% (w/v) in D2O) were added for solubility. 
1H NMR (500 MHz, Deuterium Oxide) δ 3.55 (t, J = 7.1 Hz, 2H), 3.20 (t, J = 6.3 Hz, 1H), 
2.61 (t, J = 7.4 Hz, 2H), 1.73 – 1.48 (m, 6H), 1.35 (p, J = 7.7 Hz, 2H), 1.26 (s, 6H), 0.83 (t, 
J = 6.5 Hz, 3H). 13C NMR (126 MHz, D2O) δ 202.59, 183.62, 55.88, 46.81, 45.77, 34.37, 
30.74, 28.70, 27.47, 27.11, 22.65, 21.85, 13.32. ESI+-HRMS calculated for C13H27N2O2S+: 
275.1793; found: [M+H]+: 275.1782. 
General information about cloning. All PCR reactions were carried out on a 
T100 thermocycler from Bio-Rad (Hercules, CA, USA). Primers and double stranded DNA 
fragments (gBlocks) were purchased from Integrated DNA Technologies (Coralville, IA, 
USA). dNTPs, SYBR Safe DNA gel stain and Agarose were purchased from Invitrogen 
(Waltham, MA, USA). Q5 High-Fidelity DNA polymerase, Q5 High-Fidelity DNA 
polymerase Master Mix, HiFi DNA Assembly Master Mix, Restriction Enzymes, competent 
High Efficiency E. coli cells (NEB 5-alpha and NEB 10-beta), T4 DNA Polynucleotide 
Kinase, T4 DNA Ligase and Monarch Gel Extraction Kit were purchased from New 
England Biolabs (Ipswich, MA, USA). Gel Green DNA gel stain was purchased from 
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Biotium (Freemont, CA, USA). DNA Clean & Concentrator Kit and Plasmid Miniprep Kit 
were purchased from Zymo Research (Irvine, CA, USA). DNA concentrations were 
determined with a TECAN Nanoquant plate on an Infinite M1000Pro plate reader (Tecan, 
Männedorf, Switzerland). DNA sequencing (Sanger sequencing) was performed at the 
University of Pennsylvania DNA Sequencing Facility (Philadelphia, PA, USA). Agarose 
gels were visualized on a Typhoon Imager (GE Healthcare, Marlborough, MA, USA) or a 
SmartBlue transilluminator (Southern Labware, Cumming, GA 30028). pET His6-SUMO-
TEV (2S-T) plasmid was a gift from Scott Gradia (Addgene plasmid # 29711; 
http://n2t.net/addgene:29711; RRID: Addgene_29711). pEVOL-mmOctKRS plasmid was 
a gift from Prof. Wenshe Liu (Department of Chemistry, Texas A&M University, College 
Station, TX, USA). pET22b-T5 sfGFP and pET22b-T5 sfGFP(Y151Z) plasmids were a gift 
from Prof. Abhishek Chatterjee (Department of Chemistry, Boston College, Chestnut Hill, 
MA, USA). 
General procedure for PCR. Primers were dissolved in Milli-Q grade water to be 
at a concentration of 50 µM. The amount of plasmid used ranged from 0.1 – 1 ng total 
DNA. Primers, plasmid and buffer components were mixed according to manufacturer 
recommendations. PCR was carried out for 35 cycles at annealing temperatures 
calculated with the New England Biolabs Tm calculator tool 
(https://tmcalculator.neb.com). Alternatively, a ‘Touchdown protocol’ was used, where 
annealing started with 70° in the first cycle and was reduced in each of the 19 subsequent 
cycles by 0.5°C each, followed by 15 rounds of amplification at 55°C. 
Following amplification PCR product was isolated using a DNA Concentrator & 
Cleanup Kit. PCR product was quantified to verify successful PCR amplification. PCR 
product was circularized by mixing 2 µL PCR product with 5 µL Milli-Q grade water, 1 µL 
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10x T4 DNA Ligase Buffer, 1 µL T4 Polynucleotide Kinase, 0.5 µL T4 DNA Ligase and 0.5 
µL DpnI. This mixture was incubated at 37°C for 45 minutes, cooled on ice and 50 µL of 
competent NEB 5-alpha cells were added. Cells were transformed and plated on an LB-
Agar plate containing appropriate antibiotic. Individual colonies were picked, grown up in 
5 mL LB-medium and their DNA was extracted using a Plasmid Miniprep Kit according to 
manufacturer’s protocol. Quantified DNA was submitted for sanger sequence analysis to 
verify correct sequence. Sequencing primer was provided by Sequencing Center and 
aligns with T7 promoter unless otherwise noted. 
General procedure for Gibson Assembly. Primers were dissolved in Milli-Q 
grade water to be at a concentration of 50 µM. The amount of plasmid used ranged from 
0.1 – 1 ng total DNA. Vector and insert were amplified simultaneously using a ‘Touchdown 
protocol’, where annealing started with 70° in the first cycle and was reduced in each of 
the 19 subsequent cycles by 0.5°C each, followed by 15 amplifications at 55°C. PCR 
product was purified using a 1% Agarose gel containing SYBR Safe or GelGreen Dye. Gel 
was visualized using a Blue light transilluminator and bands of the expected size were 
excised. DNA was extracted was extracted using a DNA gel extraction kit according to 
manufacturer’s protocol and isolated DNA was quantified. DNA assembly was performed 
with 100 ng of vector DNA and 2 equiv of insert DNA (5 equiv for insert <300 bp) using a 
HiFi DNA Assembly Mix according to manufacturer’s protocol. 2 µL of the ligated product 
were transformed in 50 µL competent NEB10β cells according to manufacturer’s 
instructions and plated on an LB-Agar plate containing appropriate antibiotic. Individual 
colonies were picked, grown up in 5 mL LB-medium and their DNA was extracted using a 
Plasmid Miniprep Kit according to manufacturer’s protocol. Quantified DNA was submitted 
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for sanger sequence analysis to verify correct sequence. Sequencing primer was provided 
by Sequencing Center and aligns with T7 promoter unless otherwise noted. 
Cloning of pEVOL-mmchAcK3RS. Plasmid was constructed using Gibson 
Assembly. The Vector donor plasmid was pEVOL-mmOctKRS and was a present from 
Prof. Wenshe Liu. The insert sequence was obtained from the published amino acid 
sequence for chAcKRS3237. The sequence was optimized for E. coli using IDT’s codon 
optimization tool and was purchased as gBlock from IDT. Sequencing was submitted with 
custom sequencing primers from 3’ and 5’ end to cover the whole range of interest. 
gBlock (5’ to 3’ strand only): 
GCTAACAGGA GGAATTACTA GTATGGACAA AAAACCGCTG GATGTTCTGA 
TTAGCGCAAC CGGTCTGTGG ATGAGCCGCA CCGGTACACT GCATAAAATC 
AAACATTATG AAATCAGCCG CAGCAAAATC TATATTGAAA TGGCATGTGG 
TGATCATCTG GTGGTGAATA ATAGCCGTAG CTGTCGTCCG GCACGTGCAT 
TTCGTTATCA CAAATATCGT AAAACCTGCA AACGTTGTCG TGTTAGCGGT 
GAAGATATTA ACAATTTTCT GACCCGTAGC ACCGAAGGTA AAACCAGCGT 
TAAAGTTAAA GTTGTGAGCG AGCCGAAAGT GAAAAAAGCA ATGCCGAAAA 
GCGTTAGCCG TGCACCGAAA CCTCTGGAAA ATCCGGTTAG CGCAAAAGCA 
AGCACCGATA CCAGCCGTAG CGTTCCGAGT CCGGCAAAAA GCACCCCGAA 
TAGTCCGGTT CCGACCAGCG CAAGCGCACC GGCACTGACC AAAAGCCAGA 
CCGATCGCCT GGAAGTTCTG CTGAATCCGA AAGATGAAAT TAGCCTGAAT 
AGCGGTAAAC CGTTTCGTGA ACTGGAAAGC GAACTGCTGA GCCGTCGTAA 
AAAAGATCTG CAGCAGATTT ATGCCGAAGA ACGCGAAAAC TATCTGGGTA 
AACTGGAACG TGAAATCACC CGTTTTTTTG TGGATCGTGG TTTCCTGGAA 
ATCAAAAGCC CGATTCTGAT TCCGCTGGAA TATATTGAAC GTATGGGCAT 
TGATAACGAT ACCGAACTGA GCAAACAAAT CTTTCGCGTG GATAAAAACT 
TTTGTCTGCG TCCGATGATG GCACCGAACA TTTTTAACTA TGCACGCAAA 
CTGGATCGTG CACTGCCGGA TCCGATTAAA ATCTTTGAAA TTGGTCCGTG 
CTACCGCAAA GAAAGTGATG GTAAAGAACA CCTGGAAGAA TTTACGATGC 
TGAACTTTTT TCAGATGGGT AGCGGTTGTA CCCGTGAAAA TCTGGAAAGC 
ATTATTACCG ATTTTCTGAA CCATCTGGGC ATCGATTTCA AAATTGTTGG 
TGATAGCTGC ATGGTGTATG GTGATACCCT GGATGTTATG CATGGTGATC 
TGGAACTGAG TAGCGCAGTT GTTGGTCCGA TTCCTCTGGA TCGCGAATGG 
GGTATTGATA AACCGTGGAT TGGTGCCGGT TTTGGTCTGG AACGCCTGCT 
GAAAGTTAAA CACGACTTCA AAAACATTAA ACGTGCAGCA CGTAGCGAGA 
GCTATTACAA TGGTATTAGC ACCAACCTGT AAGTCGACCA TCATCATCAT 
Forward primer for vector: 
5’ – ACCAACCTGT AAGTCGAC – 3’ 
Reverse complement primer for vector: 
5’ – CATACTAGTA ATTCCTCCTG TTAGC – 3’ 
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Forward primer for sequencing: 
5’ – CTACCTGACG CTTTTTATCG CA – 3’ 
Reverse complement primer for sequencing: 
5’ – TTTATCAGAC CGCTTCTGCG TT – 3’ 
Cloning of pET sfGFP. Plasmid was constructed using Gibson Assembly. The 
Vector donor plasmid was pET His6-SUMO-TEV -EcoR1. The insert donor plasmid was 
pET22b-T5-sfGFP and was a gift from Prof. Abhishek Chatterjee. Primers were designed 
to introduce 10 nt overlaps, i.e. the 5’ and 3’ and of insert contained 10 nt of the vector 
and vice versa. This created the necessary 20 nt overlap for Gibson assembly. 
Forward primer for vector: 
5’ – CCACCACTAA CGGATCCGCG ATCG – 3’ 
Reverse complement primer for vector: 
5’ – CTTTGCTCAT ATGTATATCT CCTTCTTAAA GTTAAACAAA ATTATTTCTA G– 3’ 
Forward primer for insert: 
5’ – AGATATACAT ATGAGCAAAG GAGAAGAAC – 3’ 
Reverse complement primer for insert: 
5’ – CGCGGATCCG TTAGTGGTGG TGGTGGT – 3’ 
Cloning of pET sfGFP(Y151Z). Plasmid was constructed using Gibson Assembly. 
The Vector donor plasmid was pET His6-SUMO-TEV -EcoR1. The insert donor plasmid 
was pET22b-T5-sfGFP(Y151Z) and was a gift from Prof. Abhishek Chatterjee. Primers 
were designed to introduce 10 nt overlaps, i.e. the 5’ and 3’ and of insert contained 10 nt 
of the vector and vice versa. This created the necessary 20 nt overlap for Gibson 
assembly. 
Forward primer for vector: 
5’ – CCACCACTAA CGGATCCGCG ATCG – 3’ 
Reverse complement primer for vector: 
5’ – CTTTGCTCAT ATGTATATCT CCTTCTTAAA GTTAAACAAA ATTATTTCTA G– 3’ 
Forward primer for insert: 
5’ – AGATATACAT ATGAGCAAAG GAGAAGAAC – 3’ 
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Reverse complement primer for insert: 
5’ – CGCGGATCCG TTAGTGGTGG TGGTGGT – 3’ 
 
Figure 7-8: Plasmid maps showing vector backbones used. Left: pEVOL plasmid 
containing mmchAcK3RS gene (green) under control of araBAD. Right: pET 
plasmid contining sfGFP gene (green) under control of the lac operon. 
Expression of sfGFP (WT or Y151Z). pET plasmid containing sfGFP (WT) was 
transformed into BL21 (DE3) cells and plated on LB-Agar plates containing Ampicillin (100 
µg/mL). pET plasmid containing sfGFP (Y151Z) and pEVOL plasmid containing desired 
synthetase (mmchAcK3RS or mmOctKRS) were co-transformed into BL21 (DE3) cells 
and plated on LB-Agar plates containing Ampicillin (100 µg/mL) and Chloramphenicol (25 
µg/mL). Non-inducing medium (NIM) and autoinducing medium (AIM) containing Lactose 
and Arabinose were prepared as described by Mehl239, except for the use 25x M-salts 
instead of 50x M-salts (to extend shelf life). A single colony was picked and grown in 3 mL 
LB media containing Ampicillin (100 µg/mL) for WT sfGFP expression or Ampicillin (100 
µg/mL) and Chloramphenicol (25 µg/mL) for sfGFP (Y151Z) expression at 37°C with 250 
RPM shaking overnight. Next day, 25 mL cultures with AIM in 125 mL Erlenmeyer flasks 
were prepared by adding 20 mM nicotinamide, UAA (1 mM for Lys(HeptO/S) and 10 mM 
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for Lys(AcO/S)), and antibiotics (Ampicillin (100 µg/mL) for WT sfGFP expression or 
Ampicillin (100 µg/mL) and Chloramphenicol (25 µg/mL) for sfGFP (Y151Z) expression). 
Secondary cultures were inoculated with 0.5% (v/v) overnight culture and grown at 37°C 
with 250 RPM shaking for 24 hours. At this point for each culture three 1:10 dilutions (1 
mL each) were prepared and OD600 and fluorescence (exitation: 395 nm; emission: 510 
nm; 2 nm slit width, 0.1 sec integration time) measured in triplicates. For SDS-PAGE 
analysis, cells from 500 µL were pelleted by spinning at 13.2 k RPM in a tabletop 
microcentrifuge for 3 minutes. The supernatant was discarded and cell pellet frozen until 
further use. When needed, cell pellets were thawed on ice and resuspended in 50 µL 1x 
LDS buffer containing 200 mM DTT and sample was boiled at >90°C for 5 minutes before 
loading 15 µL sample. 
Cells were harvested by centrifugation at 4,000 RPM in a GS3 rotor and Sorvall 
RC-5 centrifuge for 20 min at 4°C. The supernatant was discarded and the cell pellet was 
suspended in 5 mL lysis buffer (40 mM Tris, 500 mM NaCl, 1 mM PMSF, pH 8.3) 
containing a broad-spectrum protease inhibitor. Resuspended cells were then lysed on 
ice by sonication (30 amps power, 1 second pulse, 2 second rest, 3 minutes total 
sonication time) and then pelleted at 14,000 RPM in an SS-34 rotor (Sorvall RC-5 
centrifuge) for 30 min at 4°C. In the meantime, 1 mL (settled volume) of Nickel Agarose 
beads were washed with 5 mL equilibration buffer (50 mM HEPES, pH 7.5). The crude 
cell lysate was incubated with the washed nickel resin for 1 h on ice with shaking. The 
slurry was then added to a fritted syringe and the liquid was allowed to flow through. The 
resin was then washed with 5 mL of equilibration buffer, 5 mL of wash buffer 1 (50 mM 
HEPES, 5 mM imidazole, pH 7.5), 5 mL wash buffer 2 (50 mM HEPES, 50 mM imidazole, 
pH 7.5) before being eluted from the resin in 2.5 mL of elution buffer (50 mM HEPES, 300 
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mM imidazole, pH 7.5). The crude protein was buffer exchanged using PD-10 desalting 
columns equilibrated with 10 mM NH4HCO3 according to manufacturer’s instruction 
(gravity protocol) and stored at -20°C until further use.  
Table 7.1: HPLC Gradients used for Small Molecule Purification. 
No. CV %B No. CV %B No. CV %B 
7A 0 CV 25 7B 0 CV 10 7C 0 CV 10 
2 CV 25 2 CV 10 2 CV 10 
12 CV 60 12 CV 50 3 CV 30 
13 CV 60 13 CV 50 13 CV 65 
13 CV 100 13 CV 100 14 CV 65 
15 CV 100 15 CV 100 14 CV 100 
    16 CV 100 
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
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Chapter 8 APPENDIX 
Appendix A: Synthesis of flexizyme substrates to probe the ribosomal exit 
tunnel 
The Deutsch Lab was interested in studying the effects of steric bulk on the 
elongation kinetics of nascent peptides in the ribosomal exit tunnel. As part of our 
collaboration, we synthesized dinitrobenzylesters of various modified cysteines. These 
dinitrobenzylesters were used to aminoacylate tRNA in an in vitro aminoacylation assay 
using Flexizyme, a catalytic RNA developed by the Suga Lab240. The synthesis of these 
compounds and their use have been published241. 
The overall synthetic scheme is shown in Figure 8-1: The synthesis starts with the 
tert-Butyloxycarbonyl (Boc) protection of the two Nα-groups of Cystine to yield 8-4. In the 
second step, the dintrobenzyl ester was formed resulting in compound 8-5, before Boc-
deprotection to yield cystine dinitrobenzyl ester 8-6. After reduction of the disulfide bond, 
the resulting thiol was modified with N-etyhlmaleimide or with maleimides 8-1, 8-2 or 8-3 
resulting in compounds 8-7a-d. Tryptophan cyanomethyl ester was synthesized as well 
and used as a control in experiments. 
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Figure 8-1: General synthesis scheme for dinitrobenzyl esters of (trialkyl-
ammonium)maleimide modified cysteine. i) Boc2O, TEA, H2O; ii) 3,5-
Dinitrobenzylchloride, NaI, DIPEA, DMF; iii) TFA; iv) TCEP, N-ethylmaleimide/2-8a-
c, H2O, pH 6.0 
General information: All chemicals were purchased from Sigma-Aldrich or Fisher 
Scientific and used without further purification. Electrospray ionization mass spectra (ESI-
MS) were obtained on a Waters Acquity Ultra Performance LC connected to a single 
quadrupole detector (SQD) mass spectrometer. Nuclear magnetic resonance (NMR) 
spectra were obtained on a Bruker DRX 500 MHz instrument (Billerica, MA, USA). 
Preparative HPLC was performed on a Varian Prostar HPLC system (currently Agilent 
Technologies, Santa Clara, CA, USA. HPLC column (Sunfire C18 OBD, 19x150mm, 5µm) 
was purchased from Waters Corporation (Milford, MA, USA). 
Synthesis of maleimido-quatenary ammoniums: A synthesis of maleimido-
quaternary ammoniums was developed by modification of the published work of from Lu 
et al242.  These modifications include the replacement of saturated sodium bicarbonate 
solution for reaction workup by a mixture of saturated sodium bicarbonate solution/water 
(1:3), extension of the reaction time to 2 h and performing the reaction at 0 °C. These 
modifications significantly reduced the amount of hydrolyzed, ring-opened byproduct 8-3 
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(see Figure 8-2). Adjustment of the buffer pH to 7.8 or lower was attempted but did further 
improve the reaction outcome.  After 2 h, the reaction was quenched by addition of 25 mL 
of 0.1 % trifluoroacetic acid (TFA) in water.  The crude reaction mixture was purified by 
HPLC with the following conditions: Solvent A: 0.1% TFA in water; Solvent B: 0.1% TFA 
in acetonitrile (HPLC grade); Flowrate: 8 mL/min (isocratic) or 14 mL/min (gradient).  
Trimethylamino(TMA)-maleimide 8-2a and Triethylamino(TEA)-maleimide 8-2b eluted 
isocratically with 0% and 2% Solvent B respectively. Tributylamino(TBA)-maleimide 8-2c 
eluted on gradient 8A at approximately 28% Solvent B. Note: Purified TEA maleimide 
contained unreacted N-Methoxycarbonylmaleimide, which was not separable on HPLC.  
However, this contaminant could be separated after reaction of 8-2b with cysteine-
dinitrobenzyl ester 8-6. 
 
Figure 8-2: Synthesis of maleimido-quaternary ammoniums. i) (a) N-(Bromoethyl)-
phtalimide, MeCN; (b) HBr (48%); ii) N-methoxycarbonylmaleimide, ¼ sat. NaHCO3. 
Nuclear magnetic resonance (NMR) spectroscopy and electrospray ionization 
mass spectrometry (ESI-MS): 
8-2a:  1H NMR (500 MHz, D2O): δ 3.25 (m, 9H), 3.63 (m, 2H), 4.05 (m, 2H), 6.95 
(m, 2H); ESI-MS: m/z ([M]+; calculated: 183.11; found: 183.19) 
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8-2b:  1H NMR (500 MHz, D2O): δ 1.37 (t, 9H, J=7.5 Hz), 3.41 (m, 8H), 3.96 (m, 
2H), 6.96 (s, 2H); ESI-MS: m/z ([M]+; calculated: 225.16; found: 225.27) 
8-2c:  1H NMR (500 MHz, CD3CN): δ 0.98 (t, 9H, J=7.5 Hz), 1.37 (sextet, 6H, J= 
7.5 Hz), 1.66 (m, 6H), 3.17 (m, 6H), 3.29 (m, 2H), 3.80 (m, 2H), 6.86 (s, 2H); ESI-MS: m/z 
([M]+; calculated: 309.25; found: 309.44) 
Synthesis of N-(trialkylammonium)ethylmaleimido)cysteine dinitrobenzyl 
esters: L-Cystine (2.08 mmol) and Triethylamine (TEA) (6.24 mmol) were dissolved in 10 
mL H2O.  After a few min of stirring, the solution became clear and di-tert-butyl dicarbonate 
(6.24 mmol) was added.  The reaction was stirred for 3 h before being partioned between 
100 mL EtOAc and H2O (50 mL each).  The aqueous layer was acidified to pH 2 and 
extracted 3 times with EtOAc.  All organic layers were combined, dried over MgSO4 and 
filtered.  Solvent was removed in vacuo to yield 8-4 as a white powder (1.55 mmol, 55.5%). 
Disulfide 8-4 (0.70 mmol), dinitrobenzylchloride (2.8 mmol), sodium iodide (3.4 
mmol) and N,N-diisopropylethylamine were dissolved in 5 mL anhydrous dimethyl-
formamide and stirred under inert atmosphere overnight.  The crude reaction mixture was 
partioned between 100 mL EtOAc and H2O containing 10% brine (50 mL each).  The 
organic phase was washed 3 times with 15 mL saturated ammonium chloride solution, 
then concentrated and the resulting residue was purified over silica (50% EtOAc in 
Hexanes).  Fractions containing the product 8-5 were combined and solvent was removed 
in vacuo.  The crude product was triturated with 20% EtOAc in Hexanes, then filtered and 
the filtrate was washed first with 50% EtOAc in hexanes, then with 100% EtOAc.  The 
filtrate was dried to yield 8-5 as white powder in high purity and modest yield (0.125 mmol, 
18.0%). 
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Disulfide 8-5 (10 µmol) was dissolved in 1 mL TFA and stirred at room temperature 
for 30 min, after which solvent was removed in vacuo.  8-6 was dissolved in 1 mL water. 
Tris(2-carboxyethyl)phosphine hydrochloride (15.0 µmol) added and the pH was adjusted 
to 6.0 with 0.1 M sodium hydroxide. A solution of maleimide (30.0 µmol) in 600 µL 
acetonitrile was added to the reaction and the pH was readjusted to 6.0.  After 45 min, the 
reaction was quenched by reducing the pH through addition of 12 mL 0.1% TFA in water.  
The crude reaction mixture was purified by HPLC on a C18 reversed-phase column to 
yield 8-7a-d in the following amounts: 8-7a: 7.05 mg, 52.2%, 8-7b: 7.60 mg, 46.4%, 8-7c: 
7.68 mg, 49.8%, 8-7d: 9.55 mg, 55.3%. Solvent A: 0.1% TFA in water; Solvent B: 0.1% 
TFA in acetonitrile; Flowrate: 14 mL/min; Gradient 8A. Note: HPLC retention times listed 
below include two peaks for 8-7b, 8-7c, and 8-7d since the diasteromers were resolvable.  
NMR spectra were obtained for mixtures of the two diasteromers, which appear to slowly 
equilibrate.  
NMR spectroscopy and ESI-MS: 
8-4: 1H NMR (500 MHz, DMF-d7): δ 1.42 (s, 18H), 3.10 (dd, 2H, J=13.6/9.8 Hz), 
3.31 (m, 2H), 4.45 (dt, 2H, J=9.0/4.2 Hz), 7.09 (d, 2H, J=8.0 Hz); ESI-MS: m/z ([M+H]+; 
calculated: 441.14; found: 441.39; [M+Na]+; calculated: 463.12; found: 463.38) 
8-5:  1H NMR (500 MHz, DMF-d7): δ 1.39 (s, 18H), 3.19 (dd, 2H, J=14.0/9.5 Hz), 
3.37 (dd, 2H, J=14.0/5.0 Hz), 4.60 (dt, 2H, J=8.5/4.5 Hz), 5.55 (dt, 4H, J=13.5/10.0 Hz), 
7.47 (d, 2H, J=8.0 Hz), 8.80 (s, 4H), 8.89 (s, 2H); ESI-MS: m/z ([M+HCO2]-; calculated: 
845.16; found: 845.41) 
8-7a: 1H NMR (500 MHz, MeCN-d3): δ 1.08 (dt, 3H, J=7.2/2.5 Hz), 2.45 (m, 1H), 
3.14 (m, 1H), 3.31 (dd, 0.5H, J=14.8/7.6 Hz), 3.46 (m, 2H), 3.52 (d, 1H, J=5.4 Hz) , 3.61 
(dd, 0.5H, J=14.8/5.1 Hz), 3.98 (m, 0.5H) , 4.03 (m, 0.5H) , 4.44 (dd, 0.5H, J=5.1/2.5 Hz) 
204 
 
, 4.53 (t, 0.5H, J=5.3 Hz) , 5.44 (m, 2H), 8.65 (t, 2H, J=2.7 Hz), 8.88 (t, 1H, J=2.0 Hz); ESI-
MS: m/z ([M+H]+; calculated: 429.09; found: 429.39) 
8-7b: 1H NMR (500 MHz, MeCN-d3): δ 2.53, (dt, 0.5H, J=19.0/4.5 Hz) 3.09 (s, 9H), 
3.21 (m, 1.5H), 3.29 (m, 0.5H), 3.49 (m, 3.5H), 3.85(m, 2H), 4.14 (dt, 1H, J=10.0/5.0 Hz), 
4.38 (dt, 1H, J=10.3/4.9 Hz), 5.41 (m, 2H), 8.80 (s, 2H), 8.88 (s, 1H); ESI-MS: m/z ([M]+; 
calculated: 484.15; found: 484.50) 
8-7c: 1H NMR (500 MHz, MeCN-d3): δ 1.267 (t, 9H, J=7.2 Hz), 2.54 (dt, 1H, 
J=18.7/5.5 Hz), 3.27 (m, 9.5H), 3.48 (m, 1H), 3.58 (dt, 0.5H), 3.76 (m, 2H), 4.13 (m, 1H) 
4.44 (m, 1H), 5.43 (m, 2H), 8.66 (s, 2H), 8.88 (t, 1H, J=1.8 Hz); ESI-MS: m/z ([M]+; 
calculated: 526.20; found: 526.56) 
8-7d: 1H NMR (500 MHz, DMSO-d6): δ 0.94 (dt, 9H, J=7.5/1.5 Hz), 1.33 (q, 6H, 
J=7.5 Hz), 1.62 (m, 6H), 2.56 (m, 1H), 3.21 (m, 1.5H), 3.28 (m, 8.5H), 3.42 (dd, 0.5H, 
J=14.5/5.5 Hz), 3.50 (dd, 0.5H, J=14.5/6.0 Hz), 3.74 (m, 2H), 4.13 (m, 1H) 4.55 (m, 1H), 
5.54 (s, 2H), 8.77 (m, 2H), 8.83 (t, 1H, J=1.8 Hz); ESI-MS: m/z ([M]+; calculated: 610.29 
found: 610.69) 
Synthesis of L-Tryptophan cyanomethyl ester: Nα-Boc-L-Tryptophan (0.5 
mmol), sodium iodide (1.50 mmol) and N,N-diisopropylethylamine (2.0 mmol) were 
dissolved in 6 mL Chloroacetonitrile and stirred overnight at room temperature. The 
solvent was removed in vacuo and residue dissolved in CH2Cl2. Crude product was 
partioned between 100 mL CH2Cl2 and H2O containing 10% brine (50 mL each). Aqueous 
phase was extracted one more time with 30 mL CH2Cl2. The combined organic layers 
were washed twice with saturated ammonium chloride solution and once with H2O, before 
being dried over MgSO4 and filtered. The crude product was purified over silica using 2% 
MeOH in CH2Cl2 to yield 8-8 in decent yield (0.25 mmol, 50%). 
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Boc-L-Tryptophan cyanomethyl ester 8-8 (166 μmol) was dissolved in 1 mL CHCl3 
and 1 mL TFA. Reaction mixture was stirred at room temperature for 45 minutes after 
which the solvent was removed in vacuo and the crude product was rinsed twice with 
MeCN. The product was purified by HPLC on a C18 reversed-phase column using 
gradient 8B to yield compound 8-9 in good yield (86.9 μmol, 52%). 
 
Figure 8-3: Synthesis of L-Tryptophan cyanomethyl ester. i) NaI, DIPEA, ClCH2CN; 
ii) TFA, CHCl3. 
NMR spectroscopy and ESI-MS: 
8-8: 1H NMR (500 MHz, Chloroform-d) δ 8.39 (s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 
7.36 (d, J = 8.1 Hz, 1H), 7.22 (t, J = 7.4 Hz, 1H), 7.15 (t, J = 7.4 Hz, 1H), 7.02 (s, 1H), 5.12 
(d, J = 8.1 Hz, 1H), 4.72 (q, J = 6.9, 6.5 Hz, 1H), 4.66 (d, J = 15.7 Hz, 1H), 4.52 (d, J = 
15.7 Hz, 1H), 3.31 (d, J = 5.8 Hz, 2H), 1.45 (s, 9H). ESI-MS: m/z ([M+H]+; calculated: 
344.16; found: 344.26; [M+Na]+; calculated: 366.14; found: 366.29) 
8-9: 1H NMR (500 MHz, DMSO-d6) δ 11.14 (d, J = 1.4 Hz, 2H), 8.65 (s, 3H), 7.54 
(dd, J = 7.9, 1.1 Hz, 1H), 7.38 (dt, J = 8.2, 0.9 Hz, 1H), 7.23 (d, J = 2.5 Hz, 1H), 7.11 (ddd, 
J = 8.1, 7.0, 1.2 Hz, 1H), 7.02 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 5.07 (d, J = 0.7 Hz, 2H), 4.41 
(t, J = 6.5 Hz, 1H), 3.36 – 3.24 (m, 2H). ESI-MS: m/z ([M+H]+; calculated: 244.11; found: 
244.18; [M+Na]+; calculated: 266.09; found: 266.17) 
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Table 8.1: HPLC gradients used for compound purification. 
No. Time (min) %B No. Time (min) %B    
8A 0:00 15 8B 0:00 2    
3:00 15 10:00 2   
7:00 25 15:00 20   
17:00 35 30:00 25   
20:00 100 33:00 100   
25:00 100 37:00 100   
26:00 15 38:00 2   
Solvent A: 0.1% (v/v) TFA in water; Solvent B: 0.1% (v/v) TFA in acetonitrile 
 
Table 8.2: Compound purification retention times. 
Compound Gradient Retention Time 
(N-ethylmaleimido)-cysteine 8A 2.9 min 
(N-ethylmaleimido)cysteine dinitrobenzyl ester (8-7a) 8A 13.8 min 
(N-(trimethylammonium)ethylmaleimido)cysteine 
dinitrobenzyl ester (8-7b) 8A 7.3 / 7.8 min 
(N-(triethylammonium)ethylmaleimido)cysteine 
dinitrobenzyl ester (8-7c) 8A 8.7 / 9.0 min 
(N-(tributylammonium)ethylmaleimido)cysteine 
dinitrobenzyl ester (8-7d) 8A 17.7 / 18.0 min 
(N-Methoxycarbonylmaleimido)cysteine 
dinitrobenzyl ester 8A 10.1 min 
Cysteine dinitrobenzyl ester 8A 10.5 min 
Cystine dinitrobenzyl ester (8-6) 8A 14.6 min 
Dinitrobenzyl alcohol 8A 15.5 min 
L-Tryptophan cyanomethyl ester (8-9) 8B 19.2 min 
207 
 
Appendix B: Synthesis of flexizyme substrates to study the mechanism of 
a quadruplet-codon reader 
 
The Hou Lab is interested in studying the mechanism of a quadruplet codon reader 
tRNA. For this purpose they are generated various aminoacylated tRNA constructs using 
the Flexizyme method developed by the Suga Lab240. We provided them with purified 
dinitrobenzyl esters for in vitro aminoacylation reactions. This study has not yet been 
published. 
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Fisher 
Scientific (Waltham, MA, USA). Boc protected proline derivatives were purchased from 
ChemImpex (Wood Dale, IL). All reagents were used without further purification. High 
resolution electrospray ionization mass spectra (ESI-HRMS) were collected with a Waters 
LCT Premier XE liquid chromatograph/mass spectrometer (Milford, MA, USA). Low 
resolution electrospray ionization mass spectra (ESI-LRMS) were obtained on a Waters 
Acquity Ultra Performance LC connected to a single quadrupole detector (SQD) mass 
spectrometer. Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker 
DRX 500 MHz instrument (Billerica, MA, USA). Preparative HPLC was performed on a 
Varian Prostar HPLC system (currently: Agilent Technologies, Santa Clara, CA, USA) 
using with water and acetonitrile each containing 0.1% trifluoroacetic acid (TFA) as mobile 
phase. A Waters Sunfire C18 OBD Prep column was used to purify all final products. 
Figure 8-4: Generalized synthesis scheme for Dinitrobenzyl esters. Reagents and 
conditions: i) (3,5)Dinitrobenzyl chloride, NaI, DIPEA, THF; ii) TFA, CHCl3 
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Synthesis of trans-L-4-Hydroxyproline dinitrobenzyl ester (8-12a): 
 
Figure 8-5: Synthesis of trans-L-4-Hydroxyproline dinitrobenzyl ester (8-12a). 
Boc-trans-L-4-hydroxyproline 8-10a (231 mg, 1.00 mmols), 3,5-Dinitrobenzyl-
chloride (543 mg, 2.5 mmols) and sodium iodide (450 mg, 3.00 mmols) dissolved in 
Tetrahydrofuran (10 mL). Diisopropylethylamine (695 μL, 4.00 mmols) added and stirred 
at room temperature overnight. The next day the crude reaction mixture was partioned 
between 100 mL H2O/EtOAc (1:1). The organic phase was washed twice with saturated 
NH4Cl solution and once with brine before dried over MgSO4. The solution was filtered 
and the solvent was removed in vacuo. Crude product was dissolved in CH2Cl2 and 
purified over silica using 5% MeOH in CH2Cl2 (Rf = 0.3). Pure fractions were combined 
and solvent removed in vacuo. Purified compound 8-11a was yielded in 46.0% yield as 
orange foam. 
Boc-trans-L-4-hydroxyproline dinitrobenzyl ester 8-11a (95 mg, 0.23 mmols) was 
dissolved in CHCl3 (1mL) and Trifluoroacetic acid (TFA; 1mL) was added under stirring. 
After 1 hour stirring at room temperature, the solvent was removed in vacuo. The crude 
product was dissolved in 50% MeCN in H2O and purified by reverse phase HPLC. The 
desired product 8-11a eluted with approximately 24% MeCN was isolated in high purity. 
After lyophilization the product was dissolved in DMSO to yield a 25 mM stock solution 
used in later experiments. 
  
209 
 
Synthesis of cis-L-4-Hydroxyproline dinitrobenzyl ester (8-12b): 
 
Figure 8-6:Synthesis of cis-L-4-Hydroxyproline dinitrobenzyl ester (8-12b). 
Boc-cis-L-4-hydroxyproline 8-10b (231 mg, 1.00 mmols), 3,5-Dinitrobenzylchloride 
(543 mg, 2.5 mmols) and sodium iodide (450 mg, 3.00 mmols) dissolved in 
Tetrahydrofuran (10 mL). Diisopropylethylamine (695 μL, 4.00 mmols) added and stirred 
at room temperature overnight. The next day the crude reaction mixture was partioned 
between 100 mL H2O/EtOAc (1:1). The organic phase was washed twice with saturated 
NH4Cl solution and once with brine before dried over MgSO4. The solution was filtered 
and the solvent was removed in vacuo. Crude product was dissolved in CH2Cl2 and 
purified over silica using 5% MeOH in CH2Cl2 (Rf = 0.3). Pure fractions were combined 
and solvent removed in vacuo. Purified compound 8-11b was yielded in 30.4% yield as 
orange foam. 
Boc-cis-L-4-hydroxyproline dinitrobenzyl ester 8-11b (62 mg, 0.15 mmols) was 
dissolved in CHCl3 (1mL) and TFA (1mL) was added under stirring. After 1 hour stirring at 
room temperature, the solvent was removed in vacuo. The crude product was dissolved 
in 50% MeCN in H2O and purified by reverse phase HPLC. The desired product 8-12b 
eluted with approximately 26% MeCN was isolated in high purity. After lyophilization the 
product was dissolved in DMSO to yield a 25 mM stock solution used in later experiments. 
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Synthesis of 2-Carboxyazetidine dinitrobenzyl ester (8-12c): 
 
Figure 8-7: Synthesis of 2-Carboxyazetidine dinitrobenzyl ester (8-12c). 
Boc-L-azetidine-2-carboxylic acid 8-10c (201 mg, 1.00 mmols), 3,5-
Dinitrobenzylchloride (543 mg, 2.5 mmols) and sodium iodide (450 mg, 3.00 mmols) 
dissolved in Tetrahydrofuran (10 mL). Diisopropylethylamine (695 μL, 4.00 mmols) added 
and stirred at room temperature overnight. The next day the crude reaction mixture was 
partioned between 100 mL H2O/EtOAc (1:1). The organic phase was washed twice with 
saturated NH4Cl solution and once with brine before dried over MgSO4. The solution was 
filtered and the solvent was removed in vacuo. Crude product was dissolved in CH2Cl2 
and purified over silica using 2% MeOH in CH2Cl2 (Rf = 0.3). Pure fractions were combined 
and solvent removed in vacuo. Purified compound 8-11c was yielded in 70.3% yield as 
red oil. 
Boc-L-azetidine-2-carboxylic acid dinitrobenzyl ester 8-11c (134 mg, 0.35 mmols) 
was dissolved in CHCl3 (1mL) and TFA (1mL) was added under stirring. After 1 hour 
stirring at room temperature, the solvent was removed in vacuo. The crude product was 
dissolved in 50% MeCN in H2O and purified by reverse phase HPLC. The desired product 
8-12c eluted with approximately 27% MeCN was isolated in high purity. After lyophilization 
the product was dissolved in DMSO to yield a 25 mM stock solution used in later 
experiments. 
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Synthesis of Thiaproline dinitrobenzyl ester (8-12d): 
 
Figure 8-8: Synthesis of Thioproline dinitrobenzyl ester (8-12d). 
Boc-L-Thiaproline (8-10d) (116 mg, 0.50 mmols) and 3,5-Dinitrobenzylchloride 
(217 mg, 1.0 mmols) were dissolved in Tetrahydrofuran (5 mL).  Diisopropylethylamine 
(348 μL, 2.00 mmols) added and stirred at room temperature overnight. The next day the 
crude reaction mixture was partioned between 100 mL H2O/EtOAc (1:1). The organic 
phase was washed twice with saturated NH4Cl solution and once with brine before dried 
over MgSO4. The solution was filtered and the solvent was removed in vacuo. Crude 
product was dissolved in CH2Cl2 and purified over silica using 1% MeOH in DCM (Rf = 
0.4). Pure fractions were combined and solvent removed in vacuo. Purified compound 8-
11d was yielded in 77.5% yield as yellow oil. 
Boc-L-Thiaproline dinitrobenzyl ester 8-11d (160 mg, 0.39 mmols) was dissolved 
in CHCl3 (1mL) and Trifluoroacetic acid (TFA; 1mL) was added under stirring. After 1 hour 
stirring at room temperature, the solvent was removed in vacuo. The crude product was 
dissolved in 50% MeCN in H2O and purified by reverse phase HPLC. The desired product 
8-11d eluted with approximately 30% MeCN was isolated in high purity. After lyophilization 
the product was dissolved in DMSO to yield a 25 mM stock solution used in later 
experiments. 
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Nuclear magnetic resonance (NMR) spectroscopy and electrospray 
ionization mass spectrometry (ESI-MS) characterization: 
1-(tert-butyl) 2-(3,5-dinitrobenzyl) (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate 
(8-11a): 1H NMR (500 MHz, Chloroform-d) δ 8.93 (dt, J = 18.1, 2.1 Hz, 1H), 8.54 (dd, J = 
14.5, 2.1 Hz, 2H), 5.39 – 5.24 (m, 2H), 4.51 – 4.42 (m, 2H), 3.56 (ddd, J = 15.8, 11.6, 4.2 
Hz, 1H), 3.47 (ddt, J = 34.5, 11.6, 1.8 Hz, 1H), 2.38 – 2.24 (m, 1H), 2.08 – 1.98 (m, 1H), 
1.33 (d, J = 38.8 Hz, 9H). ESI+-HRMS: calculated for C17H21N3O9Na+: 434.1175; found [M 
+ Na]+: 434.1171. 
1-(tert-butyl) 2-(3,5-dinitrobenzyl) (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate 
(8-11b): 1H NMR (500 MHz, Chloroform-d) δ 8.96 (dt, J = 10.0, 2.1 Hz, 1H), 8.59 (dd, J = 
9.2, 2.1 Hz, 2H), 5.43 (t, J = 13.4 Hz, 1H), 5.34 (dd, J = 13.7, 7.3 Hz, 1H), 4.52 – 4.44 (m, 
1H), 4.44 – 4.39 (m, 1H), 3.61 – 3.51 (m, 2H), 3.03 (s, 1H), 2.42 – 2.30 (m, 1H), 2.23 – 
2.13 (m, 1H), 1.39 (d, J = 35.2 Hz, 9H). ESI+-HRMS: calculated for C17H21N3O9Na+: 
434.1175; found [M + Na]+: 434.1205. 
1-(tert-butyl) 2-(3,5-dinitrobenzyl) (S)-azetidine-1,2-dicarboxylate (8-11c): 1H NMR 
(500 MHz, Chloroform-d) δ 8.88 (s, 1H), 8.53 (d, J = 2.1 Hz, 2H), 5.36 (d, J = 2.8 Hz, 2H), 
4.67 (dd, J = 9.2, 5.4 Hz, 1H), 3.91 (dtd, J = 45.7, 8.4, 5.9 Hz, 2H), 2.59 – 2.41 (m, 1H), 
2.25 – 2.08 (m, 1H), 1.30 (s, 9H). ESI+-HRMS: calculated for C16H21N3O8Na+: 404.1070; 
found [M + Na]+: 404.1086 
3-(tert-butyl) 4-(3,5-dinitrobenzyl) (R)-thiazolidine-3,4-dicarboxylate (8-11d): 1H 
NMR (500 MHz, Chloroform-d) δ 8.92 (d, J = 6.6 Hz, 1H), 8.53 (d, J = 2.1 Hz, 2H), 5.47 – 
5.28 (m, 2H), 4.93 – 4.76 (m, 1H), 4.56 (dd, J = 22.7, 8.9 Hz, 1H), 4.42 (t, J = 8.0 Hz, 1H), 
3.40 – 3.26 (m, 1H), 3.22 – 3.13 (m, 1H), 1.37 (d, J = 36.1 Hz, 9H). ESI+-HRMS: calculated 
for C16H19N3O8SNa+: 436.0791; found [M + Na]+: 436.0796 . 
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3,5-dinitrobenzyl (2S,4R)-4-hydroxypyrrolidine-2-carboxylate (8-12a): 1H NMR 
(500 MHz, DMSO-d6) δ 9.75 (s, 2H), 8.82 (t, J = 2.1 Hz, 1H), 8.75 (d, J = 2.1 Hz, 2H), 5.60 
(s, 1H), 5.49 (s, 2H), 4.66 (dd, J = 10.7, 7.6 Hz, 1H), 4.48 – 4.44 (m, 1H), 3.38 (dd, J = 
12.1, 4.2 Hz, 1H), 3.13 (dt, J = 12.1, 1.6 Hz, 1H), 2.30 – 2.14 (m, 2H). ESI+-HRMS: 
calculated for C12H14N3O7+: 312.0832; found [M + H]+: 312.0833. 
3,5-dinitrobenzyl (2S,4S)-4-hydroxypyrrolidine-2-carboxylate (8-12b): 1H NMR 
(500 MHz, DMSO-d6) δ 9.74 (s, 2H), 8.81 (t, J = 2.1 Hz, 1H), 8.74 (d, J = 2.1 Hz, 2H), 5.51 
(d, J = 2.1 Hz, 2H), 4.71 (dd, J = 9.7, 3.4 Hz, 1H), 4.40 (dt, J = 4.2, 2.1 Hz, 1H), 3.73 (s, 
1H), 3.28 (dd, J = 11.9, 4.0 Hz, 1H), 3.21 (dt, J = 11.5, 1.5 Hz, 1H), 2.36 (ddd, J = 13.8, 
9.7, 4.3 Hz, 1H), 2.24 (ddt, J = 13.4, 3.4, 1.8 Hz, 1H). ESI+-HRMS: calculated for 
C12H13N3O7Na+: 334.0651; found [M + Na]+: 334.0673. 
3,5-dinitrobenzyl (S)-azetidine-2-carboxylate (8-12c): 1H NMR (500 MHz, DMSO-
d6) δ 8.82 (t, J = 2.2 Hz, 1H), 8.75 (d, J = 2.1 Hz, 2H), 5.50 (s, 2H), 5.28 (t, J = 9.0 Hz, 
1H), 4.01 (dt, J = 10.0, 8.8 Hz, 1H), 3.81 (ddd, J = 10.0, 8.6, 7.1 Hz, 2H), 2.73 – 2.64 (m, 
2H). ESI+-HRMS: calculated for C11H12N3O6+: 282.0726; found [M + H]+: 282.0728. 
3,5-dinitrobenzyl (R)-thiazolidine-4-carboxylate (8-12d): 1H NMR (500 MHz, 
DMSO-d6) δ 8.80 (t, J = 2.1 Hz, 1H), 8.70 (d, J = 2.1 Hz, 2H), 5.43 (d, J = 4.5 Hz, 2H), 
4.31 (dd, J = 7.1, 5.7 Hz, 1H), 4.17 (q, J = 9.1 Hz, 2H), 3.13 (dd, J = 10.5, 7.1 Hz, 1H), 
3.03 (dd, J = 10.4, 5.7 Hz, 1H). ESI+-HRMS: calculated for C11H12N3O6S+: 314.0447; found 
[M + H]+: 314.0443. 
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Synthesis of fMet-Pro-Pro-DBE (8-16): 
 
Figure 8-9: Synthetic scheme for the synthesis of fMet-Pro-Pro-DBE. 
Tert-butyl (S)-2-((S)-2-(((3,5-dinitrobenzyl)oxy)carbonyl)pyrrolidine-1-carbonyl)-
pyrrolidine-1-carboxylate (Boc-Pro-Pro-DBE; 8-14): Boc-Pro-OSu (343 mg, 1.10 mmols) 
and L-Proline (115 mg, 1.00 mmol) dissolved in 10 mL CHCl3 and 1 mL MeOH. DIPEA 
(348 μL, 2.00 mmols) added and stirred at room temperature for 3 hours until formation of 
Boc-Pro-Pro-OH (8-13) was complete. 3,5-Dinitrobenzylchloride (432 mg, 2.00 mmols) 
and more DIPEA (174 μL, 1.00 mmol) added and stirred overnight at room temperature. 
The next day solvent was removed in vacuo and the reaction mixture was purified over 
silica using 1% MeOH in CH2Cl2 (Rf = 0.2). The crude product was around 40% pure and 
was further purified by reverse phase HPLC. The desired product 8-14 eluted with 
approximately 65% MeCN was isolated in high purity. After lyophilization the product 
yielded as white powder (41.5 mg, 0.092 mmols, 9.2%). 1H NMR (500 MHz, Chloroform-
d) δ 8.98 – 8.95 (m, 1H), 8.53 (s, 2H), 5.32 (d, J = 10.6 Hz, 2H), 4.85 (s, 1H), 4.62 (ddd, J 
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= 11.0, 8.4, 4.6 Hz, 1H), 4.44 (ddd, J = 52.7, 8.4, 3.9 Hz, 1H), 3.86 – 3.78 (m, 1H), 3.71 – 
3.41 (m, 2H), 3.42 – 3.33 (m, 1H), 2.31 – 2.21 (m, 1H), 2.20 – 1.87 (m, 6H), 1.87 – 1.77 
(m, 1H), 1.40 (d, J = 25.9 Hz, 9H). ESI+-HRMS: calculated for C22H28N4O9Na+: 515.1754; 
found [M + Na]+: 515.1730. 
3,5-dinitrobenzyl L-prolyl-L-prolinate (Pro-Pro-DBE; 8-15): Compound 8-14 was 
dissolved in 2 mL CHCl3. 2 mL TFA added and stirred at room temperature for 1 hour. 
The solvent was removed in vacuo and the product was rinsed twice to remove excess 
TFA. The product was dissolved in 50% (v/v) MeCN in H2O and lyophlized to yield product 
8-15 in quantitative yield as white powder. 1H NMR (500 MHz, Chloroform-d) δ 8.97 (t, J 
= 2.1 Hz, 1H), 8.53 (d, J = 2.0 Hz, 2H), 7.55 (s, 1H), 5.43 (d, J = 13.6 Hz, 1H), 5.30 (d, J 
= 13.6 Hz, 1H), 4.73 (s, 1H), 4.65 (dd, J = 8.6, 5.4 Hz, 1H), 3.75 – 3.67 (m, 1H), 3.58 (dt, 
J = 9.9, 6.9 Hz, 1H), 3.55 – 3.46 (m, 3H), 2.61 – 2.49 (m, 1H), 2.44 – 2.33 (m, 1H), 2.22 – 
1.99 (m, 6H). ESI+-HRMS: calculated for C17H21N4O7+: 393.1410; found [M + H]+: 
393.1414. 
3,5-dinitrobenzyl formyl-L-methionyl-L-prolyl-L-prolinate (fMet-Pro-Pro-DBE; 8-
16): Formyl-methionine (26.6 mg, 150 μmols) and PyBOP (78.0 mg, 150 μmols) dissolved 
in 3 mL CH2Cl2 and DIPEA (52.2 μL, 300 μmols) added. After 10 minutes, Compound 8-
15 (15.4 mg, 30.0 μmols) added and stirred at room temperature for 30 minutes, after 
which the reaction was complete. The solvent was removed in vacuo and the crude 
product was purified by reverse phase HPLC. The desired product 8-16 eluted with 
approximately 43% MeCN was isolated in high purity. After lyophilization the product 
yielded as white powder (11.0 mg, 20.0 μmols, 66.7%) and was dissolved in DMSO to 
yield a 25 mM stock solution used in later experiments. ESI+-HRMS: calculated for 
216 
 
C23H29N5O9SNa+: 574.1584; found [M + Na]+: 574.1569. The 1H NMR of compound 8-16 
is shown in Figure 8-10. 
 
 
 
Figure 8-10: NMR of fMet-Pro-Pro-DBE. 
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